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Abstract 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is an oncogenic human herpes virus 
that has been linked to the development of multiple malignancies including Kaposi’s 
sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Like all 
members of the herpesvirus family, KSHV establishes a lifelong persistence in the 
infected host. However, immediately upon infection, the virus has to overcome many 
challenges in the hostile cellular environment before it can establish a long-term 
infection. The remarkable success of the virus in establishing lifelong persistence in the 
infected host indicates that the virus is well equipped to manipulate the host environment 
very efficiently, even before it has a chance to fully express its genome. In order to 
understand how KSHV manipulates the host environment immediately upon infection, 
we must first understand which molecules are packaged in the virions and which viral 
genes are expressed during the initial time points following entry of the virus into the 
host cells. In chapter I, we probe these questions by performing a comprehensive analysis 
of the viral transcriptome in the purified KSHV virions. We also examine the dynamics 
of viral transcriptome at very early time-points following de novo infection of multiple 
cell lines permissive to long-term infection of KSHV. For this comprehensive study of 
viral transcriptome analysis, we used a high throughput approach of next-generation 
RNA sequencing. The results of this study identified many viral transcripts that are 
packaged into the virions and the transcripts that are actively transcribed during the initial 
infection period. Overall, the results of this study lay a foundation for future research 
targeting the viral genes whose expression may be critical for establishing a successful 
viral infection.  
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 One critical aspect of KSHV infection is its ability to persist throughout the life of 
the host. This can be attributed to its ability to efficiently hide from the host’s immune 
surveillance.  In chapter II, we identify a novel mechanism that helps the virus hide from 
the radar of host immunity. Our data sheds light on how one of the viral proteins, 
Latency- associated nuclear antigen (LANA), reduces the expression of major 
histocompatibility class II (MHC II) molecules, which are the molecules that are critical 
for reporting viral antigens to the immune cells of the host. We demonstrated that LANA 
binds with the proteins of regulatory factor X (RFX) complex, which are essential 
components of MHC II transcription machinery. The association of LANA with RFX 
complex reduces binding of the transcription factor called class II transactivator (CIITA) 
to the highly conserved promoters of MHC II genes.  Binding of the CIITA to MHC II 
promoters is absolutely necessary for the expression of MHC II genes; by reducing the 
association of CIITA with the promoters of MHC II genes, LANA inhibits the expression 
of MHC II genes.  
 KSHV infection is known to induce multiple pro-angiogenic cytokines that aid in 
extensive angiogenesis associated with Kaposi’s sarcoma tumors. In chapter III, we 
demonstrate that LANA induces expression of a secreted angiogenic cytokine epidermal 
growth factor-like multiple 7 (EGFL7). Our data shows that LANA induces expression of 
EGFL7 in B cells, suggesting that it may act in a paracrine fashion during KSHV 
infection. The results of this research provide insight into an additional mechanism used 
by KSHV to promote angiogenesis. Targeting EGFL7 in combination with other 
important angiogenic cytokines induced during KSHV infection may increase the 
effectiveness of currently available anti-angiogenic therapy for Kaposi’s sarcoma. 
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Introduction and Background 
1. Herpes viruses 
Herpes viruses are the leading cause of viral diseases in animals and humans. The 
family name ‘Herpesviridae’ is derived from the Greek word herpein, referring to latent, 
recurring infections that are characteristic of herpes viruses. They are enveloped DNA 
viruses containing relatively large linear double-stranded DNA genomes (~130–250 kb) 
with a capacity to encode 70–200 genes (35, 89). The viral DNA is encased within an 
icosahedral protein capsid approximately 125 nm in diameter and a tegument matrix. 
Viral DNA replication and capsid assembly occur in the nucleus of the infected host cell, 
and viral particles become enveloped by lipids as the particles leave the nucleus (8).  
Herpes viruses are classified into three distinct subgroups, alpha, beta and gamma, 
based on genomic sequence similarities and biological properties such as tissue and host 
specificity (42, 43, 113). One common attribute of all of the members of the herpesvirus 
family is their ability to establish life-long latent infection in permissive cells, with 
periodic reactivation of productive, lytic replication cycles. Alpha herpes viruses 
establish latency in neuronal cells, beta herpes viruses establish latency in myeloid 
progenitor cells and/or lymphocytes, and gamma herpes viruses establish latency in cells 
of lymphoid origin (113).  
Out of over 100 known herpes viruses, only eight are known to infect humans. 
These include Herpes simplex type I (HHV-1), Herpes simplex type II (HHV-2), 
Varicella-Zoster virus (VZV/HHV-3), Epstein-Barr virus (EBV/HHV-4), 
Cytomegalovirus (CMV/HHV-5), Human herpesvirus type 6 (HBLV/HHV-6), Human 
herpesvirus type 7 (HHV-7) and Kaposi’s sarcoma-associated herpes virus (KSHV/HHV-
	   2	  
8). A large majority of the human population is estimated to be infected with at least one 
of these eight herpes viruses (165). KSHV was discovered by Patrick Moore and Yuan 
Chang in 1994 by using the Representational Difference Analysis (RDA) technique in 
biopsy samples of Kaposi’s sarcoma (KS), an AIDS-associated tumor (33). Later, KSHV 
was found to be associated with several other malignancies including body cavity-based 
lymphomas. Having been linked to both lymphomas and sarcomas (104), KSHV 
classifies as an oncogenic virus (103).  
2. KSHV-related diseases 
Primary KSHV infection in immune-competent hosts is largely asymptomatic; 
however, the virus often causes cancer in immunosuppressed hosts. KSHV has been 
established as a causative agent of KS, a highly vascularized tumor of endothelial origin. 
In addition to KS, the virus also causes primary effusion lymphoma (PEL) and 
Multicentric Castleman disease (MCD).  
2.1 Kaposi’s sarcoma (KS) 
KS was initially described by Moritz Kaposi in 1872 as an aggressive pigmented 
tumor of skin (34). At that time, KS was most common amongst elderly men of 
Mediterranean, eastern European or Middle Eastern heritage. However, following the 
onset of the AIDS pandemic in the 1980s, rates of KS incidence became so high in HIV 
co-infected individuals that KS became an AIDS-defining tumor. Since then, four 
subtypes of KS have been described. The first subtype, classic KS, is the one originally 
described by Moritz Kaposi. Classic KS is more predominant in men than in women. 
This form is characterized by benign lesions on the legs, ankles or soles of the feet, and is 
rarely aggressive (45). The second subtype, African endemic KS, is associated with HIV-
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positive and HIV-negative individuals, including children, and is associated with 
significant mortality (54, 100). The third subtype, Iatrogenic KS, is the form that 
develops in organ transplant patients following immunosuppressive therapy (54, 100). 
The fourth subtype, AIDS-associated epidemic KS, is a highly aggressive tumor 
primarily associated with HIV co-infected individuals whose immune systems are 
severely compromised. This subtype is the most aggressive form of KS and is not 
restricted to the skin. The tumors frequently develop on the internal organs such as liver, 
spleen, gastrointestinal tract and lungs. AIDS-associated epidemic KS is the most 
common malignancy associated with HIV infection, and causes significant morbidity and 
mortality in this group of patients (54). 
2.2 Primary effusion lymphoma (PEL) 
Primary effusion lymphoma, also known as body cavity-based lymphoma, is a 
rare but aggressive B cell tumor that arises within the pericardial, pleural, and peritoneal 
body cavities (54). PEL occurs in HIV-positive as well as HIV-negative individuals, and 
5- 20% of HIV co-infected patients develop PEL. It is a very aggressive form of 
lymphoma, with an average survival time of only 6 months from diagnosis (21, 100).  
2.3 Multicentric Castleman’s disease (MCD) 
Castleman’s disease is angiofollicular lymph node hyperplasia that is either 
unicentric (localized) or multicentric. MCD has two clinical variants – a hyaline vascular 
variant that is not associated with KSHV infection, and a plasmoblastic variant that is 
associated with KSHV infection. In KSHV/HIV co-infected patients, progression of 
MCD is very aggressive. 
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2.4 KSHV-inflammatory cytokine syndrome (KICS) 
KICS is an inflammatory condition arising due to severe systemic lytic 
reactivation of KSHV. KICS is associated with high systemic viral load, KS and 
excessive cytokine production, notably high levels of interleukin 6 (IL-6). KICS has been 
proposed as a new KSHV-associated disease (132, 154).  
3. KSHV cell tropism and transmission 
KSHV is a lymphotropic gammaherpesvirus, subclassified as ϒ2-herpesvirus. 
However, it infects a variety of cell types in vivo and in vitro. KSHV is known to infect 
endothelial cells, epithelial cells, monocytes, keratinocytes and B cells in vivo. Whereas 
KSHV can infect T cells in vivo, KSHV infection of T cells is abortive (106). Some 
studies suggest that KSHV can also infect mesenchymal stem cells (MSCs) and 
hematopoietic progenitor cells (HPCs), which may serve as reservoirs for KSHV 
infection (56, 116, 169). In vitro, KSHV has even broader tropism. The virus can 
successfully infect human dermal microvascular endothelial  (HMVEC-d) cells, human 
umbilical vein endothelial (HUVEC) cells, human foreskin fibroblast (HFF) cells, 
telomerase-immortalized human umbilical vein endothelial (TIVE) cells, human 
embryonic kidney 293 (HEK293) cells, human epithelial SLK cells, monkey kidney 
epithelial VERO cells, monkey kidney CV-1 cells, and mouse fibroblasts (158).   
 There are many transmission routes of KSHV. In KSHV-infected humans, the 
oropharynx is thought to be the primary site of virus replication, where the virus is shed 
into the saliva (106). High KSHV loads have been detected in saliva, irrespective of 
KSHV titers in the peripheral blood (55). Saliva is thus the main reservoir of infectious 
KSHV virions, and also the main route of infection in the context of both sexual and non-
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sexual KSHV transmission. However, KSHV can also be transmitted through parenteral 
routes such as needle sharing, blood transfusion and solid-organ transplantation (54). 
Vertical transmission from mother to child is thought to be rare for KSHV.  
4. KSHV virion structure and assembly 
The KSHV architecture is built from conserved structural elements of 
herpesviruses. A typical KSHV virion is composed of a viral genomic DNA encased in 
an icosahedral capsid shell (~125 nm in diameter) composed of 162 capsomeres (165). 
KSHV capsids are made up of a repeating pattern of five viral proteins including ORF25, 
ORF26, ORF62, ORF17.5 and ORF65 (54, 108, 168). The envelope surrounding the 
capsid is a lipid bilayer spiked with the virally-encoded glycoproteins ORF8 (gB, 
glycoprotein B), ORF22 (gH), ORF39 (gM), ORF47 (gL), ORF53 (gN), ORF68 and 
ORFK8.1 (15, 54, 177). These glycoproteins mediate the attachment and entry of the 
virus into host cells. A KSHV virion also contains a tegument, an electron-dense, 
proteinaceous material located between the capsid and the envelope. KSHV tegument 
proteins are known to be involved in several phases of the viral life cycle including virion 
assembly and egress, transportation of incoming virions towards the nucleus, and 
immune evasion (145).  
The KSHV genome is a double-stranded DNA with a typical ϒ2-herpesviruses 
genome structure (93, 134). The genome is circularized and maintained as an 
extrachromosomal episome during latent infection, but is linearized during virion 
packaging and replication. The length of the genome is variable, usually 160–170 Kb, 
containing approximately 145 kb of coding sequences. These sequences are flanked by 
multiple copies of 801 bp, GC-rich terminal repetitive (TR) DNA, a region that is not 
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known to have any coding capacity so far (93). The number of TRs varies amongst 
KSHV isolates, which accounts for the variation in genome sizes of KSHV isolates. The 
coding sequences of the KSHV genome reside in at least 89 open reading frames (ORFs), 
67 of which have homologues in the closely-related ϒ2-herpes virus known as 
herpesvirus saimiri (93). KSHV genes are numbered from left to right as ORF1 to ORF75 
(54). The KSHV genes that do not share a clear homology with herpesvirus saimiri are 
designated as ORFs starting with the prefix ‘K’. There are 19 such genes, including ORFs 
K1 to K15, K4.1, K4.2, K8.1 and K 10.5. Often, these genes share homology with 
cellular genes and encode proteins that mimic cellular proteins involved in immune 
modulation, cellular growth and metabolic regulation (93). In addition, KSHV encodes 
several mRNAs, miRNAs and noncoding RNAs (14, 26, 88, 122, 129, 141, 152). A long 
(1.1 kb) noncoding RNA termed polyadenylated nuclear RNA (PAN RNA) is one of the 
most abundant transcripts detected in KSHV-infected cells (137).  A schematic map of 
the KSHV genome is shown in Figure 1. 
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 Figure 1: The KSHV episome. This image from ‘Kaposi’s sarcoma and its associated 
herpesvirus’ is reprinted here with the original publisher’s permission (100). KSHV 
encodes at least 87 open reading frames (ORFs) and 17 microRNAs (purple boxes), 14 of 
which are co-expressed as a cluster. A striking feature of KSHV is the number (at least 
14) of ORFs that encode cellular orthologues. Identified ORFs and encoded proteins are 
indicated in the figure. Putative latent transcripts are indicated in green, and cellular 
orthologues in yellow. Infection occurs when glycoproteins on the surface of mature 
virions bind to receptors on the cell surface. After binding, clathrin-mediated endocytosis 
facilitates virion entry into the cell. Next, the viral DNA is rapidly transported into the 
nucleus and circularized, forming a dormant episome like other herpesviruses. Viral 
reactivation can occur when the promoter of ORF50 is activated (by demethylation, for 
example), resulting in the expression of replication and transcription activator (RTA), the 
main regulator for the viral lytic replication programme. Early lytic genes include those 
encoding viral proteins required for DNA replication or viral gene expression, whereas 
late lytic genes are those encoding viral structural proteins, such as envelope and capsid 
proteins that are required for assembly of new virions. 
 
 
 During the lytic phase of viral replication, when new virions are assembled, 
KSHV capsid proteins bind to KSHV DNA. The KSHV DNA is packaged into capsids as 
a single-copy linear DNA free of nucleosomes or other DNA binding proteins. The DNA-
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containing capsids then acquire tegument and envelope proteins and bud through the 
nuclear membrane into cytoplasm. These virions are transcytosed toward the plasma 
membrane within vesicles that ultimately fuse with the plasma membrane to release the 
virions into the extracellular space (108). 
5. KSHV entry into host cells 
KSHV entry into host cells is a complex multistep process involving virion 
attachment, endocytosis, trafficking, and nuclear transport. Virion attachment to the host 
cell is itself a two-stage process mediated by KSHV envelope glycoproteins which bind 
to host cell surface molecules (121, 158). First, KSHV glycoproteins gB (ORF 8), gH 
(ORF22), ORF4, and gpK8.1A bind to heparan sulfate, a cellular proteoglycan located on 
a variety of host cell types. Binding to heparan sulfate serves as an initial docking event, 
facilitating further interactions of the virion with more cell-specific receptors (2, 17, 59, 
162). One of these receptors is DC-SIGN, which facilitates binding to activated B cells, 
myeloid dendritic cells and macrophages (158). In addition, KSHV glycoprotein gB 
(ORF 8) contains a conserved integrin-binding RGD motif, enabling the protein to bind 
to integrins, α3β1 αVβ3, and αVβ5 (158). Furthermore, the 12-transmembrane 
glutamate/cysteine exchange transporter protein xCT, and the tyrosine kinase receptor 
EphA2 also serve as entry receptors for KSHV (60, 64). The use of multiple cellular 
receptor molecules is responsible for KSHV’s broad tropism. The interactions between 
KSHV envelope glycoproteins and cellular receptors trigger multiple downstream 
signaling cascades, leading to internalization of the virus by endocytosis or by direct 
fusion of the viral envelope with the plasma membrane. The viral capsid is transported 
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through the cytosol and the viral DNA is delivered into the host nucleus, where KSHV 
begins its life cycle (31).  
6. KSHV life cycle 
Following an acute primary infection, KSHV establishes life-long persistence in 
immune-competent individuals. As with all other herpesviruses, KSHV exhibits two 
distinct phases of gene expression in its life cycle – a latent phase and a lytic phase (19). 
During latency, only a handful of viral genes are expressed, in order for the virus to avoid 
detection by the host immune system. During the lytic phase, the entire KSHV genome is 
expressed in a highly ordered fashion in order to ensure efficient replication of viral DNA 
and its packaging into new virions. Whereas latency efficiently maintains the KSHV 
genome, periodic reactivation to lytic replication is necessary for the transmission and 
dissemination of KSHV into new cells and new hosts (172). Thus, both stages of the viral 
life cycle are essential for viral maintenance and propagation. The appropriate regulation 
of latent and lytic gene expression is extremely critical for viral pathogenicity, and KSHV 
has evolved complex regulatory mechanisms in order to ensure that the correct genes are 
active at the correct times.  
6.1 KSHV latency 
Latency is established rapidly following KSHV infection (within 24 hours of 
infection) and is considered the predominant stage of the KSHV life cycle (69). During 
latency, the KSHV genome persists as multi-copy circular episomes that are assembled 
into chromatin like nucleosomal structures; hence, the KSHV genome is chromatinized 
(172). KSHV episomes replicate using host cell machinery and segregate into the 
daughter cells during mitosis (159). As mentioned earlier, only a small proportion of 
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KSHV genes are transcribed during latency. Limited expression of KSHV genes during 
latency allow the virus to “hide,” as the majority of viral epitopes are not available for 
detection by the host immune surveillance. The handful of KSHV genes that are 
transcribed during latency ensures efficient maintenance of KSHV episomes, immune 
evasion, regulation of the host cell cycle, inhibition of host cell apoptosis, and 
suppression of KSHV lytic gene expression. 
The genes that are actively transcribed during latency are clustered in the latency 
locus of the KSHV genome (Fig 2). This locus transcribes viral genes including latency-
associated nuclear antigen (LANA or LANA-1,ORF73), viral cyclin (vCyc, ORF72), 
viral FLICE inhibitory protein (vFLIP, ORF71), Kaposin (ORF K12) and viral 
microRNAs (26, 47, 143). Regulation of latent gene transcription is a complex process 
that involves multicistronic transcripts, several alternative promoters and epigenetic 
regulation (65). LANA, vCyc, and vFLICE are expressed from the same major latency 
5.7 kb transcript that is differentially spliced. A separate 1.7 kb transcript contains 
vCyclin and vFLIP coding sequences. Transcription of the major latency mRNA 
encoding ORF71 to ORF73 is regulated by at least two promoters - a constitutively-
active latent promoter (LTc) and an alternate inducible promoter (LTi) which is normally 
inactive but can be activated by KSHV replication and the transactivator protein (RTA, 
ORF50) (157).  
In addition to these genes that are expressed in all latently-infected cells, the viral 
interferon regulatory factor (vIRF-3 or LANA-2, K10.5) is expressed in all latently-
infected PEL cells but not in latently-infected KS spindle cells (40, 136, 166). Whereas 
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the above-mentioned genes are considered “classic” latent genes, some other viral genes 
such as K1 and vIL6 are also likely to be expressed at low levels during latency (32). 
 
 
Figure 2: The KSHV latent transcript. This image from ‘Kaposi's sarcoma-associated 
herpesvirus latency-associated nuclear antigen induction by hypoxia and hypoxia-
inducible factors’ is reprinted here with the permission from the original publisher (157). 
Schematic diagram of the genomic organization of the region spanning ORFK12 
(Kaposin) through K14 (v-OX2) in the KSHV genome; this region includes ORF71 
through ORF73 (LANA) as well as the KSHV miRNA cluster. The numbers above the 
closed arrows correspond to positions of initiation/termination codons of the ORFs. Two 
arrows between K14 (v-OX2) and LANA denote the LANA constitutive (LTc) and RTA-
inducible (LTi) mRNA start sites. 
 
6.1.1 vCyclin 
vCyclin, the product of KSHV ORF72, is a functional homologue of the cellular 
gene cyclin D2. Each protein can form active holoenzymes with cyclin-dependent kinases 
(CDK) 4 and 6. However, vCyclin has a broader substrate range than its cellular 
counterpart, possessing the ability to associate with CDK-2 and CDK-9. In addition, the 
vCyclin-CDK6 holoenzyme is refractory to several cell cycle control mechanisms, thus 
deregulating the cell cycle. Intriguingly, overexpression of vCyclin induces p53-
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dependent growth arrest and cell apoptosis, activates the DNA damage response and 
increases autophagy (120).  
6.1.2 vFLIP 
vFLIP, encoded by K13, is a viral homologue of the cellular inhibitory protein 
FLICE (FADD-like interleukin-1 beta converting enzyme/caspase-8). vFLIP is capable of 
activating both classical and alternative NF-kB pathways, and is also known to block 
autophagy. Furthermore, vFLIP induces expression of inflammatory cytokines in 
endothelial cells in vitro (11).  
6.1.3 Kaposins 
The ORF K12 encodes three proteins, Kaposin A, Kaposin B and Kaposin C, by 
alternative splicing of a multicistronic transcript (140). Kaposin transcripts are some of 
the most abundant latency-associated viral transcripts. Kaposin A can induce cell 
transformation, whereas Kaposin B stabilizes AU-rich mRNAs. Since many cytokine 
mRNAs contain AU-rich elements, Kaposin B thus stabilizes transcripts of cytokines 
including IL-6 and GM-CSF (99). Knowledge regarding the function of Kaposin C is still 
limited. The relative expression of Kaposins A, B and C varies amongst different KSHV-
infected tissues (82). 
6.1.4 KSHV microRNAs 
KSHV encodes over 12 pre-miRNAs from the latent Kaposin promoter. Cellular 
proteins Drosha and Dicer process these pre-miRNAs to generate more than 24 mature 
miRNAs. Despite having a common promoter, the levels of these miRNAs are variable in 
latent KSHV-infected cell lines. In PEL cell lines, KSHV miRNAs are the most 
predominant miRNAs, indicative of their essential functions in regulation of the viral life 
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cycle (26, 54).  KSHV miRNAs target diverse cellular pathways in order to promote 
angiogenesis, regulate the cell cycle, inhibit apoptosis, evade host immunity, transform 
the infected cell and promote tumorigenesis (101, 124). KSHV-encoded miRNAs also 
suppress lytic reactivation in latently-infected cells by modulating the expression of 
cellular transcription factors including MYB, C/EBPα and Ets-1 (124).  
6.1.5 vIRF3 
KSHV encodes four interferon regulatory factors (vIRF1 to vIRF4) encoded by 
the cluster of ORFs K9, K11/11.1, K10.5/10.6, and K10. vIRFs share homology with 
cellular interferon regulatory factors (IRFs), and modulate the activities of cellular IRFs 
and interferons (IFNs). vIRF3, also known as latency-associated nuclear antigen-2 
(LANA-2), is encoded by ORF K10.5 and is constitutively expressed in PEL cell lines. 
Expression of vIRF3 has also been detected in MCD tumors, but not in KS spindle cells. 
vIRF3 shares significant homology with cellular IRF4 in its C terminus and with vIRF2 
in its N terminus (13, 147). vIRF3 is known to be an oncogene required for continuous 
proliferation and survival of PEL cells (166). vIRF3 also acts as a immune suppressor, in 
that it inhibits recognition of infected cells by CD4 T cells through CIITA-dependent and 
-independent interference with MHC II antigen presentation (138, 146, 166).  
6.1.5 LANA 
Latency-associated nuclear antigen (LANA, LANA-1), the key viral protein 
required for establishment and maintenance of KSHV latency, is encoded by KSHV 
ORF73. LANA is highly expressed in all latently-infected cells, whether normal or 
malignant (62, 67, 156, 161). LANA is a functional homologue of the Epstein Barr Virus 
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(EBV)-encoded protein EBNA1. Both are nuclear proteins that interact with numerous 
viral and cellular proteins (161).   
The LANA protein sequence consists of 1,162 amino acids, with a theoretical 
molecular mass of 135 kDa, but migrates on SDS-PAGE gels as if it was 220 kDa (161). 
LANA can be subdivided into three major domains: an N-terminal proline-rich domain, a 
central domain containing a glutamine-rich region and a variable number of acidic amino 
acid repeats, and a conserved C-terminal domain containing a leucine zipper motif (Fig 3) 
(62, 110). The N-terminal domain contains a chromosome binding site (CBS) and a 
nuclear localization signal (NLS). LANA has another NLS in its C-terminus, the N-
terminal NLS seems to be functionally dominant, as N-terminal deletion mutants of 
LANA accumulate in the cytoplasm (110). The C-terminal domain mediates LANA’s 
ability to dimerize and to bind to DNA. Post-translational modifications that regulate 
LANA activity include phosphorylation, acetylation, PARylation (Poly ADP-
ribosylation), SUMOylation (small ubiquitine-like modification), and arginine 
methylation ((10, 28, 29, 36, 51, 94, 111, 125).  
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Figure 3: A schematic showing the domain structure of LANA. LANA is an 1162 aa 
protein containing two nuclear localization sequences (NLS). The N-terminal domain 
contains a chromosome-binding site (CBS), the central domain contains an acidic region 
rich in aspartic and glutamic acid residues, a glutamine-rich region, and a leucine zipper 
motif (L-ZIP). LANA forms homodimers through its C-terminal domain and facilitates 
binding to LANA-binding sequences (LBS) in the KSHV genome.  
 
LANA is a multifunctional protein that interacts with many viral and cellular 
proteins (66) and binds to DNA. One of the main functions of LANA is the establishment 
and maintenance of viral episomes during latency. LANA binds to the terminal repeat 
region (TR) of the KSHV genome and employs host cell DNA replication machinery to 
replicate KSHV episomes (95). LANA also ensures the proper segregation of KSHV 
genomes during mitosis by tethering the episomes to host chromatin; this is accomplished 
by binding of the CBS to histones. LANA also binds to several cellular chromatin-
binding proteins, which together aid LANA in its episome tethering function. Some of 
these proteins include bromodomain-containing protein Brd4, methyl-CpG binding 
protein MeCP2, DEK, and nuclear mitotic apparatus protein (NuMA) (12, 39, 58, 62, 87, 
123, 156, 175).  
In addition to its role in the maintenance of viral episomes, LANA has 
demonstrated roles in cellular transformation and blocking of apoptosis (3, 22, 24, 25, 53, 
76, 95, 96, 142, 156), cell cycle regulation (70, 90), angiogenesis (24, 117, 163), and 
immune evasion (23, 37). Pro-survival and transformative activities of LANA can be 
partially attributed to LANA’s ability to bind to and inhibit the activities of the tumor 
suppressor proteins p53 and Rb.  LANA can also bind to glycogen synthase kinase 3β 
and sequester it in the nucleus, resulting in the accumulation of baccumula and 
consequent upregulation of pro-survival proteins cyclin D and c-Myc. Expression of 
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LANA in endothelial cells is known to induce expression of angiogenin, a potent 
stimulator of endothelial cell proliferation and angiogenesis (139). Furthermore, LANA 
can bind to death-domain associated protein-6 Daxx, thereby relieving Daxx’s repression 
of Ets-1-dependent VEGF receptor expression in order to boost angiogenesis (105). 
LANA also promotes angiogenesis by upregulating Hey1, an essential Notch signaling 
pathway member (163). LANA is known to deregulate host immunity by impairing 
neutrophil chemotaxis to the site of infection and interfering with the TNF-α signaling, 
interferon signaling, MHC I antigen presentation and MHC II antigen presentation 
pathways (23, 37, 71, 83, 176).  
 LANA is a potent transcription modulator of many cellular and viral genes (133). 
LANA can activate or inhibit expression of many genes through direct or indirect 
mechanisms. For example, LANA can indirectly activate transcription of genes with 
promoters containing binding sites for transcription factors such as ATF, CAAT, AP-1 or 
SP1 (133). On the other hand, LANA can indirectly repress transcription via association 
with co-repressor proteins such as mSIn3, SAP30, CIR, the methyl CpG-binding protein 
MeCP2, and the histone methyl transferase SUV39H1. LANA can also repress 
expression of KSHV genes by directly associating with the viral DNA, e.g. ORFK1 
(160). LANA inhibits expression of the transcription activator RTA (ORF50), the lytic 
master switch protein, in order to suppress the lytic replication cycle. At the same time, 
LANA can auto-regulate its own expression by binding directly to its own promoter. 
Thus, LANA serves pleiotropic roles in maintenance of KSHV latency and is 
indispensible for the life-long persistence of KSHV.   
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6.2 KSHV lytic replication 
Whereas latent infection is important for viral persistence and for maintaining a 
continuous viral reservoir, lytic infection is essential for viral spread to other cells and 
tissues of the same individual, as well as between different individuals. Whereas the 
majority of KSHV-infected tumor cells harbor the KSHV genome in a latent stage, a 
subset (1 to 3%) of these latently-infected cells are estimated to undergo spontaneous 
lytic replication (18, 30, 68, 112, 115, 151).  The lytic replication cycle has important 
pathological consequences, as many lytic proteins trigger the release of cellular 
inflammatory cytokines and several lytic proteins have oncogenic and angiogenic 
potential (5, 9, 20, 52, 77, 102, 144).  
In contrast to latency, the lytic replication cycle activates most of the KSHV 
genes, in a highly-regulated sequential manner. KSHV lytic genes can be broadly 
classified into three major groups: immediate early (IE), early or delayed early (E or DE), 
and late (L), based on their timing of expression. As the name suggests, the immediate 
early genes are the first set of KSHV genes expressed during reactivation of the lytic 
replication cycle, or following viral entry into the host cells. In the latter case, these genes 
generally do not require de novo protein synthesis, and hence their expression is 
insensitive to treatment with the eukaryotic protein synthesis inhibitor cyclohexamide. 
The immediate early KSHV proteins predominantly serve regulatory roles. The 
immediate early protein RTA (ORF50) is one of the earliest KSHV proteins detected 
following de novo infection. RTA auto-regulates its own promoter and also transactivates 
the promoters of many viral and cellular genes. Immediate early proteins are also 
required for transcription of early and late genes, which are sensitive to cyclohexamide. 
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KSHV early genes encode accessory proteins or have enzymatic activities, and are 
mainly involved viral DNA replication. Some of the early proteins also regulate gene 
expression or promote immune evasion. Late genes typically encode virion structural 
proteins such as capsid and envelope proteins (130). At the end of a productive lytic 
cycle, the infected cell is lysed, releasing new virions into the surrounding environment.  
Virally-encoded proteins ensure efficient viral DNA replication under cellular 
conditions that may not be favorable for viral DNA replication. Like other herpesviruses, 
KSHV lytic DNA replication initiates from the origin of replication and proceeds via the 
rolling circle mechanism. Two functional origins of lytic replication that share high 
sequence homology with each other have been identified in the KSHV genome. Of these 
two origins of lytic DNA replication, Ori-Lyt-L (located between K4.2 and K5) is 
sufficient to propagate the viral genome, whereas Ori-Lyt-R (located between ORF69 and 
vFLIP) is not sufficient propagate the viral genome (6, 171).  
The switch from latent to lytic infection primarily depends on the expression of 
ORF50/RTA, the key initiator that has been demonstrated to be both necessary and 
sufficient to drive productive lytic replication by numerous studies. In vitro ectopic 
expression of RTA leads to activation of the full cycle of KSHV lytic gene expression, 
and deletion or inhibition of RTA prevents lytic cycle reactivation (153). Whereas the 
majority of factors that activate lytic replication do so by activating RTA expression, 
alternative pathways are likely to exist. The discovery that lytic replication can be 
triggered by apoptosis in the absence of RTA expression strongly suggests that KSHV 
has backup pathways that detect adverse cellular conditions limiting RTA expression 
(127, 128).  
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Numerous complex mechanisms are involved in lytic reactivation and many 
triggers can activate the lytic replication cycle. These include chemicals like sodium 
butyrate and TPA that are routinely used to induce lytic replication in vitro (97). In 
addition, many cellular stresses such as oxidative stress or inflammation can lead to viral 
reactivation (130). Other physiological factors influencing lytic reactivation include co-
infection with other viruses, apoptosis and the immune status of the infected host. For 
example, during KSHV/Epstein-Barr virus (EBV) co-infection, EBV inhibits KSHV lytic 
replication, probably because the two viruses compete for the same limited cellular 
resources; hence, the two viruses have evolved mechanisms to inhibit lytic replication of 
each other (170). The immune status of the infected host is probably the most important 
factor controlling viral reactivation. A strong immune system limits KSHV lytic 
reactivation, as the immune system attacks viral epitopes and thereby keeps KSHV lytic 
replication in check. Conversely, lytic replication is unchecked when the immune system 
is compromised, as indicated by high viral titers and the resultant detection of antibodies 
against lytic proteins in the blood (97). As mentioned earlier, apoptotic signals can also 
lead to viral reactivation (127).  Thus, KSHV is well-equipped to sense adverse cellular 
conditions that could threaten viral persistence, and the virus responds to these 
unfavorable conditions by producing more virions through lytic reactivation. 
Overview of the thesis 
7.1. Transcriptome analysis of Kaposi’s sarcoma-associated herpesvirus during de 
novo primary infection of human B and endothelial cells 
 During the latent phase, the KSHV genome is silently maintained without 
production of functional virions. Hence, a latent phase on its own is not sufficient to 
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propagate viral spread in the infected host. In the absence of productive lytic replication, 
one can expect the virus to eventually disappear when the latently-infected cells die. 
Indeed, in culture, latent KSHV episomes tend to be lost from a wide variety of dividing 
cells (57). Accordingly, a continuous lytic replication is necessary for the spread of the 
virus within the infected host. Due to this necessity, a small proportion (1-5%) of the 
latently infected cells routinely undergo spontaneous lytic replication. Nascent virions 
that are released at the end of lytic replication cycle infect fresh cells in order to 
perpetuate viral infection. The process of nascent virions infecting fresh cells is called de 
novo, or primary, infection. De novo infection begins when newly-released virions bind 
to cell surface receptors of uninfected target cells. A successful viral infection involves 
virion internalization in an endosome, fusion of the viral envelope with the endosomal 
membrane, transport of the viral capsid to the nucleus, release of the viral DNA from the 
capsid in the nucleus and finally formation of latent episomes (31). 
During these early events the virus has to face many challenges. For example, 
detection of KSHV as an intracellular pathogen may trigger innate and adaptive host 
immune responses that may result in apoptosis or destruction of the infected cell. A 
successful viral infection critically depends upon whether the virus is capable of 
overcoming these challenges successfully. Fortunately for the virus, it is well-equipped to 
face the challenges imposed by the host. During the very early period of de novo 
infection, proteins present in the virion manipulate the cellular environment to make it 
conducive for viral infection. In order to understand the host-virus interactions that make 
KSHV an extremely successful intracellular pathogen, we must first know which proteins 
are present in the virion and which viral genes are activated during early infection. 
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Hence, this calls for a clear understanding of the viral genes that play an important role 
during the early events of infection. Several previous studies have probed the events that 
happen during early KSHV infection (14, 15, 69, 107). These studies have revealed that 
during de novo infection, KSHV typically establishes latency by 24 hours post infection 
(15). Before that, there is an initial burst of viral gene expression that includes a subset of 
lytic genes. However, the lytic cycle that is induced during this period is transient and is 
followed by rapid establishment of latency, as indicated by the presence of latent gene 
transcripts. Additionally, KSHV virions are known to contain a variety of proteins and 
several RNA species including viral gene transcripts, cellular and viral microRNAs and 
noncoding RNAs (14,	  88).	  Whereas these studies have provided significant insights into 
the elements present in the virion and the viral genes that are expressed immediately 
following infection, the complete picture has not fully emerged. The open questions 
necessitate further research on this process. The study included here as Chapter 1, and 
originally published as “Transcriptome Analysis of Kaposi’s sarcoma-Associated 
Herpesvirus during De Novo Primary Infection of Human B and Endothelial cells” in the 
March 2015 issue of the Journal of Virology, extends the previous studies by analyzing 
the viral genes that are transcribed early during de novo infection of human peripheral 
blood mononuclear cells (PBMCs), CD14+ monocytes, and telomerase-immortalized 
vascular endothelial cells (TIVES) (129). In this study, we performed a comprehensive 
analysis of the KSHV transcriptome during multiple time-points of infection (0, 4, 24, 48, 
72 and 120 h post infection) in these three cell types. We used unbiased RNA 
sequencing, followed by confirmation of the findings by quantitative real-time PCR 
(qPCR). We also distinguished between the transcripts that are actively transcribed upon 
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infection and the transcripts that are brought into the cell by the virion. Furthermore, we 
identified viral transcripts that appear to be selectively packaged into the virion, by 
comparing the relative abundance of the transcripts in the virions versus the relative 
abundance in the infected cells during virion assembly. The data obtained in this study 
have provided insights into the early events that happen during de novo infection by 
KSHV. In this study, many more transcripts were identified than reported previously. The 
key findings of this study include: (i) several latent and lytic transcripts co-exist, 
indicative of a complex pattern of gene expression during early infection. Importantly, 
(ii) many of the viral transcripts we detected are those required for active lytic 
replication, raising the possibility that the viral genome is actively replicated during early 
infection. In fact, we observed a significant increase in the KSHV genome copy number 
following de novo infection. This replication presumably accounts for the large number 
of viral episomes observed in latently-infected cells.  Finally, (iii) transcripts of a larger 
number of latent and lytic genes were detected in this study as compared to the previous 
studies, possibly due to the transcripts that are packaged by the virions. Many noncoding 
RNAs were also detected in this study.  
7.2 KSHV LANA inhibits MHC II expression by disrupting enhanceosome assembly 
through binding with the RFX complex 
One important characteristic of KSHV infection is the virus’s ability to persist for 
life in the infected host. Whereas a healthy immune system is capable of controlling 
KSHV infection and its associated malignancies, the immune system does not recognize 
latently-infected cells and thus can never fully eradicate the virus from the body. KSHV 
is a very sophisticated virus in terms of immune evasion. Over millions of years of co-
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evolution with humans, KSHV has developed an impressive array of immune evasion 
and modulation strategies to protect the virus from being eliminated by the host immune 
response. Not surprisingly, at least 22 KSHV proteins are thought to have immune 
modulatory functions, many of which were copied from the host during evolution (4, 38, 
135). The list of KSHV genes implicated in immune evasion/modulation is ever-
increasing and not only includes proteins but also miRNAs and noncoding RNAs such as 
PAN RNA. Immune modulatory mechanisms employed by KSHV are elaborate and 
finely-coordinated, that effectively disrupt nearly every aspect of host immunity, both 
innate and adaptive (reviewed in (78-80, 85)). 
Sustained latency in the infected host is a hallmark of KSHV infection. Whereas 
immune evasion is essential for KSHV at all stages of its life cycle, immune evasion is 
more critical during latency due to its long-term nature. A successful latency requires 
minimal exposure of KSHV epitopes to the host immune system and hence latency is 
characterized by expression of only a limited number of KSHV genes (85). Amongst the 
handful of genes that are expressed during latency, most have demonstrated immune 
modulatory roles. For example, vFLIP is involved in anti-apoptotic and anti-autophagy 
activities (16, 49, 81, 91). Furthermore, expression of vFILIP in endothelial cells in 
transgenic mice has been shown to cause immune dysfunction by interfering with 
germinal center formation and Ig maturation (11). The miRNAs miR-k9 and miR-k5 
have been demonstrated to regulate TLR/IL1R signaling (1, 78). miR-K-12-10 inhibits 
expression of the pro-inflammatory chemokines IL-8 and MCP-1 by blocking the activity 
of TWEAKR (tumor necrosis factor-like weak inducer of apoptosis receptor) (131). 
vIRF3 can interfere with the interferon pathway, a critical component of innate immunity, 
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by associating with nuclear interferon regulatory factors 3, 5 and 7 (IRF-3, IRF-5 and 
IRF-7). vIRF3 also interferes with adaptive immunity by down-regulating MHC II 
expression, at least in part through inhibition of class II transactivator (CIITA) 
expression, a critical transcription factor for MHC II genes (178). LANA, being an 
essential multifunctional protein for establishing and maintaining KSHV latency, can be 
expected to play important roles in immune evasion by the virus during latency. Indeed, 
several immune evasive/modulatory roles for LANA have been identified, and many 
more are likely to exist. For example, LANA regulates its own expression and acts in cis 
to inhibit transcription of other viral genes, reducing the number of epitopes available for 
detection (176). LANA also interferes with neutrophil recruitment, TNF-α signaling and 
INF-ϒ signaling (37, 83). 
Adaptive host immunity plays a critical role in controlling KSHV infection and 
progression of KSHV-associated tumors. However, efficient activation of the adaptive 
immune system requires the processed antigens to be displayed in conjugation with either 
MHC I (expressed on all cells) or MHC II (expressed on antigen-presenting cells such as 
macrophages and B cells). Interestingly, B cells are the primary reservoir of KSHV 
latency. LANA has previously been shown to inhibit both MHC I and MHC II antigen 
presentation pathways (23, 71, 176). Expression of MHC II genes, which is 
predominantly controlled at the level of transcription, requires binding of CIITA to the 
highly-conserved promoters of the MHC II genes. Transcription of CIITA itself is 
activated by interferon regulatory factor 4 (IRF-4). LANA binds to IRF-4, preventing it 
from activating CIITA transcription, decreasing the levels of CIITA protein, which 
decreases transcription of MHC II genes and thereby decreases antigen presentation (23). 
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In Chapter 2 of this thesis, originally published as ‘KSHV LANA Inhibits MHC II 
Expression by Disrupting the Enhanceosome Assembly through Binding with the RFX 
Complex’ in the March 2015 issue of the Journal of Virology, we describe yet another 
mechanism employed by LANA that interferes with the MHC II antigen presentation 
pathway. The mechanism that we have elucidated appears to be operating one step 
downstream of the inhibition of CIITA transcription by LANA. We show that LANA 
also interacts with the proteins of the regulatory factor X complex, proteins critical for 
recruitment of CIITA to the MHC II promoters. When LANA binds to the regulatory 
factor X complex, it impedes recruitment of CIITA to the MHC II promoters, a process 
that is mandatory for the expression of MHC II genes (155). The fact that LANA 
employs multiple mechanisms to target the MHC II pathway emphasizes the importance 
of avoiding MHC II antigen presentation during KSHV latency. 
7.3 KSHV LANA induces expression of EGFL7 to promote angiogenesis 
KSHV is named after Kaposi’s sarcoma, a highly angiogenic multifocal 
malignancy caused by its infection. Angiogenesis refers to the formation of new blood 
vessels from pre-existing ones. KS is a highly-vascularized tumor of endothelial cell 
origin that contains high levels of multiple inflammatory cytokines and pro-angiogenic 
molecules which contribute to the pathogenesis of the disease (46). The importance of 
angiogenesis in KS tumor progression is highlighted by the fact that KS tumors are 
highly vascularized even at the early stages of the tumor development. Several well-
known angiogenic cytokines including vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (b-FGF), angiopoietin-2, angiogenin and cyclooxygenase-2 
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(COX-2) are known to be induced during KSHV infection (107, 119, 126, 139, 148-150, 
173, 174).  
Epidermal growth factor-like protein 7 (EGFL7), also known as vascular 
endothelial statin (VE statin), is a small (~30 kDa) secreted pro-angiogenic cytokine that 
is highly conserved in vertebrates (109). Under physiological conditions, its expression is 
normally restricted to actively-proliferating endothelial cells during wound healing, 
pregnancy and embryonic development (27, 50, 109). However, in many solid tumors, 
which depend on angiogenesis for survival, tumor cells secrete EGFL7 to promote 
angiogenesis (44, 63, 167). A number of independent observations when taken together 
suggest that EGFL7 upregulation might have important implications during KSHV 
infection. For example, a few recent studies have established EGFL7 as a gene regulated 
by oxygen levels, with hypoxia being an inducer of EGFL7 expression (7, 84, 92). 
Interestingly, KS tumors frequently arise at locations with low oxygen levels such as the 
feet (41). Furthermore, hypoxia induces lytic reactivation of KSHV, which contributes to 
the progression of KS tumors. Additionally, EGFL7 seems to execute its pro-angiogenic 
effects through the activation of MAPK, PI3K and Notch signaling pathways (98). 
Interestingly, KSHV also targets these same signaling pathways in order to modulate 
cellular functions for its own advantage (48, 61, 72-75, 86, 114, 163). Collectively, these 
findings point towards an important role for EGFL7 during KSHV infection.  
LANA has been shown to promote endothelial cell proliferation and angiogenesis 
through manipulation of multiple signaling pathways (25, 118, 164). In particular, LANA 
is known to modulate the Notch signaling pathway in order to promote angiogenesis 
(163), similar to EGFL7. In an unbiased sequencing screen to identify cellular genes 
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modulated by LANA in KSHV-negative BJAB cells, we identified EGFL7 as a cellular 
gene induced by LANA. Considering the biological importance or EGFL7 in promoting 
angiogenesis in a variety of cancers, and based on the indirect evidence that points 
towards the role of EGFL7 in KSHV-induced angiogenesis, we aimed to study the 
regulation of EGFL7 expression by LANA. 
In the study described in Chapter 3 of this thesis, we show that LANA upregulates 
expression of EGFL7. Whereas this study is still in its early stages, we have convincing 
data that LANA positively regulates expression of EGFL7. Interestingly, in addition to 
inducing EGFL7 expression in endothelial cells, LANA also induces expression of 
EGFL7 in B cells. Since B cells are not known to be directly involved in the process of 
angiogenesis, an involvement of paracrine mechanisms for promotion of angiogenesis by 
KSHV is highly plausible. Our data show that KSHV-positive tissues and KSHV-positive 
PEL cells show increased expression of EGFL7. The mechanism of EGFL7 up-regulation 
by LANA seems to involve sequestration of DAXX (a suppressor of Ets-1 expression) by 
LANA. Ets-1 is a transcription factor required for the expression of EGFL7. We further 
show that increased expression of EGFL7 contributes to the promotion of angiogenesis 
by LANA, as knockdown of EGFL7 in LANA-expressing endothelial cells using siRNA 
results in decreased in vitro tubulogenesis. Further research is required to fully elucidate 
the detailed mechanism and significance of LANA-mediated upregulation of EGFL7 
expression. 
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Kaposi’s sarcoma-associated herpesvirus (KSHV) infects many target cells (e.g., 
endothelial, epithelial, and B cells, keratinocytes, and monocytes) to establish lifelong 
latent infections. Viral latent-protein expression is critical in inducing and maintaining 
KSHV latency. Infected cells are programmed to retain the incoming viral genomes 
during primary infection. KSHV transcribes many lytic genes immediately after 
infections that modulate various cellular pathways to establish successful infection. 
Analysis of the virion particle showed that the virions contain viral mRNAs, micro-RNAs, 
and other noncoding RNAs that are transduced into the target cells during infection, but 
their biological functions are largely unknown. We performed a comprehensive analysis 
of the KSHV virions packaged transcripts and the profiles of viral genes transcribed after 
de novo infections of various cell types (human PBMCs, CD14+ monocytes, and TIVE 
cells), from viral entry until latency establishment. A next-generation sequence analysis 
of the total transcriptome showed that several viral RNAs (polyadenylated nuclear RNA, 
ORF58, ORF59, T0.7, and ORF17) were abundantly present in the KSHV virions and 
effectively transduced into the target cells. Analysis of the transcription profiles of each 
viral gene showed specific expression patterns in different cell lines with majority of the 
genes, other than latent genes, silencing after 24h post-infection. We differentiated the 
actively transcribing genes from the virions transduced transcripts using a nascent RNA 
capture approach (Click-It chemistry), which identified transcription of a number of viral 
genes during primary infection. Treating the infected cells with phosphonoacetic acid 
(PAA), to block the activity of viral DNA polymerase, confirmed the involvement of 
lytic DNA replication during primary infection. To further understand the role of DNA 
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replication during primary infection, we performed de novo PBMC infections with a 
recombinant ORF59 deleted KSHV virus, which showed significantly reduced viral 
copies in the latently infected cells. In summary, the transduced KSHV RNAs as well as 
the actively transcribed genes control critical processes of early infection to establish 
KSHV latency. 
Importance: 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of multiple 
human malignancies in immunocompromised individuals. KSHV establishes a lifelong 
latency in the infected host, during which only a limited number of viral genes are 
expressed. However, a fraction of latently infected cells undergo spontaneous reactivation 
to produce virions that infect the surrounding cells. These newly infected cells are primed 
early on to retain the incoming viral genome and induce cell growth. KSHV transcribes a 
variety of lytic proteins during de novo infections that modulate various cellular pathways 
to establish the latent infection. Interestingly, a large number of viral proteins and RNA 
are encapsidated in the infectious virions and transduced into the infected cells during a 
de novo infection. This study determined the kinetics of the viral gene expression during 
de novo-KSHV infections and the functional role of the incoming viral transcripts in 
establishing latency. 
Introduction: 
Kaposi’s sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 
(HHV8), is a double-stranded DNA virus that causes Kaposi’s sarcoma, primary effusion 
lymphomas, and multicentric Castleman’s disease (1-3). Like other herpesviruses, KSHV 
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exhibits both latent and lytic modes of infection, persisting predominantly in the latent 
state in which only a subset of the viral proteins are expressed, including the latency-
associated nuclear antigen (LANA) protein (4-8). Although the expression of latent 
proteins plays a critical role in inducing and maintaining KSHV latency, the infected cells 
are primed early on during the primary infection to retain the viral genomes and induce 
tumors (9). During the primary infection, KSHV undergoes a short lytic-replication cycle 
that transcribes an array of viral genes, which are shown to modulate various pathways 
for establishing the latent infection (9). In addition, a small fraction (1–5%) of the 
infected cells spontaneously undergo lytic reactivation to produce infectious virions, 
which is likely to be essential for increasing the population of infected cells and inducing 
viral pathogenesis (10-13). 
The infection of target cells with KSHV is a complex multistep process involving 
a variety of host-cell surface receptors and multiple viral glycoproteins. Irrespective of its 
mechanism of entry, for a successful infection, KSHV must overcome the obstacles it 
encounters during the transportation of viral capsids from the plasma membrane into the 
nucleus. The main obstacles include apoptosis triggered by the virus’s binding and entry, 
autophagy, and the induction of various intrinsic, innate, and adaptive immune responses 
(14, 15). The mechanisms by which KSHV successfully circumvents these obstacles are 
beginning to be resolved. During de novo infections, KSHV generally establishes latency 
by 24 h post-inoculation (hpi) in cell culture systems (14, 16-20). However, very early on, 
immediately after a de novo infection, KSHV undergoes a limited initial burst of lytic 
transcript accumulation (14). At this point, the viral gene expression shows a more 
complex pattern, wherein the latent and lytic genes are expressed concurrently, with an 
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initial moderate proportion of lytic transcripts followed by the onset of accumulating 
more latent transcripts (14).  
It has been shown that another gamma herpesvirus, Epstein-Barr virus (EBV), 
exhibits a similar pattern during early infection. The primary infection of B cells by EBV 
shows an expression of lytic genes (21-23). The expression in the lytic genes before the 
latent genes during early infection suggests that this initial expression of lyitc gene are 
important for the successful establishment of EBV latency (21, 22). It has also been 
shown that EBV viral particles contain mRNAs and other nonstructural RNAs that are 
transduced into the target cells early during infection (22). These mRNAs play crucial 
roles during infection to establish the EBV latency (22). The detection of lytic transcripts 
early on during de novo-KSHV infections followed by the latent transcripts suggests that 
a mechanism similar to that of EBV may be occurring during the primary infection of 
KSHV. Additionally, the concurrent expression of ORF73 and ORF50 transcripts, 
detected early during KSHV infection at 2 and 4 hpi (9), respectively, indicates that these 
transcripts might be transported into the newly infected cell during the virus entry and are 
involved in altering the cellular environment prior to transcription from the incoming 
viral genome. 
Indeed, several recent studies have shown that herpesviruses, including KSHV 
virus particles, contain a variety of viral proteins (24, 25) and diverse RNA species such 
as viral mRNA, non-coding RNA, viral and cellular micro-RNA (miRNA), and unusual 
small RNA (usRNA) (26, 27). These RNAs are selectively packaged during virion 
budding and released into the target cells during de novo infection, and they have been 
shown to be biologically functional (27). The KSHV ORF59 transcript is also present in 
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the virions and translated very early during primary infection (27). Recent studies have 
similarly shown that several of the viral and cellular miRNAs are selectively packaged 
into the virions and released into the target cells during infection (26). However, the exact 
composition of the virion transcripts in the KSHV particles and their functions remain 
unclear (27). A recent study reported a higher transient expression of lytic genes at 24 hpi 
in comparison to the latently infected cells. Moreover, the KSHV genome undergoes 
rapid chromatinization following infection, indicating that the initial burst of lytic gene 
transcription likely originates from transcriptionally permissive chromatin rather than 
from incoming naked DNA (28). 
This study aimed to analyze the viral genes transcribed early on during the 
primary infection of PBMCs, CD14+ and TIVE cells. To differentiate the RNAs present 
in the virion and transcribed early during primary infection, non-internalized virions were 
removed from the cell surface by treating the cells with trypsin at 2 hpi, followed by 
capturing the nascently transcribing RNA after 4 and 24hpi. Also, the cells were collected 
at 0, 4, 24, 48, 72, 96, and 120 hpi to extract total RNA for the transcriptomic profiling 
and real-time quantitative PCR (qPCR) analysis. The encapsulated RNA in the virions 
was determined by an RNA-sequencing (RNA-seq) analysis as well as by reverse 
transcription quantitative real-time PCR (RT-qPCR) for all of the viral genes. We 
captured newly synthesized RNA with a Click-iT technology during the de novo-PBMC 
infections to identify the actively transcribing gens. The treatment of KSHV infected 
human PBMCs with phosphonoacetic acid (PAA), to block the viral DNA polymerase 
activity, determined the involvement of lytic DNA replication during primary infection. 
To understand the functional significance of the lytic genes transcription during KSHV 
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infection and the establishment of latency, we investigated the role of ORF59, an 
abundantly packaged mRNA in the virions that is transcribed during primary infection. 
The infectious recombinant KSHV BAC36WT and its ORF59-deletion mutant 
(BAC36ΔORF59) were used for de novo-PBMC infections. The infected cells showed 
that virions from the ΔORF59 cells were not able to attain latent genomic copies as high 
as the wild-type BAC36 virus, suggesting a defect in the lytic DNA replication. Overall, 
our data shows that a large number of virion transcripts are transduced into the host cells 
along with the viral genome during the infection of the target cells, which helps in 
amplifying the viral genome copies and latency establishment. 
Materials and Methods: 
Cell culture, plasmids, and antibodies  
The KSHV-positive cell line TRExBCBL1-RTA, provided by Dr. Jae Jung 
(University of Southern California), was cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 5 U/mL penicillin, 5 µg/mL 
streptomycin, and 20 µg/mL hygromycin B. Cells (293L) harboring either BAC36WT or 
BAC36ΔORF59 were cultured in Dulbecco modified Eagle medium supplemented with 
10% FBS, 2 mM L-glutamine, 5 U/mL penicillin, 5 µg/mL streptomycin, and 50 µg/mL 
hygromycin B. Telomerase-immortalized vascular endothelial (TIVE) cells, kindly 
provided by Dr. Erle S. Robertson, were cultured in endothelial basal medium-2 (Lonza) 
supplemented with endothelial growth factor supplements (Lonza). Human PBMCs 
(ReachBio, WA) were cultured in RPMI 1640 medium (Hyclone) supplemented with 
10% FBS, 2 mM L-glutamine, and penicillin/streptomycin (5 U/mL and 5 µg/mL, 
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respectively). Human CD14+ cells were isolated from cord blood received from the 
Colorado Cord Blood Bank (University of Colorado). Cells were maintained in Iscove 
Modified Dulbecco Medium (Hyclone), supplemented with 20% heat-inactivated FBS 
(Hyclone), 50 ng/mL macrophage colony-stimulating factor (M-CSF), 50 ng/mL stem 
cell factor, 50 ng/mL granulocyte CSF (G-CSF), 50 ng/mL GM-CSF, and 50 ng/mL 
interleukin-3 (R&D Systems), at a density of 1 × 106 cells/mL on a low cell-binding plate 
(Nunc Hydrocell). Protocols to obtain blood-associated cells were approved by the 
Institutional Review Board and Office of Human Research Protection at the University of 
Nevada, Reno. The plasmid pA3F-LANA, carrying a flag-tagged ORF73, has been 
previously described (29, 30). Commercially available antibodies mouse anti-K8.1 and 
rat anti-LANA (Advanced Biotechnologies, Inc.), were used in this study. 
KSHV virion purification  
KSHV virions were purified as previously described (26, 27). Approximately 100 
million TRExBCBL1-RTA cells were induced with doxycycline (1 µg/mL) for 5 days, 
after which the culture supernatant was collected, centrifuged at 4000 rpm for 10 minutes, 
and filtered through a 0.45 µM filter to remove cellular debris before concentrating the 
virus by centrifugation at 25,000 rpm for 2 h at 4°C. The concentrated virions were 
resuspended in 1 mL phosphate-buffered saline (PBS), layered onto a 30–50% sucrose 
gradient, and centrifuged at 70,000 × g for 2 h. The purified virions formed a white 
opaque ring, which was collected in a syringe by puncturing the tube with the needle at 
the band site. The collected band was diluted with PBS before centrifuging for 2 h at 
25,000 × g to pellet the virions. 
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Western blot  
The purified virus particles were resuspended in 100 µL of lysis buffer [50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.25% sodium deoxycholate, and 1% 
NP40] supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 10 
µg/mL pepstatin, 10 µg/mL leupeptin, and 10 µg/mL aprotinin). The lysates were 
centrifuged at high speed, mixed with protein sample buffer, resolved the protein on a 4-
15% SDS-PAGE, and Western blotted using standard protocols (Bio-Rad Laboratories). 
The KSHV-encoded structural glycoprotein K8.1 was detected using mouse anti-K8.1 
antibody followed by incubation with infrared dye-tagged (IR680, IR800) secondary 
antibodies and scanning with an Odyssey infrared scanner (LI-COR Biosciences, Lincoln, 
NE). 
KSHV de novo infection  
Approximately 8 × 107 human PBMCs were infected with KSHV purified from 
the induced TRExBCBL1-RTA cells. Two hours after infection at 37°C in the presence 
of 8 µg/mL polybrene, the cells were washed once with 0.005% trypsin in PBS and three 
times with PBS to remove the loosely bound virions, after which they were resuspended 
and maintained in RPMI 1680 medium until harvesting. The de novo KSHV-infected 
PBMCs (~5 × 106) were collected at different time points, washed twice with PBS, and 
processed separately to isolate the DNA and RNA. 
Indirect immunofluorescence microscopy  
At 120 hpi, KSHV-infected PBMCs were washed with PBS, spread evenly on 
cover slips, and air-dried. The cells were fixed for 10 min at room temperature with 4% 
paraformaldehyde and permeabilized with 0.2% Triton X-100 in PBS for 10 min, also at 
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room temperature. The cells were blocked by incubating in PBS containing 0.4% fish 
skin gelatin and 0.05% Triton X-100. The fixed cells were then incubated with primary 
rat anti-LANA antibody for 1 h at room temperature, washed with PBS, incubated with 
Alexa Fluor 488 secondary antibody (Molecular Probes) for 45 min at room temperature, 
and washed with PBS. The nuclear stain TO-PRO-3 (Molecular Probes) was used for 
counterstaining the nucleus. Images were obtained using a laser scanning confocal 
microscope (Carl Zeiss, Inc.). 
Flow cytometry  
PBMCs de novo-infected with KSHV were harvested 120 hpi and fixed in Streck 
tissue fixative (STF, Streck Laboratories) for 30 min. The fixed cells were washed twice 
in 1× PBS, permeabilized with 0.2% Triton X-100, blocked with 0.4% fish skin gelatin, 
and incubated with fluorescently tagged mouse anti-CD19 (Alexa Fluor 488), mouse anti-
CD3 (Alexa Fluor 488; Rockland Immunochemicals, Inc.), and rat anti-LANA 
(Advanced Biotechnologies, Inc.), which was detected with a secondary antibody 
conjugated to Alexa Fluor 555 (Rockland Immunochemicals, Inc.). The data were 
acquired on a FACSCalibur flow cytometer equipped with CellQuest Pro software and 
analyzed using FlowJo software. 
Viral genome extraction and quantification  
De novo-infected cells were collected by centrifugation (~2 × 106 cells per 
sample) and washed twice with PBS before extracting the total DNA using a modified 
Hirt lysis method (31). The PCR primers used for the KSHV genome quantification were 
selected from the ORF73 gene as previously described (9, 32). Two-fold serial dilutions 
of the pA3F-LANA plasmid were used as template in qPCR reactions to produce a 
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standard curve for the quantifications. The extracted total DNA was resuspended in 50µL 
sterile water, and a 5µL aliquot of the DNA was used for the qPCR amplification of the 
KSHV-ORF73-specific sequence. The viral DNA copy numbers were calculated with 
reference to the standard curve 
RNA preparation and sequencing  
The RNA-seq of the KSHV virions and de novo-infected PBMCs was performed 
on a HiSeq next-generation sequencer (Illumina, Inc.). Total RNA was isolated from the 
purified KSHV virions after treating them with micrococcal nuclease (NEB) for 30 min 
at 37°C and terminating the reaction with EGTA. The total RNA was isolated with 
TRIzol reagent per the manufacturer instructions (Life Technologies), and viral DNA was 
eliminated by treating with DNase I (GE Health Care Life Sciences), which was 
subsequently inactivated. The total RNA from the de novo-infected PBMCs was prepared 
using an Illustra RNAspin Mini kit with an in-column DNase treatment per the 
manufacturer instructions (GE Health Care Life Sciences). The concentration and purity 
of the extracted RNA was determined with a NanoDrop 2000c spectrophotometer 
(NanoDrop Technologies). A TrueSeq RNA sample preparation kit v2 (Illumina, Inc.) 
was used to prepare cDNA libraries for the RNA-seq according to the manufacturer 
instructions. The fragment sizes and purity of the mature libraries were confirmed by 
analyzing on a Bioanalyzer 2100 (Agilent Technologies). The quantities of the libraries 
required for RNA-seq were determined by real-time qPCR using a KAPA library 
quantification kit for the Illumina platform (Kapa Biosystems). The libraries were 
sequenced using HiSeq (Illumina), and the sequences were mapped to the KSHV 
reference genome (accession number NC_009333) using the RNA-Seq Analysis tool in 
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the CLC Genomic Workbench 7 (CLC Bio) software. The relative expression of the viral 
genes at different time points was determined based on RPKM (reads per kilobase of 
exon per million mapped reads) values, which were also similarly used to generate heat 
maps showing the relative expression of those genes at different time points utilizing the 
hierarchical-clustering feature of the CLC Genomic Workbench 7 software. 
Nascent RNA capture by Click-iT technology  
To identify the newly synthesized RNA during the de novo infections, a Click-iT 
RNA capture technology was used as described by the manufacturer (Life technologies, 
Inc.). Briefly, 8 × 107 human PBMCs were infected with KSHV purified from the 
induced TRExBCBL1-RTA cells as described above. Four hours post-infection, the cells 
were incubated for 1 h with ethylene uridine (33) ribonucleotide homologs containing an 
alkyne-reactive group. Additionally, a de novo infection of KSHV was performed in the 
presence of phosphonoacetic acid (PAA), an inhibitor of viral DNA polymerase and lytic 
DNA replication. The PBMCs were pretreated with 0.5mM PAA for 1 h prior to the 
infection, with the treatment continuing until harvesting at 24 hpi, similarly to a 
previously described method (34, 35). The de novo-infected PBMCs were collected 4 and 
24 hpi and washed twice with PBS before isolating total RNA with an Illustra RNAspin 
Mini kit per the manufacturer instructions (GE Health Care). Biotin azide was 'clicked on’ 
to the isolated RNA, and the newly synthesized RNA was captured using streptavidin 
magnetic beads. DMSO instead of biotin azide was added as control for the click reaction. 
The captured RNAs were further utilized for preparing cDNA libraries with a TrueSeq 
RNA sample preparation kit v2 (Illumina, Inc.) and for the RNA-seq analysis on a Hi-seq 
Illumina sequencer. Relative copies of the newly synthesized transcripts were determined 
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by the ratios of the biotin enriched (clicked) versus control, DMSO enriched (non-
clicked) copies of the transcripts identified by RNA-sequence analysis. 
Quantitative real-time PCR  
The real-time qPCR reactions were performed in a 96-well plate in a total volume 
of 20 µL that included 10 µL of SYBR green PCR 2× master mix (Applied Biosystems) 
and 0.5 µM of each KSHV ORF-specific primer. Primers for the human housekeeping 
genes β-actin and GAPDH were included for normalizing the Ct values. Purified 
genomic DNA samples or the virion cDNA samples and KSHV-infected PBMCs were 
amplified on an ABI StepOnePlusTM Real-Time PCR machine (Applied Biosystems). 
As a standard practice, a no reverse-transcription (no-RT) control reaction was included 
for all of the prepared RNA samples to ensure their purity. 
Accession numbers  
The RNA-seq data was deposited in the NCBI Gene Expression Omnibus (GEO) 
database, and the accession number for the complete data set is GSE62344. 
Results: 
Purification of the KSHV virions  
We isolated the KSHV particles from doxycycline-induced (1µg/mL) 
TRExBCBL1-RTA cells and purified them on a 20–50% sucrose gradient. The three 
white bands observed on the sucrose gradient (Fig. 1A) were consistent with previous 
reports (26, 36), representing the A-type (empty virus particles), B-type (intermediate 
virus particles), and C-type KSHV particles (mature virions). The lower band 
representing the mature C-type KSHV virion particles was collected with a syringe and 
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diluted before pelleting the 
virions by ultracentrifugation. 
These purified virions were 
tested for the presence of the 
KSHV envelope glycoprotein 
K8.1 by immunoblotting with 
anti-K8.1 antibody (Fig. 1B). 
The virion DNA was extracted 
to quantify the number of viral 
copies in a real-time qPCR 
assay using ORF73-specific 
primers (Fig. 1C), which 
showed approximately 8.0 × 
107 virions/ml. This fraction of 
mature virions, which was 
confirmed by both analyses, 
was further used for de novo 






KSHV viral transcripts were abundantly present during the primary infection of 
human PBMCs, CD14+ and TIVE cells  
To determine the profiles of the viral transcripts expressed during the primary 
infection of B and endothelial cells (natural target cells of KSHV), purified virions were 
used for the de novo infection of human PBMCs, CD14+ monocytes, and endothelial 
(TIVE) cells.  An RNA-seq analysis was performed on total RNA extracted from these 
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infected cells at different time points (4, 24, 48, 72, and 120 hpi). Furthermore, 10pM of 
the quantified libraries were sequenced and mapped to the reference KSHV genome 
(NC_009333). The transcriptome analysis revealed that several of the KSHV lytic and 
latent transcripts accumulated as early as 4hpi (Figs. 2A–C and 3).   
 Apart from the ORF50 replication and trans-activator protein (RTA), a number of 
other lytic transcripts involved in immune modulation, lytic-DNA replication, and nucleic 
acid processing/synthesis were detected in significant amounts early during the infection. 
These included polyadenylated nuclear (PAN) RNA, ORF58/59, kaposin B, K2, K4, K6, 
ORF11, ORF17, ORF45, ORF27, ORF37, ORF57, ORF64, ORF65, ORF73, and the 
recently identified T0.7.  Among these, PAN RNA was the most abundant as determined 
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by the relative peak height (Figs. 2A–C) and RPKM values (Fig. 3) in all the three tested 
cell types.  Although the overall patterns of the viral gene expressions were similar, i.e. 
majority of the genes expressing at 24hpi in all the three tested cells, CD14+ monocytes 
showed complete silencing of viral gene expressions, other than LANA, after 24hpi (Figs. 
2A–C and 3). However, the human PBMCs and TIVE showed detectable levels of PAN 
RNA and ORF58/59 transcripts along with LANA after 48hpi (Figs. 2A–C and 3).  
 This suggests a cell type specific viral gene expression patterns during primary de 
novo infection and latency establishment. Relative abundance of many of the viral 
transcripts including ORF1, K2, K4, T1.5, PAN RNA, ORF17.5, ORF26, ORF27, 
ORF37 ORF38, ORF45, K8, K8.1, ORF52, vIRF-1, ORF58/59, K12/T0.7 and LANA 
showed an increase in their abundance in PBMCs at 4hpi and 24hpi when compared with 
their abundance in the virions (Fig. 2A). However, the CD14+ monocytes cells showed 
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increases in the abundance of only fewer genes as compared to the PBMCs (Fig. 2B). 
Importantly, LANA was the only gene abundantly detected after 72hpi in these CD14+ 
cells representing a true latency model of KSHV infection. The endothelial cells (TIVE) 
showed detectable levels of viral transcripts but their relative abundance increased only 
slightly at 24hpi (Fig. 2C). The heat-maps generated based on the RPKM values showed 
an increase in their copies from 4hpi to 24hpi, suggesting an active transcription and 
these included, PAN RNA, ORF73, ORF45, ORF58, T0.7, Kaposin B, ORF59, K4, K6, 
ORF17, ORF65, ORF27, K8.1, ORF11, ORF37, ORF38, ORF57, ORF69, ORF52, 
ORF54 and T1.5 (Fig. 3). The viral DNA polymerase, ORF9 along with other lytic DNA 
replication proteins were detected but their expression level did not increase (Fig. 3). 
Also, there were several other detectable transcripts (K1, ORF4, ORF10, K6, ORF43, 
ORF44, ORF67, ORF68, and K14) but their abundance did not increase and the RPKM 
values remained unchanged during the time course tested, suggested that these genes did 
not transcribe but were present due to their transduction through the virion particles 
during infection.  
Earlier studies reported that immediately after de novo infection, the 
herpesviruses express genes involved in lytic DNA replication (28, 37, 38). Our RNA-seq 
analysis detected the transcripts of proteins involved in viral DNA replication as early as 
4 hpi, and these included ORF59 (processivity factor), ORF9 (DNA polymerase), ORF6 
(single-stranded DNA binding protein), ORF56 (DNA replication protein), ORF40 
(primase-associated factor), ORF54 (dUTPase) along with ORFs 60 and 61 
(ribonucleoprotein reductase), ORF70 (thymidylate synthase), and ORF 37 (alkaline 
exonuclease). Apart from these transcripts, several other transcripts encoding the viral 
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structural proteins ORF8 (glycoprotein B), K8.1 (glycoprotein), and ORFs 64 and 75 
(tegument protein) were also detected in our transcription profiling data. Moreover, many 
of the noncoding RNAs, including 
PAN RNA, T0.7, and T1.5 (OriLyt 
transcript), were abundantly detected 
in the RNA-seq analysis. RNA-seq 
profiling of the virion encapsidated 
RNA, as relative abundance, showed 
packaging of a large number of viral 
transcripts, which are brought into the 
target cells by the KSHV virion during 
the de novo infection (Fig. 2 and Table 
1).  
 In agreement with the previous 
report, our results showed the 
concurrent expression of ORF50 and 
ORF73 transcripts during early 
primary infection (Figs. 2A–C and 3). 
However, the expression of ORF50 
decreased after 24 h, whereas the 
expression of ORF73 increased 
exponentially (Fig. 3, heat maps). The 
KSHV latency-associated protein ORF73 is the predominant protein expressed during 
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latency and is responsible for immune evasion, latent DNA replication, and genome 
maintenance, whereas the ORF50-encoded protein RTA activates lytic cycle-specific 
KSHV genes in a cascaded manner to facilitate the lytic replication process (39-43). 
 
 63 
In a cell culture system, the over-expression of RTA is capable of triggering the lytic 
DNA replication (39, 43). Our data detected the transcripts of ORF50 and other lytic 
genes along with ORF73 during early infection suggest that KSHV may enter into a DNA 
replicative phase before establishing latent infection. 
Quantitative real-time PCR validation of the RNA sequencing analysis  
To further confirm the results of the transcriptome analysis by an independent 
method, we performed a real-time qPCR analysis on de novo-infected PBMCs harvested 
at different time points (4, 24, 48, 96, and 120 hpi). A custom qPCR array of the KSHV 
genes in a 96-well format (Bar Harbor Biotechnology) was used for the quantification of 
the viral mRNA levels. The fold-changes of the individual KSHV genes were calculated 
for the various times post-infection using the ΔΔCt method and plotted separately (Fig. 4). 
The viral genes showed expression kinetics similar to those seen with the RNA-seq 
analysis. As first shown by the RNA-seq analysis, even at 4 hpi, several lytic transcripts 
(ORF58/59, ORF11, ORF8, K8, K8.1, ORF17, ORF22, ORF57, ORF 45, ORF27, ORF 
37, and ORF64) were detected at high levels, and the expression of these transcripts was 
gradually depleted after 24 hpi (Fig. 4). In addition, latent transcripts (ORF73, K12, and 
ORF72) were consistently detected at significant levels during early infection (Fig. 4).  
 64 
 As reported previously (9), the real-time qPCR analysis showed the concurrent 
expression of ORF50 and ORF73 at 4 hpi, and ORF50 showed a much higher fold-
increase during early infection than ORF 73. However, the expression of the ORF73 
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transcript increased exponentially until 96 hpi. Additionally, the non-coding PAN RNA 
and recently identified T0.7 transcripts were also detected abundantly at 4 hpi (Fig. 4). 
The qPCR validation of the RNA-seq analysis suggested that the limited lytic-gene 
accumulation observed during primary infection might have been influenced by the RTA 
mediated gene expression as well as by the transduction of viral transcripts with the 
virions during the de novo infection.  
Detection of actively transcribing genes during de novo infection  
The transcriptome analysis of de novo-infected cells during early infection 
revealed a significantly higher expression of several genes, which are expressed during 
lytic replication cycle including ORF50, ORF6, ORF9, ORF8, ORF7, ORF10, ORF11, 
ORF22, ORF27, ORF31, ORF37, ORF40/41, ORF45, ORF54, ORF55, ORF56, ORF58, 
ORF59, and ORF69 (Figs. 2A–C and 3). In addition, many of the immediate-early KSHV 
unique genes such as K7, K8, K3, K5, K9, and K12, as well as late K8.1, were also 
detected. Many of these transcripts have crucial regulatory roles in immune evasion and 
nucleic acid processing and synthesis, which are associated with lytic-DNA replication. 
The real-time qPCR analysis of the viral transcripts fully corroborated the RNA-seq 
analysis (Fig. 4). 
To further identify the actively transcribing genes during de novo infection, we 
used an approach to capture the nascent transcribed RNA from the KSHV infected 
PBMCs by labeling them with EdU and isolating them by Click-It approach. The 
sequencing of newly synthesized RNA captured from the KSHV infected PBMCs 
showed peaks of many viral genes at 4hpi and these included ORF2, K3, T1.5, PAN 
RNA, ORF26, ORF29, ORF36, ORF37, ORF40, ORF50, K8.1, ORF55, vIRF-2, 
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ORF58/59, ORF60, ORF63, ORF64, ORF67, T0.7, ORF72, ORF73 and ORF74 (Fig. 
5A). Importantly, majority of these were showing increased expression in relative 
abundance graph as well as in the heat maps (Figs. 2, 3 and 5). Interestingly, majority of 
the active transcription were limited to the ORF73, detected by the sequence reads, at 
24hpi suggested for the beginning of a latency establishment (Fig. 5, 24h panel).  We also 
confirmed the transcription during de novo infection by treating the cells with 
actinomycin D to block active transcription. Comparison of the transcript levels at 4 hpi 
in the untreated with actinomycin D treated cells revealed almost similar profiles to the 
nascent RNA capture data of gene transcription at 4hpi (data not shown). As expected, 
the ORF50 gene showed a moderate level of de novo transcription within 4 hpi (Fig. 5). 
Interestingly, not all the genes required for lytic DNA replication showed an active 
transcription during de novo infection, but were detected in RNA-seq analysis suggesting 
that those genes were transduced with the virions. Not surprisingly, the ORF50 gene 
transcripts and those of genes regulated by ORF50 decreased after 24 hpi. Also, a gradual 
increase in ORF73 transcripts by 24 hpi may aid in suppressing the expression of other 
viral genes to promote the establishment of latency. 
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KSHV genome copy numbers increased exponentially after de novo infection  
 To investigate whether the detection of lytic-reactivation genes leads to lytic-
DNA replication and genome amplification, we analyzed the KSHV genome copy 
number during the de novo infection of PBMCs. Total DNA from different time points (0, 
4, 24, 48, 72, 96, and 120 hpi) were subjected to a real-time qPCR analysis to analyze the 
relative viral copies in the infected cells. We used ORF73-specific primers and ORF73-
plasmid standards to obtain the copy numbers of the KSHV genome. The relative number 
of KSHV genome copies was calculated in the real-time qPCR assay by amplifying the 
ORF73 gene and normalizing it against GAPDH. KSHV viral DNA was detected as early 
as 4 hpi, which increased exponentially up to 48 hpi, and then slightly decreased over 
time after establishing latency (Fig. 6A). This exponential increase in the genome copies 
confirms for a genome replication during early infection till the establishment of latency. 
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The punctate immunolocalization of LANA in the de novo-infected PBMCs (120 hpi) 
clearly demonstrated the establishment of latency in these cells (Fig. 6B). A flow 
cytometry analysis of de novo-infected PBMCs using anti-LANA and B- and T-
lymphocyte markers gated for LANA expression showed that the populations of both the 
B- (~55.94%) and T-lymphocytes (~24.75%) were successfully infected with KSHV (Fig. 
6C and D). Since the viral genome copies increased about 6 fold at 48 hpi from the 4 hpi 
(the non-internalized virions were removed at 2 hpi by treating the cells with trypsin), we 
wanted to determine whether the virus has undergone to latent or lytic modes of DNA 
synthesis to amplify the genome copies. To this end, we treated the cells with a viral 
DNA polymerase inhibitor, phosphonoacetic acid (PAA) to block the lytic DNA 
replication. The cells pretreated with PAA or untreated were infected with KSHV virions 
for 4h and 24h for the transcriptome analysis. Analysis of the selected genes of latent, 
immediate early and early genes showed almost no effect of PAA on the transcription of 
latent (ORF73) and immediate early genes (ORF50) at 4 hpi (Fig. 6E). However, the 
expression of late gene (ORF65) was significantly reduced with PAA at both, 4 and 24 
hpi (Fig. 6D). We also determined the genome copies during de-novo infection of 
PBMCs in the presence of PAA. The relative genome copies showed a significant 
reduction in viral genome amplification in cells treated with PAA (Fig. 6F). Since there 
was still slight increase in the viral genome copies at 24 hpi, we speculate that other 





KSHV virions packaged the viral transcripts  
To analyze the RNA composition in the encapsidated virions, total RNA extracted 
from the purified C-type KSHV virions was used for the RNA-seq analysis. After 
confirming the purity of the RNA, the total RNA from two independent virus 
purifications was used to construct cDNA libraries. After quantifying, 10 pM of the 
mature library samples were used for the RNA-seq analysis. In comparison with previous 
reports (26, 27), the transcriptome analysis with the CLC Genomic Workbench 7 
software using KSHV as the reference genome detected a larger number of KSHV 
mRNAs in the virions. A previous DNA microarray study identified 11 KSHV mRNAs 
in the virions (27), but in this study, we identified more than 60 KSHV-specific 
transcripts, including mRNAs for latent genes (Table 1). The mRNAs with 50 or more 
specific-gene reads and a 10-fold higher abundance in the qPCR assays were considered 
significant (Fig. 7A and Table 1). The most abundant transcripts detected in the virions 
included PAN RNA, K7, K14, K12, ORF58/59, and the recently identified T0.7, with 
PAN RNA being the most abundant (Fig. 7A). In addition, many lytic-specific mRNAs 
were also present in the virions, such as ORF50, ORF8, ORF9, ORF21, ORF22, ORF31, 
ORF40/41, ORF45, ORF54, ORF55, ORF69, and ORF75. Moreover, many of the 
immediate-early and early KSHV-unique K genes (K7, K8, K3, K5, K9) and the late 
K8.1 gene were also detected. Interestingly, in contrast to the previous report (27), a 
significant amount of latent-specific ORF73 mRNA was detected in the virions (Fig. 7A). 
Both this and the previous studies suggest that virion transcripts are released into the 
target cells immediately after de novo infection (26, 27). This may be the reason for the 
immediate concurrent expression of ORF50 and ORF73 in the target cells (9). It has been 
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shown that proteins encoded by these transcripts have significant regulatory roles in 
various cellular pathways, including cell signaling, immune modulation, and apoptosis, 
that could critically affect the phenotype of the newly infected cell and its 
microenvironment (14, 15, 44, 45) to provide the necessary factors required for a 
successful infection.  
Virion-packaged transcript specificity  
To further clarify the RNA-Seq results, we performed a real-time qPCR analysis 
on cDNA prepared from the same source of total RNA (extracted from purified C-type 
KSHV virions) used in the sequencing analysis. A custom qPCR array representing each 
of the KSHV-specific ORF primers was used for the analysis. The uninfected PBMCs 
used as a reference control did not amplify, and a no-RT control was used to ensure the 
quality of the RNA. The qPCR data showed results similar to those of the RNA-seq 
analysis, confirming the presence of viral transcripts in the virions.  
To determine whether there is a specific mechanism of RNA encapsidation during 
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virion assembly, we compared the abundance of viral transcripts in the virions with the 
amounts present during the lytic reactivation of the cells. An earlier study indicated that 
RNA encapsidation by the KSHV virion could be a specific event (27), and a recent 
report on KSHV virion miRNA also suggested that transcript encapsidation might be a 
specific process (26). To confirm this, we performed transcriptome (Fig. 7B) and real-
time qPCR analyses of the viral genes in the cDNA extracted from induced BCBL1 cells 
for comparison with the transcripts present in the purified virions (Fig. 7A and B). Many 
of the transcripts present in the virions were expressed in abundance during lytic 
reactivation in the TRExBCBL1-RTA cells. To understand the specificity of RNA 
encapsidation in the virion, we calculated the ratio of virion transcripts to the transcript 
expression levels present during reactivation in the induced TRExBCBL1-RTA cells. 
Several of the transcripts, including PAN RNA, T0.7, DR1, ORF58, and ORF59, that 
were detected in high abundance in the virions were highly expressed during reactivation, 
and thus the ratios of encapsidated to mRNA transcripts in the induced cells were lower. 
We therefore concluded that they were packaged simply due to their abundance, not 
because of any specificity. However, some of the transcripts, including ORF73, ORF31, 
ORF40, ORF50, ORF56, ORF49, and ORF64, showed significantly higher ratios (≥0.5) 
of virion transcripts in comparison to their abundance during reactivation, suggesting the 
involvement of a specific mechanism in their encapsidation. The viral genes with the 
ratio of virion packaged to the induced cells above 0.5 were considered significant and 
are marked by asterisks in Fig. 7C. Many of the virion-encapsidated latent- and lytic-
specific transcripts that were detected early during de novo infection showed a 
significantly higher ratio; the ratio for the latent transcript ORF73 was 1.0843, whereas 
 72 
the ratio for the lytic transcript ORF50 was 2.6103. Taken together, this suggests that 
KSHV may selectively encapsidate the latent and lytic transcripts required during early 
infection for priming the cells to successfully establish latency. 
 
Early ORF59 expression is required for KSHV de novo infection and genome 
amplification 
Our transcriptome data showed a high expression of ORF59 during the primary 
early infection of both B and endothelial cells, which led us to believe that ORF59 may 
be required during the early events of KSHV infection and latency establishment. To this 
end, we used a recombinant KSHV with a stop codon in the ORF59 gene 
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(BAC36ΔORF59) (46) for de novo infection. Knowing that the ORF59-deleted BAC36 
cannot produce virion particles, we generated a 293L-cell line stably expressing the 
ORF59 gene fused with DsRed to complement the ORF59 in BAC36ΔORF59. These 
bacterial artificial chromosomes (BACs), WT in 293L and BAC36ΔORF59 in ORF59-
DsRed-complemented 293L, were transfected and selected with hygromycin to obtain 
pure cell populations maintaining the BACs. These stable cells were induced with sodium 
butyrate (NaB) and tetradecanoyl phorbol acetate to produce virion particles, and the C-
type virions were purified by sucrose density-gradient centrifugation for DNA extraction 
and the infection studies.  
To determine the composition of the KSHV virion-encapsidated RNA in 
BAC36WT and BAC36ΔORF59, we performed an RNA-seq analysis on the virions from 
these two cell lines. Unsurprisingly, the patterns of the viral mRNA transcripts were 
similar (Fig. 8A and Table 2). We also compared the virion mRNA patterns from the 
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BACs with those of the TRExBCBL1-RTA virions, which showed a slightly different 
packaging of the viral mRNA, but similar levels of PAN RNA (Fig. 8A). Interestingly, 
the virions produced in the 293L cells complemented with ORF59-DsRed and containing 
BAC36ΔORF59 also encapsidated ORF59, which was confirmed by mapping the 
sequence reads with ORF59-DsRed (Fig. 8B). The sequence reads from BAC36WT 
mapped only to the ORF59 
regions, confirming that 
BAC36WT packaged the 
parental ORF59 gene (Fig. 8B), 
as expected. Interestingly, the 
total number of virions 
produced by BAC36ΔORF59 
was three logs lower than that 
produced by BAC36WT (Fig. 
9B), even with the ORF59-
DsRed complementation, 
which is reflected in the C-type 
band intensity in the 
BAC36ΔORF59 tube (Fig. 9A).  
 We normalized the 
number of virions used for the 
infection of human PBMCs by 
extracting the virion DNA and quantifying it in a real-time qPCR assay. Cells were 
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collected at 4, 24, 48, 72, 96, and 120 hpi and analyzed for viral gene expression and the 
number of KSHV genome copies during 
early infection. Our results showed that 
both BAC36WT and BAC36ΔORF59 
trans-complemented with ORF59-DsRed 
produced infectious virions and infected 
PBMCs (Fig. 9C). However, the KSHV 
genome copy analysis of the PBMCs 
infected with the trans-complemented 
BAC36ΔORF59 showed a reduced number 
of KSHV genome copies in comparison to 
BAC36WT (Fig. 9C). This suggested that 
the lytic-cycle gene ORF59 is required for 
amplifying the viral genome during 
primary infection, probably by allowing 
DNA replication through lytic origins.  
The total RNA extracted from the de 
novo-infected PBMCs at different time 
points (4, 24, and 48 hpi) were used for a 
transcriptome analysis to determine 
whether there were differences in the viral 
gene expression profiles in the ORF59-
deleted virus. The expression profiles of the viral genes were determined based on RPKM 
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values and compared with the wild-type virus at each of the time points. The heat map 
generated based on the RPKM values showed subtle differences in the viral gene 
expression profiles (Fig. 10). The genes required for lytic-DNA replication (ORF9, ORF6, 
ORF40/41, ORF44, ORF56, ORF50, and K8), encircled by red boxes showed almost no 
difference in their expression profiles (Fig. 10). ORF59 showed a gradual decrease in 
virion-released ORF59 transcripts for the ORF59-deleted virus. However, BAC36WT 
showed a slight increase in the number of ORF59 transcripts. The PAN RNA levels were 
comparable in the wild type and ORF59-deleted viruses at the time points analyzed. The 
K2 and ORF17 expression was distinctly different in the ORF59-deleted virus, being 
expressed earlier than in the PBMCs with the BAC36WT virus (Fig. 10). Interestingly, 
the ORF59-deleted virus showed a higher expression of the ORF73 gene (LANA) at 
earlier time points than did BAC36WT, suggesting an early onset of latency in the virus 
lacking ORF59. Overall, these data suggest that ORF59 is required for replicating the 
DNA and amplifying the viral genome during primary infection of human PBMCs. 
Discussion: 
KSHV infection is a complex multi-step process involving the regulation of various 
cellular pathways. KSHV infects a variety of cellular targets and establishes a latent 
infection, generally by 24 hpi (14, 16-20). To understand the differential expression of 
viral transcripts early during infection, PBMCs, CD14+, and TIVE cells were de novo 
infected with KSHV for different lengths of time (0, 4, 24, 48, 72, and 120 h). The 
transcriptome and real-time qPCR analyses on the de novo-infected PBMCs revealed that 
several lytic- and latent-specific mRNAs were concurrently expressed very early on 
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following the de novo infections. Previous reports have shown that immediately after de 
novo infection with herpesviruses such as EBV and herpes simplex virus, the virus 
undergoes a short lytic DNA replication phase (37, 38). Our data also showed the 
presence of the lytic DNA replication-associated transcripts, suggesting the activation of 
a lytic cycle. Many of the lytic-cycle replication-associated transcripts were detected as 
early as 4 hpi, including ORF59 (processivity factor), ORF9 (DNA polymerase), ORF6 
(single-stranded DNA binding protein), ORF56 (DNA replication protein), ORF40 
(primase associated factor), ORF54 (dUTPase), ORFs 60 and 61 (Ribonucleoprotein 
reductase), ORF70 (thymidylate synthase), ORF37 (alkaline exonuclease). In addition, 
the ORF50, ORF2, K3, PAN RNA, ORF26, ORF29, ORF37, ORF55, ORF60 ORF63, 
ORF73 and ORF74 transcripts were found to be actively transcribing at 4 hpi detected by 
capturing the nascent RNA and the actinomycin D treatment.  
Apart from these lytic transcripts, the expression of several other transcripts 
encoding structural proteins such as K8.1 (glycoprotein), and ORFs 65 (tegument 
protein) were also detected early during infection. Moreover, many of the noncoding 
RNAs, including PAN RNA, T0.7, and T1.5 (OriLyt transcript), were also expressed 
during early infection. PAN RNA has been shown to modulate viral and cellular 
transcription as well as activate KSHV lytic cycle by interacting with the ORF50 
promoter and viral genome (47, 48). Furthermore, there were a large number of viral 
transcripts, whose expression did not increase from their levels at 4 hpi suggesting that 
those were transduced with the virions. 
The detection of PAN RNA in the virion and during infection suggests that PAN 
RNA could be playing major role in triggering lytic cycle cascade. The KSHV ORF50-
 78 
encoded immediate-early protein RTA is known to activate the cascade of lytic genes for 
facilitating the lytic replication process (39-43). Studies on the primary infection of B 
cells by EBV showed an accumulation of lytic transcripts during infection, indicating the 
requirement of a short lytic replication prior to the establishment of latency (21, 23). 
Earlier studies have shown that the KSHV virion also contains several KSHV lytic 
proteins, including ORF50, ORF8, ORF25, ORF26, K12, ORF62, ORF63, and ORF75, 
that are brought into the target cells during de novo infection (24). The ORF50 protein 
accompanying the virion may also be important for orchestrating the activation of RTA-
responsive genes early on during infection to induce a short lytic cycle. A significant 
amount of the concurrent expression of ORF50 and the KSHV latent protein, ORF73 was 
detected as early as 4 hpi. Similar observations were reported in a previous study based 
on microarray and real-time qPCR analyses, but the possibility of lytic DNA replication 
was not proposed due to the lack of detecting all of the proteins required for lytic-DNA 
replication (9). 
A recent study on histone modifications of the KSHV genome during de novo 
infection demonstrated that there is a distinct pattern of activating the histone H3K4me3 
mark across the KSHV genome, which is gradually replaced by the repressive 
H3K27me3 mark by the LANA-mediated displacement of soluble sp100 (49). 
Additionally, in comparison to the repressive H3K27me3 mark and the rest of the 
genome, a LANA ChIP-seq analysis of TRExBCBL1-RTA and TIVE-LTC showed a 
clear association of H3K4me3 mark and RNA pol II activation on the latent gene 
promoters (50). Our results showed that immediately after the de novo infection of 
PBMCs, the viral genome increased exponentially up to 48 hpi, followed by a slight 
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decrease at 72 hpi. The accumulation of ORF50 and other RTA-regulated lytic-cycle 
genes during early infection is suggestive of the involvement of lytic-DNA replication for 
genome amplification. Treating the cells with a late gene expression inhibitor, PAA 
showed significantly reduced viral genome copies further substantiated the involvement 
of lytic DNA replication for genome copies amplification in human PBMCs.  
Discriminating whether the transcripts detected at 4 hpi were due to the virion-
transduced mRNA or active transcription, RNA-seq analysis of the newly synthesized 
transcripts at 4 hpi of human PBMCs showed transcription of only a limited number of 
genes during primary infection. However, a large number of viral transcripts are detected 
at 4 hpi as well as in the virions particles, which confirms that those transcripts are 
introduced into the infected cells along with the virions. Detection of actively 
synthesizing mRNA in KSHV infected PBMCs at 24 hpi showed transcription of 
primarily the ORF73 gene, which confirmed that the viral genome gets chromatinized 
and epigenetically modified for restricted gene expression by 24 hpi. An earlier study 
reported the viral gene transcription of ORF59 during primary infection (27), and here we 
provide a comprehensive list of the genes transcribed during a de novo infection. The 
transcription of the viral genes as early as 4 hpi suggests that the viral DNAs entering the 
targets cells are capable of transcribing genes before the assembly of the epigenetic 
histone marks. Not surprisingly, the latent protein ORF73 gene showed active 
transcription at 4 hpi, suggesting that LANA begins transcription as early as 4 hpi and 
accumulates over time to help establish latency. The immediate-early protein ORF50 
undergoes a moderate level of transcription immediately after infection, which may 
contribute in triggering the transcription of the lytic cascade to complete the DNA 
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replication. The KSHV virions have also been shown to encapsidate a small quantity of 
the RTA protein, which may also be important in triggering the lytic-gene expression 
cascade (24, 27). 
It has been shown that both KSHV and EBV encapsidate biologically functional 
virion transcripts that are transported into the target cells during de novo infections (22, 
26, 27). A previous study using a DNA microarray and real-time qPCR identified 11 of 
the virus transcripts packaged into the virion (27). In this study, using RNA-seq and 
transcriptome analyses, we detected additional KSHV latent- and lytic-cycle transcripts 
encapsidated in the virions that were also transported into the targets cells. This data was 
validated by a real-time qPCR analysis using KSHV gene-specific primer arrays, which 
showed consistent results. The transcriptome analysis identified a variety of virion 
transcripts in high abundance, including PAN RNA, K7, K14, K12, ORF 58/59, and the 
recently identified T1.5 and T0.7. Additionally, many lytic-specific mRNAs (ORF50, 
ORF8, ORF9, ORF21, ORF22, ORF31, ORF 40/41, ORF45, ORF54, ORF55, ORF 69, 
and ORF75) were present in the virion in moderate amounts. A number of immediate-
early and early KSHV-unique K genes (K7, K8, K3, K5, K9, and late K8.1) were also 
detected in the virion, in addition to a significant amount of latent-specific mRNAs 
(ORF73, ORF72, and K2). 
The mechanism of RNA encapsidation by KSHV is currently unknown. Reports 
show that, similarly to the herpes simplex virus, the RNA packaging and encapsidation 
by KSHV could be a specific event (26, 27). In addition, the specific encapsidation of 
miRNA by the KSHV virion has recently been demonstrated (26). However, both the 
previous study and this study determined that the majority of mRNAs detected in the 
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KSHV virions were present at very high levels during lytic reactivation (9, 27). This 
suggests that these transcripts might have been randomly packaged into the virions 
simply due to their higher abundance. Nonetheless, the qPCR analysis to determine the 
specificity of the virion versus the reactivated TRExBCBL1-RTA showed that the 
ORF31, ORF40, ORF50, ORF56, ORF49, ORF64, and ORF73 transcripts had 
significantly higher proportions of encapsidated mRNA than did the PAN RNA, ORF58, 
ORF59, T0.7, and DR1 transcripts, suggesting a specific packaging mechanism for those 
transcripts. 
Several of these highly expressed KSHV lytic genes have been shown to have 
regulatory roles in immune modulation, anti-apoptosis, and lytic DNA replication, 
indicating that their expression may be priming the host cell for retaining the incoming 
viral DNA during the initial infection. This is evident from the de novo infection of 
PBMCs with virions produced from the BAC36ΔORF59 virus. Although significantly 
fewer virions were produced from BAC36ΔORF59 than from BAC36WT, a similar 
number of virions were used to compare the viral genome copy numbers and expression 
profiles. The lower number of virion copies in BAC36ΔORF59 complemented with 
ORF59-DsRed may have been due to a comparably lower expression of ORF59 in those 
cells. The transcriptome analysis of the de novo-infected PBMCs showed the differential 
expression of only a few latent- and lytic-specific genes (PAN RNA, T0.7, K2, K4, 
ORF17, ORF18, ORF58, ORF45, and ORF73), confirming that the incoming DNA is 
transcription competent. 
The virions from both the BAC36WT and ORF59-complemented cells showed 
the packaging of ORF59 transcripts. However, the BAC36ΔORF59 virus genome in de 
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novo-infected PBMCs failed to show an appreciable increase of copy number in 
comparison to BAC36WT. This indicates that the extended expression of ORF59 during 
early infection is probably required for synthesizing viral DNA through lytic DNA 
replication to increase the copy number. The exact mechanism requiring the initial 
transient accumulation of lytic-specific transcripts for the establishment of latency 
currently remains elusive. To fully understand the early events of KSHV infection:- 
latency establishment and genome amplification, further experiments identifying the viral 
proteins expressed and the mechanism of viral DNA replication during primary infection 
in various cells are currently ongoing.  
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Abstract: 
Major histocompatibility class II (MHC II) molecules play central role in adaptive 
antiviral immunity by presenting viral peptides to the CD4+ T cells.  Due to their key role 
in adaptive immunity, many viruses including Kaposi’s sarcoma associated herpesvirus 
(KSHV) have evolved multiple strategies to inhibit MHC II antigen presentation pathway. 
Expression of MHC II, which is mainly controlled at the levels of transcription, is strictly 
dependent upon the binding of class II transactivator (CIITA) to the highly conserved 
promoters of all MHC II genes. Recruitment of CIITA to MHC II promoters requires its 
direct interactions with pre-assembled MHC II enhanceosome consisting of cyclic AMP 
response element-binding protein (CREB), nuclear factor Y complex (NF-Y) and 
regulatory factor X complex (RFX) proteins. Here, we show that KSHV encoded latency 
associated nuclear antigen (LANA) disrupts the association of CIITA to MHC II 
enhanceosome by binding to the components of RFX complex. Our data show that 
LANA is capable of binding with all the three components of RFX complex: RFXAP, 
RFX5 and RFXANK in vivo, however, more strongly with the RFXAP component in an 
in vitro binding assay. Levels of MHC II proteins were significantly reduced in KSHV 
infected as well as LANA expressing B-cells. Additionally, an expression of LANA in 
luciferase promoter reporter assay showed reduced HLA-DRA promoter activity in a 
dose dependent manner. Chromatin immunoprecipitation assay showed LANA binding to 
MHC II promoter along with RFX proteins and an over expression of LANA disrupted 
the association of CIITA to the MHC II promoter. These assays conclude that the 
interaction of LANA with RFX proteins interferes the recruitment of CIITA to MHC II 
promoters, resulting into an inhibition of MHC II genes expression. Thus, the data 
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presented here identifies a novel mechanism used by KSHV to downregulate the 
expressions of MHC II genes. 
Importance:  
Kaposi’s sarcoma associated herpesvirus is the causative agent of multiple human 
malignancies. It establishes a life-long latent infection and persists in the infected cells 
without being detected by the host’s immune surveillance system. Only a limited number 
of viral proteins are expressed during latency and these proteins play a significant role in 
suppressing both the innate and adaptive immunities of the host. Latency Associated 
Nuclear Antigen (LANA) is one of the major proteins expressed during latent infection. 
Here, we show that LANA blocks MHC II gene expression to subvert host immune 
system by disrupting the MHC II enhanceosome through binding with RFX transcription 
factors. Therefore, this study identifies a novel mechanism utilized by KSHV LANA to 
deregulate MHC II gene expression, which is critical for CD4+ T cell response in order to 
escape the host immune surveillance. 
Introduction: 
Kaposi’s sarcoma associated herpes virus (KSHV) is an oncogenic γ-herpesvirus that 
causes several malignancies such as Kaposi’s sarcoma (KS), Primary Effusion 
Lymphomas (PELs) and Multicentric Castleman’s Disease (MCD) in 
immunocompromised individuals (1, 2). The life cycle of KSHV consists of a 
predominant latent phase marked by restricted gene expression and a transient lytic 
replication phase characterized by the production of functional virions. KSHV maintains 
a life long persistent infection in susceptible hosts after primary infection (3, 4). One of 
the main factors contributing to a successful life-long persistence of KSHV is its 
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astounding ability to hide from the surveillance of host immunity. During the course of 
evolution, KSHV has evolved multiple mechanisms to evade and modulate nearly all 
aspects of both the innate and adaptive immunities of the infected hosts (5-7).  
 Latency associated nuclear antigen (LANA or LANA-1) is the most abundantly 
expressed proteins in all the KSHV infected cells (8-10). LANA is a large multifunctional 
protein that plays diverse roles in maintaining successful KSHV latency such as 
maintenance of viral episomes, transcriptional regulation of many viral and cellular genes 
and the progression of cell cycle (1, 11, 12). Since latency is the immunologically silent 
stage of KSHV life cycle and LANA is the major latent protein, it is speculated to play 
active roles in the modulation of host immune response. Indeed, LANA has been shown 
to inhibit many aspects of host’s innate and adaptive immune pathways including 
interference with neutrophil recruitment and TNF-α signaling (13), interference with 
interferon signaling (14) and inhibition of MHC I peptide presentation (15, 16). Recently, 
LANA was also shown to inhibit MHC II antigen presentation pathway by inhibiting the 
transcription of class II trans activator (CIITA) (17). 
Effectiveness of adaptive immunity, which is a critical arm of the antiviral host 
defense, relies primarily on the activation of CD4+ T cells. Activation of CD4+ T cells 
seems to be particularly important for anti-KSHV immunity (18, 19). Major 
histocompatibility class II (MHC II) molecules play a central role in the activation of 
CD4+ T cells by presenting antigenic peptides to these cells (20, 21). Since peptide 
presentation in conjunction with MHC II molecules is indispensable for the activation of 
CD4+ T cells, down-regulation of MHC II molecules is a frequently employed strategy 
by many viruses (22). Reports published in the past couple of years established that 
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KSHV has the ability to downregulate MHC II molecules (17, 23-25). Since KSHV’s 
ability to persist in the infected hosts critically depends on being invisible to CD4+ T 
cells, KSHV most likely uses multiple simultaneous strategies for efficient blocking of 
MHC II antigen presentation pathway. 
MHC II molecules are highly polymorphic cell surface glycoproteins consisting 
of an alpha and a beta chain that are constitutively expressed in professional antigen 
presenting cells (26, 27). In humans, there are three “classical” isotypes, HLA-DR, HLA-
DP and HLA-DQ that are present on cell surface. MHC II gene family also includes 
“non-classical” cytoplasmic molecules HLA-DM and HLA-DO, and the invariant chain 
(Ii) involved in peptide loading. Expressions of all the members of MHC II gene family 
are highly coordinated and predominantly regulated at the levels of transcription (28-30). 
Promoters of all MHC II genes contain a highly conserved cis-acting DNA sequences 
consisting of S-X-X2-Y boxes, which is bound by various nuclear proteins. These 
proteins include regulatory factor X (RFX), nuclear factor Y (NF-Y) and cAMP response 
element binding (CREB) (29, 31). RFX complex is a hetero-trimeric complex composed 
of RFX5, RFXAP and RFXANK, which binds to the S and X boxes and the Nuclear 
Factor Y (NF-Y) and CREB binds to the Y and X2 boxes, respectively (32-39). 
Coordinated binding of these protein complexes to the conserved sequences of MHC II 
promoter makes a functional MHC II enhanceosome (reviewed in (22, 40). Among these 
proteins, RFX complex is the core DNA binding component of the MHC II 
enhanceosome. It facilitates the assembly of other enhanceosome proteins onto the MHC 
II promoters (30, 41-43). All three components of the RFX complex are indispensible for 
constitutive and induced expression of MHC II genes. Once assembled on MHC II 
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promoters, the enhanceosome complex recruits a transcriptional co-activator, CIITA 
(class II transactivator), a master regulator of MHC II expression. All the components of 
MHC II enhanceosome except CIITA are constitutively expressed in almost every cell 
types in humans (44). However, the expression of CIITA is constitutive only in antigen 
presenting cells but can be induced in most other cell types in response to IFN-γ (44). 
Binding of CIITA to the MHC II promoters is absolutely critical for the transcription of 
MHC II genes. However, CIITA does not possess any DNA binding domain to bind 
directly to MHC II promoter. Instead, it is recruited through the proteins of 
enhanceosome complex especially through direct association with RFX5. Once bound to 
MHC II enhanceosome, CIITA orchestrates transcription of MHC II genes by recruiting 
the remaining transcriptional machinery to the promoters (40, 45-47). 
 So far, two KHSV latent proteins, vIRF3 and LANA have been reported to 
down-regulate MHC II antigen presentation pathway (17, 18, 23, 25). The report by Cai 
et al demonstrated that LANA down-regulates MHC II through an inhibition of CIITA 
transcription by suppressing pIII and PIV promoter activities (17). In this study, we 
identified an additional mechanism used by KSHV LANA to inhibit the expression of 
MHC II genes. We show that LANA interferes with the assembly of functional MHC II 
enhanceosome by reducing the binding of CIITA to the HLA-DRA promoter. The 
immunoprecipitation (IP) experiments showed that LANA binds with all the three 
components of RFX complex in vivo but preferentially binds to RFXAP in the in vitro 
assays. Similarly, chromatin immunoprecipitation (ChIP) assays determined that LANA 
associates with the chromatin of HLA-DRA promoter. Electrophoretic mobility shift 
assays further supported that LANA associates with HLA-DRA promoter through its 
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interactions with the components of RFX complex. Additionally, expression of LANA 
reduced the activity of HLA-DRA core promoter in a dose dependent manner even when 
CIITA was expressed through a constitutive CMV promoter confirming that the presence 
of LANA prevents the binding of CIITA to HLA-DRA promoter. Disruption of CIITA 
binding to enhanceosome was further supported by a chromatin immunoprecipitation 
assay, which showed decreased association of CIITA at HLA-DRA promoter in presence 
of LANA. Taken together, these data identifies a novel mechanism used by KSHV 
LANA to deregulate the expression of MHC II genes. 
 
Materials and Methods: 
Cell culture 
The KSHV and EBV-negative Burkitt lymphoma cell line, BJAB; KSHV-
negative monocytic leukemia cell line, THP-1; KSHV-positive but EBV negative PEL 
cell lines, BCBL-1 and BC-3 were cultured in RPMI 1640 medium supplemented with 
10% fetal bovine serum, 2mM L-glutamine, and penicillin-streptomycin (5U/ml and 
5g/ml, respectively). Human Embryonic Kidney (HEK) cell lines, 293T cells and 293L 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum, 2mM L-glutamine, and penicillin-streptomycin (5U/ml and 5g/ml, 
respectively). All cell lines were grown at 37°C in a humidified environment 
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Antibodies 
The following commercial antibodies were used for this study: rat anti-LANA 
(Advanced Biotechnologies, Inc.), mouse anti-GAPDH (US Biological), mouse anti-Flag 
M2 (Sigma-Aldrich), mouse anti-Myc 9E10 (Sigma-Aldrich), rabbit polyclonal anti 
MHC class II (Abcam), rabbit polyclonal anti-RFXANK (Abcam), mouse monoclonal 
anti-RFX5 (Santa Cruz Biotechnology) and mouse monoclonal anti-RFXAP (Santa Cruz 
Biotechnology). Mouse monoclonal anti-LANA antibody was a gift from Ke Lan 
(Institute Pasteur of Shanghai, China). 
Plasmids 
To construct mammalian expression plasmids, RFXANK was PCR amplified 
from Myc-DDK tagged RFXANK clone (cat#RC220744) obtained from Origene USA, 
and cloned into a Flag tagged, pA3F or Myc tagged, pA3M vectors at BamHI and EcoRI 
restriction sites. RFXAP was PCR amplified from BJAB cDNA to clone into pA3F and 
pA3M vectors at BamHI and EcoRI sites. RFX5 was PCR amplified from RFX5-GFP 
construct received from Dr. Jeremy Boss, (EMORY School of Medicine), and was 
subcloned into pA3M or pA3F vectors at HindIII and EcoRV restriction sites. All the 
truncation mutants of RFXAP were PCR amplified from full-length RFXAP to subclone 
into pA3M or pA3F vectors at BamHI and EcoRI restriction sites. CIITA was similarly 
PCR amplified from CIITA plasmid, received as a gift from Dr. Jenny Ting, (UNC) to 
clone into pA3F vector using BglII and EcoRI restriction sites. In-frame positions of all 
the clones with the respective tags were confirmed by DNA sequencing done at the 
Nevada Genomics Center, University of Nevada, Reno. HLA-DRA-Luc plasmid was a 
generous gift from Dr. Jenny Ting (UNC,). Myc tagged full length LANA (pA3M-
	   95	  
LANA), Flag tagged full length LANA (pA3F-LANA) and their deletion mutants 
containing LANA N-terminal domain (1 to 340aa) or C-terminal domain (940-1162aa), 
GFP-NLS Myc, GFP LANA-N Myc (1-340aa) and its truncations: GFP LANA-N 250 
Myc (1-250aa), GFP LANA-N 150 Myc (1-150aa), GFP LANA N32 Myc (1-32aa), 
lentiviral constructs pLVX-LANA-YFP-Flag and its control construct pLVX-YFP-Flag 
have been described previously (48). shRNA expressing plasmids, Ctrl shRNA and 
LANA shRNA, are described previously (49). LANA-N GST and LANA-C GST also 
have been described previously (50). 
DNA transfections 
HEK 293T cells were seeded at the density of 5×106 cells per 100-mm dish the 
day before transfection. Plasmids of interest were transfected using polyethylenimine 
(PEI) (Polysciences, Inc). Approximately 60 µg of total plasmid DNA was mixed with 
150mM NaCl and 70µl of PEI solution (1mg/ml, pH 7.0). The resulting transfection mix 
was incubated at room temperature for 15 minutes and then added drop-wise onto the 
cells. For reporter assays, transfections were done using metafectene (Biontex 
Laboratories, GmbH) according to the manufacturer’s protocol. B cells were transfected 
using electroporation as described previously (51).  
Co-immunoprecipitation assays and western blot analysis 
Approximately 20 million cells expressing the proteins of interest were washed 
with PBS (phosphate buffered saline, 10mM NaPO4, 137mM NaCl, 2.5mM KCl, pH 7.5) 
and lysed in RIPA cell lysis buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA 
and 1% NP-40) supplemented with protease inhibitors (1mM phenylmethylsulfonyl 
fluoride, 10mg/ml pepstatin, 10mg/ml leupeptin and 10mg/ml aprotinin). Cellular lysates 
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were then sonicated to shear DNA and centrifuged at 12,000 rpm for 10 minutes at 40C to 
remove cellular debris. The supernatants were pre-cleared with protein A+G sepharose 
beads (GE Healthcare) for 30 minutes at 40C and gently rotated overnight at 40C with 
specific antibodies. Resulting immunocomplexes were captured by the addition of protein 
A and G conjugated sepharose beads and rotating the lysates for 2 hours at 40C. The 
immunocomplexes were collected by centrifuging at 2000 rpm for 2 minutes at 40C. The 
beads were washed three times with ice-cold RIPA buffer supplemented with protease 
inhibitors and boiled in 50µl of SDS PAGE sample loading buffer for 5 minutes. The 
immunoprecipitated proteins and respective total cell lysates were resolved on 9% SDS-
polyacrylamide gel and transferred onto 0.45-µm nitrocellulose membranes (GE 
Healthcare) at 100 V for 75 minutes. The blots were blocked with 5% non-fat milk in 
TBST buffer (10mM Tris-HCl, pH 7.5, 150mM NaCl, 0.05% Tween 20) and washed 
three times with TBST buffer before incubating overnight at 40C with specific primary 
antibodies. The blots were washed three times with TBST followed by incubating with 
appropriate secondary antibodies conjugated with Alexa Fluor 680 or Alexa Fluor 800 
(Molecular Probes, Carlsbad, CA) secondary antibodies at 1:10,000 dilutions. The 
membranes were scanned with the Odyssey scanner (LI-COR, Lincoln, NE).  
Yeast-two-hybrid assay 
LANA-N (1-340aa) was cloned in-frame with the DNA binding domain of GAL4 
(GAL4-DBD) of a pAS1 vector (Clontech, Mountain View, CA) to use as bait. This 
plasmid was transformed into S. cerevesiae strain Y190 (Clontech, Mountain View, CA) 
and selected on a DOBA-Trp dropout medium (Clontech, Mountain View, CA). 
Expression of LANA-N with DBD fusion protein was determined by anti-GAL4 DBD 
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antibody (Santa Cruz Biotechnology Inc.) on a Western blot. Yeast, Y190 containing 
LANA-N-DBD was transformed with cDNA library (generous gift from Dr. Erle S. 
Robertson, University of Pennsylvania) cloned into pACT vector and selected on BOBA-
Trp, His, Leu dropout medium (Clontech, Mountain View, CA) in presence of 30mM 3-
aminotriazole as described previously (52). Selected colonies were subjected for plasmid 
isolation, which was further electroporated into E. coli DH5a for their amplification. 
Plasmid DNA from individual bacterial colonies were isolated and subjected for 
sequencing at Nevada Genomics Center after determining their restriction pattern. 
Identities of the cDNA clones were determined by matching with the database sequence 
(NCBI).  
Immunofluorescence assay  
KSHV positive BCBL-1 and BC-3 cells were washed with phosphate-buffered 
saline (PBS) before spreading on coverslips. The cells were allowed to air-dry for 10 
minutes, fixed them with 4% paraformaldehyde for 10 minutes at room temperature 
followed by permeabilization with 0.2% Triton X-100 in PBS for 10 minutes at room 
temperature. Cells were blocked with PBS containing 0.4% fish skin gelatin and 0.05% 
Triton X-100 for 30 minutes at room temperature. The cells were then incubated with 
specific primary antibodies for 1 hour at room temperature, washed with PBS before 
incubating them with Alexa Fluor conjugated secondary antibodies (Molecular Probes) 
for 45 minutes at room temperature. The cells were washed three times with PBS to 
remove non-specifically bound antibodies before staining with nuclear stain, TO-PRO3 
(Molecular Probes). Images were captured using a confocal laser-scanning microscope 
(Carl Zeiss, Inc.). 
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Chromatin immunoprecipitation assay (ChIP) 
Chromatin immunoprecipitation was performed as described previously (53). 
Briefly, 15 to 20 million cells were fixed with a final concentration of 1% formaldehyde 
for 10 minutes at room temperature followed by adding glycine at a final concentration of 
125mM for 5 minutes to block cross-linking. The cells were rinsed three times with ice-
cold PBS and lysed in cell lysis buffer (5mM PIPES (pH 8.0), 85mM KCl, and 0.5mM 
NP-40) supplemented with protease inhibitors for 10 minutes on ice. The nuclei were 
enriched by low speed centrifugation and resuspended in protease inhibitors 
supplemented nuclear lysis buffer containing 50mM Tris-HCl, pH 8.1, 10mM EDTA and 
1% SDS. Chromatin was sonicated to an average length of 500 to 800 bp, centrifuged for 
10 minutes at 13,000rpm to remove the cell debris. The resulting supernatant was diluted 
5-fold with ChIP dilution buffer containing 16.7mM Tris-HCl, pH 8.1, 167mM NaCl, 
1.2mM EDTA, 0.01% SDS, 1.1% Triton X-100, and protease inhibitors. The diluted 
chromatin was pre-cleared with Protein A+G sepharose beads pretreated with 1mg/ml 
BSA and 1mg/ml sheared salmon sperm DNA for 30 minutes at 40C with rotation 
followed by incubating overnight with either control or specific antibodies at 40C with 
rotation. Immune complexes were collected by incubating with Protein A+G sepharose 
beads for 1–2h at 4°C. The beads were collected and washed subsequently with a low-salt 
buffer (0.1% SDS, 1.0% Triton X-100, 2mM EDTA, 20mM Tris [pH 8.1], 150mM 
NaCl), a high-salt buffer (0.1% SDS, 1.0% Triton X-100, 2mM EDTA, 20mM Tris [pH 
8.1], 500mM NaCl), and a LiCl wash buffer (0.25M LiCl, 1.0% NP-40, 1% 
deoxycholate, 1mM EDTA, 10mM Tris [pH 8.0]). The beads were then washed twice 
with Tris-EDTA buffer and chromatin was eluted using an elution buffer (1% SDS, 0.1M 
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NaHCO3) and reverse cross-linked by adding 0.3M NaCl at 65°C overnight. Eluted DNA 
was precipitated, treated with RNAse and proteinase K at 450C for 2h, and purified using 
Min-Elute PCR purification kit (Qiagen, USA). The purified DNA was analyzed by PCR 
for the presence of HLA-DRA promoter region.  
Primers used for HLA-DRA promoter amplification were described earlier. 
Forward: 5’-GTTGTCCTGTTTGTTTAAGAAC-3’,  
Reverse: 5’-GCTCTTTTGGGAGTCAG-3’ (44).  
KSHV TR primers have also been described earlier.  
Forward: 5′-GGGGGACCCCGGGCAGCGAG-3’,  
Reverse:  5’-GGCTCCCCCAAACAGGCTCA-3’ (51). 
Dual luciferase reporter assay 
Nearly 5×105 HEK293 L cells were seeded into 6-well plates the day before 
transfection. The cells were co-transfected with 0.5µg of DRA-Luc reporter plasmid, 
0.2µg of CIITA-Flag plasmid and increasing amounts of LANA expression vector (1, 2, 
and 3 µg). pA3F empty vector was used as filler DNA. Transfection efficiencies were 
monitored by transfecting green fluorescent protein (GFP) containing vector, pEGFP. 
Renilla luciferase-expressing plasmid (pRRLSV40) was transfected at 40ng/well for data 
normalization. All the transfections for reporter assays were done using metafectene 
(Biontex Laboratories GmbH) according to the manufacturer’s protocol. 36 hours post 
transfection cells were lysed in cell lysis buffer (Promega) and 50µl of the cell lysate was 
used for the reporter assay using dual luciferase reporter assay kit (Promega, USA). 
Relative luciferase units (RLU) were calculated after normalizing the HLA-DRA 
luciferase readings with Renilla luciferase to account for the transfection efficiencies.  A 
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portion of the cell lysates was used for Western blotting to detect LANA, CIITA and 
GAPDH. All experiments were repeated multiple times and the data shown is mean of 
three independent experiments. 
In vitro translation and GST pull-down assay 
For the GST pull-down assays, GST fusion proteins were expressed in E. coli 
BL21 cells. Briefly, the cells were induced with 1mM IPTG (isopropyl-B-d-
thiogalactopyranoside) for 4 hours at 370C and the GST fusion proteins were extracted 
from the bacterial cell lysates using glutathione-Sepharose beads (GE Healthcare, USA). 
Components of RFX complex and its truncation mutants RFXAP Δ1-70aa, RFXAP Δ1-
150aa and RFXAP Δ1-240aa, were translated in vitro using TNT T7 Quick coupled 
transcription-translation system (Promega, Madison, WI). Nearly 3µg of expression 
plasmids were translated per 50µl reaction containing 1mM (32µCi) 35S methionine 
according to the manufacturer’s protocol. The translated proteins were rotated overnight 
at 40C with either control-GST, LANA-N GST or LANA-C GST in NETN binding buffer 
(0.1% NP-40, 20mM Tris, 1mM EDTA and 100mM NaCl) supplemented with protease 
inhibitors. Control-GST, LANA-N GST and LANA-C GST proteins have been described 
earlier (54). Next day, GST bound proteins were gently washed three times in ice-cold 
NETN binding buffer supplemented with protease inhibitors and the precipitated protein 
complexes were resolved on SDS-PAGE and detected by autoradiography. 
Electrophoretic mobility shift assay (EMSA) 
EMSA was performed using a double-stranded oligonucleotide containing the 
HLA-DRA X box sequence as a probe. This sequence is known to bind with the RFX 
complex previously in gel shift assays (55). The probe was end labeled with α-32P and 
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purified on a GE Illustra ProbeQuant G-50 micro column (GE Healthcare, USA). RFX 
complex proteins and LANA-N (1-340aa) proteins were translated in vitro using a TNT 
Quick coupled transcription-translation rabbit reticulocyte lysate system (Promega, USA). 
A 40µl DNA-protein binding assay contained 12mM HEPES (pH 7.9), 12% glycerol, 
60mM KCl, 5mM MgCl2, 0.12mM EDTA, 0.3mM DTT, 0.1µg poly (dI/dC) and 0.05µg 
of denatured salmon sperm DNA as carrier (55). In vitro translated proteins were pre-
incubated on ice for 10 minutes before adding 1µl of end-labeled DNA probe. The 
reaction was incubated on ice for 30 minutes and the bound complexes were resolved on 
5% non-denaturing polyacrylamide gel in 0.5X TBE buffer (0.045M Tris Borate, pH 8.2, 
1.0mM EDTA). The gel was run at 40C at 100V for 10 to 12 hours. The signals were 
detected by autoradiography.  
Quantitative Real-time PCR (qRT-PCR) assays 
For quantitative Reverse-Transcriptase PCR assays, total mRNA from the cells 
was extracted using illustra RNAspin Mini kit (GE Healthcare) according to the 
manufacturer’s instruction and cDNA was made using High Capacity cDNA reverse 
transcription kit (Applied Biosystems, USA). Each PCR reaction consisted of 10µl of 2X 
PCR master mix (Applied Biosystems, USA), 1µM of each forward and reverse primers 
and 2µl of the cDNA. The cDNA was amplified on an ABI StepOne plus real-time PCR 
machine (Applied Biosystems, USA) and relative gene copies or the transcripts were 
calculated by the ΔΔCT method. Each experiment included duplicate samples and the 
data shown represents the mean of three independent experiments. P values were 
calculated by two-tailed t-tests using Graphpad (Prism 6) software. The primer sequences 
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used for the amplification of different HLA genes were taken from previously published 
article, which are listed in table 1 (23). 
 
Results: 
LANA interacts with the components of RFX complex  
Since LANA is a major latent protein, expresses ubiquitously in all KSHV 
infected cells and modulates various cellular pathways; we sought to identify LANA 
interacting proteins. Our yeast-two hybrid screen with amino terminal domain of LANA 
fused to Gal4-DNA binding domain (as bait), identified a number of cellular proteins, 
which are listed in Table 2. The clones of these identified proteins were detected at least 
twice in the screen. With the aim of determining LANA’s role in immune modulation, we 
focused further studies on RFXAP; a component of the RFX complex, critical for the 
transcription of HLA genes. RFX complex proteins are absolutely essential for the 
expression of MHC class II molecules. In order to determine whether RFX complex 
proteins interacted with LANA in KSHV infected cells, we performed co-
immunoprecipitation assays from KSHV infected primary effusion lymphoma (PEL) cell 
lines, BCBL-1 and BC-3. The results of these co-immunoprecipitation experiments 
showed that all the three components of RFX complex: RFX5, RFXAP and RFXANK 
co-immunoprecipitated with LANA from KSHV positive PEL cell lines, BCBL-1 and 
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BC-3 (Fig. 1A, lanes 3 and 6). Lack of RFX proteins precipitation with control antibody 
(CoAb) confirmed the specificity of LANA association with these proteins (Fig. 1A, 
lanes 2 and 5). In order to further validate the interactions between LANA and the 
components of RFX complex, we examined co-localization of LANA with RFX proteins 
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using immunofluorescence assay in BC-3 and BCBL-1 cells. As expected, LANA 
showed the typical punctate staining in the nucleus (Fig. 1B, LANA panel in red). The 
components of the RFX complex, RFX5, RFXAP and RFXANK showed distinct staining 
pattern in the nucleus (Fig. 1B, panels in green). As seen in the merged panels, all the 
three proteins of RFX complex showed varying degree of co-localization with LANA in 
the nuclear compartments of both the PEL cells, BC-3 and BCBL-1 (Fig. 1B, yellow dots 
in RFXs+LANA panels), suggesting that some fraction of LANA is in the same vicinity 
to the RFX proteins in the nucleus of KSHV infected cells. To assess whether 
KSHV/LANA altered the normal localization patterns of RFX proteins, we examined the 
staining patterns of RFX proteins in a KSHV negative, BJAB cells. Not surprisingly, 
BJAB also showed distinct staining patterns of RFX proteins, which was very much 
similar to the patterns seen in KSHV positive PEL cells (Fig. 1B, BJAB panels). LANA 
was not detected in these BJAB cells as expected. Nuclei of these PELs and BJAB cells 
were stained with TO-PRO-3 and the integrity of these cells were confirmed in DIC 
panels (Fig. 1B, DIC panels).	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In an attempt to 
determine whether all the 
components of RFX 
complex were in the same 
nuclear compartment as 
LANA, we determined co-
localization of LANA with 
two RFX proteins (RFXAP 
and RFX5) in a triple 
immunofluorescence assay. 
Co-localization of RFXAP 
with LANA in KSHV 
positive PEL cells, BCBL-1 
and BC-3 (Fig. 1C, red 
panels) showed almost 
similar co-localization 
(based on the number of 
yellow dots from multiple 
cells) as RFX5 with LANA 
(sky blue dots in LANA 
and RFX5 panel from 
multiple cells). This 
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suggested that LANA binds to the components of RFX complex in KSHV infected cells. 
BJAB cells showed perfect co-localization of RFXAP (red) and RFX5 (blue), which was 
also seen in KSHV positive PEL cells (Fig. 1C, merge all panel) confirming that these 
RFX proteins are in the same nuclear compartments. We expect RFXANK to be in the 
same loci but were unable to perform co-localization of all three RFX proteins with 
LANA because of a lack of host specific antibody for all three RFX proteins.	  
	  
LANA associates with RFX complex independent of other viral components 
Next, we wanted to determine whether LANA alone is sufficient for its 
association with the components of RFX complex, or it requires any other viral latent 
proteins to associate with the components of RFX complex.  
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To this end, we performed co-immunoprecipitation assays of individual RFX 
proteins with LANA in an over-expression system in HEK293T cells. Lysates from the 
cells co-transfected with plasmids expressing either control-Flag or LANA-Flag and Myc 
tagged RFX5, RFXAP or RFXANK were subjected to immunoprecipitation with anti-
Flag antibody. Detection of co-precipitating RFX proteins showed efficient binding of all 
three proteins of the RFX complex with LANA (Fig. 2A, 2B and 2C, IB:Myc panel). 
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Lack of co-precipitating RFX proteins in control-Flag lane confirmed the specificity of 
the assay. These results demonstrate that presence of LANA is sufficient to associated 
with the components of RFX complex.  
Since all the three components of RFX complex-RFX5, RFXAP and RFXANK 
associated with LANA in PEL cell lines as well in the overexpression systems, we 
wanted to determine whether any of these three RFX proteins of the trimeric complex is 
the main interacting partner of LANA. To answer this, we performed an in vitro binding 
assay by using in vitro translated and S35 methionine labeled proteins. The sizes of these 
in vitro translated proteins were confirmed by specific antibody in a Western blot. The 
radiolabeled proteins of RFX complex were incubated with in vitro translated Flag-
LANA of empty vector (Vector) to immunoprecipitate with anti-Flag antibody. The 
proteins resolved on SDS-PAGE and followed by autoradiography detected co-
immunoprecipitating RFX proteins, which were also confirmed by specific antibodies. 
Consistent with the results of our endogenous and expressed proteins 
immunoprecipitation assays, all the three components of the RFX complex co-
immunoprecipitated with LANA (Fig. 2D, IP-Flag LANA lane). Although all the three 
components of RFX bound with LANA, the level of RFXAP binding was higher when 
normalized to their respective inputs. The binding efficiencies calculated by taking input 
as 1 are presented in parenthesis (Fig. 2D, IP-Flag LANA lane, RFXAP at 0.81). These 
results again confirmed that LANA associates with the components of RFX complex 
independent of other KSHV components.  
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To validate these results by 
another experimental approach, we 
performed glutathione-S-
transferase (GST) fusion-protein 
pull-down experiments. In this 
assay, in vitro translated and S35 
methionine labeled RFX5, RFXAP 
or RFXANK proteins was 
individually incubated with GST 
fused LANA-N (1-340aa), LANA-
C (940-1162aa) or control-GST 
(Fig. 2E). GST pull-down assay 
showed that while LANA-N GST 
very strongly associated with 
RFXAP; it also showed weaker 
interactions with other RFX 
components, RFX5 and RFXANK (Fig. 2F, LANA-N GST panel).  Interestingly, LANA-
C GST showed very weak interaction with RFXAP (Fig. 2F, LANA-C GST panel). Lack 
of any binding with control GST confirmed the specificity of the binding assay (Fig. 2F, 
Ctrl-GST panel). A representative image of coomassie stained gel for GST-fusion 
proteins is shown in figure 2F (coomassie panel). Binding of RFXAP to the N-terminus 
of LANA was consistent with our yeast two-hybrid data where the N-terminus of LANA 
(bait) identified RFXAP as potential LANA interacting protein (Table 2). Since, RFXAP 
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was identified in the yeast-two-hybrid assay and it also bound most strongly to LANA in 
GST pull-down assay, we focused the domain-mapping experiments on RFXAP 
component of the RFX complex.   
LANA 1-150aa interacts with RFXAP  
To further ensure that amino terminus of LANA (1-340aa) is responsible for 
binding with RFXAP, a co-immunoprecipitation experiment were performed in 
HEK293T cells with RFXAP transiently co-expressed with either vector control, full 
length LANA, LANA-N (1-340aa), or LANA-C (940-1162aa). The immune detection 
with anti-Myc antibody for RFXAP showed co-immunoprecipitation of RFXAP with 
both, the full length as well as N terminus of LANA (1-340aa) but not with LANA-C 
(940-1162aa) (Fig. 3A, IB:Myc panel). Immunoprecipitated LANA and its truncations 
are indicated with an arrow (Fig. 3A, IB:Flag panel). In line with yeast-two-hybrid data 
and the GST pull-down results, this co-immunoprecipitation assay confirmed that 
RFXAP binds strongly to the amino terminal domain of LANA. We were further 
interested in determining the regions in amino terminal domain of LANA sufficient to 
interact with RFXAP.  To do this, LANA truncation regions, 1-340aa (as control of 
binding), 1-250aa or 1-150aa were transiently co-expressed with full-length RFXAP in 
HEK293T cells and a co-immunoprecipitation assay was performed. Detection of co-
precipitating RFXAP showed efficient binding with all three LANA truncations 
suggested that LANA 1-150aa is sufficient for interaction with RFXAP (Fig. 3B, IB:Flag 
panel). LANA truncations were detected by anti-Myc antibody (Fig. 3B, IB:Myc panel). 
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RFXAP interacts with LANA through its C-terminus 
RFXAP component of the RFX complex has distinct N-terminal acidic, C-
terminal glutamine-rich and a middle basic domain. Previous studies have shown that the 
last 43 amino acid region at the C-terminal glutamine-rich domain of RFXAP is 
sufficient for the expression of HLA-DRA gene however, the expression of other HLA 
genes (HLA-DQ and HLA-DP) requires a larger C-terminal segment of RFXAP (last 
130aa) (56). The last 43aa in the C-terminal domain of RFXAP have been reported to 
interact with the other two components of RFX complex- RFX5 and RFXANK (56-60). 
Hence, in order to understand the mechanism of how LANA’s binding may affect the 
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RFX complex formation and also the assembly of a functional enhanceosome to alter the 
expression of MHC II genes, we sought to determine whether LANA binds to RFXAP in 
the C-terminus or to the functionally dispensable N-terminal region of RFXAP. To this 
end, we constructed Flag tagged deletion mutants of RFXAP as shown in the schematic 
(Fig. 4A) and performed in vitro GST binding and co-immunoprecipitation assays to 
determine the RFXAP binding domain with LANA. RFXAP full length (1-272aa) and its 
truncations, 1-150aa, 151-272aa and 1-210aa efficiently translated in vitro detected as a 
distinct band by autoradiography. Binding assay with LANA-N-GST showed interactions 
with full length (1-272aa) RFXAP, as expected and the domains with C-terminus (151-
272aa) but not with N-terminal domains (1-150aa or 1-210aa) (Fig. 4B). The GST fusion 
proteins (control GST or LANA-N GST) used in this in vitro binding assay was detected 
by coomassie staining (Fig. 4C). These results suggested that LANA binds with RFXAP 
in the C-terminus region of 210 to 272aa, which is also the region that mediates the 
interaction with the other two components of RFX complex-RFXANK and RFX5. These 
binding results were further confirmed is a co-immunoprecipitation assay by co-
expressing LANA-N terminus fused to GFP-Myc with either empty Flag vector of Flag 
tagged RFXAP (1-272aa) and its truncations (1-172aa, 1-210aa, 150-272aa and 210-
272aa). The results of this co-immunoprecipitation assay also confirmed that the N-
terminal domain of RFXAP (1-210aa) was dispensable for its interaction with LANA. 
These binding assays determined that LANA binds in the C-terminal domain of RFXAP 
(210-272aa), which is also the interaction domain for other components of the RFX 
complex. We were unable to in vitro translate the smallest truncation of RFXAP (210-
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272aa), despite of repeated attempts, therefore was used only in over expression 
immunoprecipitation assay. 
LANA associates with HLA-DRA promoter  
The components of RFX complex bind, to the promoters of MHC class II 
molecules in order to promote the assembly of multi-protein enhanceosome complex for 
the recruitment of CIITA (61). Since LANA bound with RFX complex, we wanted to 
determine whether LANA associates with the promoters of MHC II genes. In order to test 
this, we performed chromatin immunoprecipitation (ChIP) assays with anti-LANA 
antibody from KSHV infected PEL cell lines, BCBL-1 and BC-3. The results determined 
by qPCR showed the copies of HLA-DRA promoter from the chromatin precipitated with 
LANA antibody but not in the chromatin with control antibody in both the, BC-3 and 
BCBL-1 cells, indicating specific association of LANA with the promoter of HLA-DRA 
gene (Fig. 5A, panel a). Since LANA associates with the terminal repeats (TR) sequence 
of KSHV genome, we used the LANA bound chromatin for the detection of TR as a 
positive control of anti-LANA ChIP. As expected, TR sequence amplified from the 
chromatin immunoprecipitated with anti-LANA antibody but not from the control 
antibody, confirming the specificity of anti-LANA ChIP (Fig. 5A, panel b). The western 
blot showing the efficiency of anti-LANA antibody immunoprecipitation is presented in 
Fig. 5A panel c). 
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The presence of LANA at the chromatin of HLA-DRA promoter was also 
detected in cells stably expressing LANA as the only KSHV protein. A KSHV negative 
B cell line, BJAB was stably transduce	  d with lentivirus vector expressing LANA-YFP-
Flag or control YFP-Flag and selected to obtain an enriched population of cells 
expressing yellow fluorescing protein (YFP). Chromatin immunoprecipitation (ChIP) 
was performed with anti-Flag antibody from both; control YFP-Flag (BJAB-YF) and 
YFP-LANA-Flag expressing BJAB cells (BJAB LYF).  DNA purified from the 
immunoprecipitated chromatin was subjected qPCR to detect the HLA-DRA promoter 
sequence. Detection of HLA-DRA promoter in the chromatin from BJAB with YFP-
FIG 5 LANA associates with HLA-DRA promoter. A. Chromatin Immunoprecipitation (ChIP) assay was done 
with anti-LANA antibody on the chromatins PEL cells, BC-3 and BCBL-1. Sonicated chromatin was 
immunoprecipitated with a) anti-LANA or control antibodies (IgG) and the chromatin bound DNA was 
subjected for the quantitation of HLA-DRA promoter by qPCR. b) Amplification of KSHV terminal region 
(TR), binding site of LANA, was included as a positive control for LANA-ChIP. c) Immune-blot showing 
specificity and efficiency of anti-LANA antibody in immunoprecipitation. B. b) Chromatin 
immunoprecipitation with anti-Flag antibody from the sonicated chromatin of BJAB cells stably expressing 
YFP-LANA-Flag tagged (BJAB-LYF) or control YFP (BJAB-YF). Presence of HLA-DRA promoter 
sequence in the immunoprecipitated chromatin was detected by qPCR. The error bars represents standard 
deviations from the mean of at least three experimental replicates. Relative binding (% Input) was 
determined by copies of the target sequence in the immunoprecipitated chromatin respective to the copies in 
the inputs. The P values were calculated by two-tailed t tests comparing the LANA ChIP with control 
antibody. *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001. (b) A western-blot showing 
specificity and efficiency of anti-Flag antibody. C. Electrophoretic mobility shift assay (EMSA) showing 
LANA’s binding to the HLA-DRA promoter bound with RFX complex proteins. EMSA was performed 
with p32 labeled double stranded X-box sequence of HLA-DRA probe and in vitro translated Flag tagged 
RFX5, RFXAP, RFXANK and Myc tagged LANA-N. Lane 1, X-box probe with rabbit reticulocyte lysate 
(RRL); lane 2, X-box probe with RFX complex (RFX-Cx Flag) showing binding of RFX-Cx Flag complex 
to the probe (arrow); lane 3, X-box probe with RFX-Cx Flag and 200x specific cold competitor probe 
(SCC), which competed with the binding of radiolabeled probe to RFX-Cx Flag; lane 4, X-box probe with 
RFX-Cx Flag and 200x non-specific cold competitor probe (NSCC) was not able to compete the binding; 
lane 5, X-box probe with RFX-Cx Flag and LANA-N Myc showing reduced mobility of the probe due to 
the binding of LANA-N Myc with RFX-Cx Flag (circle); lane 6, HLA-DRA probe with LANA-N Myc 
without RFX-Cx Flag showed no direct binding of LANA-N to the probe; lane 7, HLA-DRA probe with 
RFX-Cx Flag, LANA-N Myc, and α-Myc antibody (asterisk). α-Myc antibody further retarded the mobility 
of the probe bound to RFX-Cx: LANA-N protein by binding to the Myc epitope tag of LANA-N. The 
asterisk shows super-shifted complex; lane 8, HLA-DRA probe with RFX-Cx Flag, LANA-N Myc, and IgG 
control antibody. IgG control antibody failed to super-shift the mobility of the probe bound with RFX-Cx: 
LANA N protein complex. 
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LANA-Flag but not in YFP-Flag (Fig. 5B, panel a), confirmed specific association of 
LANA with HLA-DRA promoter.  Immunoprecipitating YFP-LANA-Flag and YFP-Flag 
were detected with anti-Flag antibody (Fig. 5B, panel b). Since LANA bound to the 
chromatin of HLA-DRA promoter in BJAB cells expressing LANA as the sole KSHV 
protein, it confirmed that LANA associates with HLA-DRA promoter without the aid of 
any other KSHV episome. This data further confirmed our findings that LANA can 
associate with RFX proteins independent of the involvement of other viral components.  
Binding of LANA to the HLA-DRA promoter was further established by an 
electrophoretic mobility shift assay (EMSA). For EMSA, radiolabelled double stranded 
RFX complex binding sequence (X-Box sequence) of HLA-DRA promoter was used as a 
probe (55). RFX complex proteins- RFX5, RFXAP and RFXANK, as well as LANA-N 
were translated with cold methionine in vitro to ensure that these proteins were free of 
other cellular proteins. Radiolabeled X-box sequence (probe) showed binding with RFX 
complex (RFX-Cx) as detected by a specific band (Fig. 5C, lane 2, arrow). The binding 
of RFX-Cx with radiolabeled probe was eliminated by an addition of 200 fold excess of 
specific cold competitor, SCC (Fig. 5C, compare lanes 2 with 3), but not with a similar 
fold excess of non-specific (scrambled) probe (non-specific cold competitor, NSCC) (Fig. 
5C, compare lanes 2 with 4). This confirmed that RFX-Cx specifically binds with X-box 
sequence of the probe. Addition of in vitro translated RFX binding domain of LANA 
(LANA-N; 1-340aa) to the RFX-Cx bound probe further retarded the mobility of the 
complex (Fig. 5C, lane 5, circle), confirming the association of LANA-N with RFX-Cx 
bound to the X-box sequence of the HLA-DRA promoter. Since LANA-N, without the 
RFX complex, was unable to alter the mobility of free probes (Fig. 5C, lane 6) it 
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confirmed that LANA-N can not bind directly to the X-box sequence of HLA-DRA 
promoter but through its association with the components of RFX complex. Specificity of 
LANA-N’s association with the RFX-Cx bound to the radiolabelled probe was 
determined by adding α-Myc antibody to the myc epitope tag of LANA-N (Fig. 5C, lane 
7). The mobility of the complex was further retarded (super shifted) in the presence of α-
Myc antibody but not with mouse IgG (control antibody)  (Fig. 5C, asterisk, compare 
lane 7 with 8). This confirmed that LANA-N forms a complex with the components of 
RFX complex at the HLA-DRA promoter. 
LANA reduces the transcriptional activity of HLA-DRA promoter 
Expression of MHC II genes is mainly controlled at the transcriptional level by 
binding of the MHC II regulatory proteins including the proteins of RFX complex at the 
MHC II promoters (62). Since LANA interacted with the RFX complex bound to the 
HLA-DRA promoter, we wanted to investigate whether the presence of LANA affects 
the activity of HLA-DRA promoter to alter the expression of MHC II molecules. To 
determine LANA’s affect, a dual luciferase reporter assays were performed using core 
HLA-DRA promoter that contained the essential cis-elements required for the 
transcription of HLA-DRA gene (63, 64). HLA-DRA reporter assay was performed in 
two different cell lines: 293L cells, a non antigen-presenting cells chosen because of the 
ease of transfection; and DG-75 cells, an antigen presenting B cells. The results of 
promoter reporter assay revealed that CIITA was able to activate the HLA-DRA 
promoter activity in both the cell lines, as expected (Fig. 6A and B, lane 2). Co-
expression of LANA in the cells expressing CIITA reduced the luciferase activity, 
determined by the relative luciferase units in both 293L and DG75 cell lines. An 
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increasing amount of LANA expression vector subsequently reduced the HLA-DRA 
promoter activity in a dose dependent manner (Fig. 6A and B, lanes 3, 4 and 5). 
Importantly, the highest concentrations of LANA, used in this assay completely 
abrogated the CIITA stimulated HLA-DRA promoter activity bringing the activity 
comparable to basal levels (Fig. 6 A and B, compare lanes 1 with 5). The amounts of over 
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expressed CIITA (by CMV promoter) was comparable among those samples with 
increasing LANA amounts confirmed that inhibition in HLA-DRA promoter was not due 
to a reduced levels of CIITA in those cells (Fig. 6A and B, IB: Flag). Detection of LANA 
by anti-Myc immune-blot showed increasing amounts of LANA in the lysate. Since the 
amino-terminal domain of LANA was able to bind with RFX complex, we wanted to 
determine whether would be sufficient to inhibit the HLA-DRA promoter activity similar 
to LANA full-length. To test this, we expressed increasing amounts of LANA-N in both 
293L and DG75 cells, which showed similar effect on reducing the HLA-DRA promoter 
activity as full length LANA (Fig. 6C and D, lanes 3, 4 and 5). In contrast, the C-terminal 
domain of LANA, which did not bind to CIITA complex, was unable to appreciably 
reduce the HLA-DRA promoter activity even high levels of LANA-C expression (Fig. 6E 
and F). Since comparable amounts of CIITA were overexpressed in all the test samples, 
abrogation of promoter activity by full-length LANA and LANA-N is most likely due to 
the inhibition of CIITA’s recruitment to the enhanceosome because of LANA binding 
with RFX complex. Dose dependent inhibition of the HLA-DRA promoter activity may 
suggest a competition between LANA and CIITA to bind with the RFX complex.  
LANA downregulates the expression of MHC II molecules  
Since RFX proteins are crucial for the expression of MHC II molecules and the 
expression of LANA inhibited the activity of one of the promoter (HLA-DRA) encoding 
MHC II gene, we hypothesized that binding of LANA with the components of RFX 
complex may have downstream effect on the transcription of MHC II molecules. We 
therefore analyzed the levels of MHC II transcripts in two antigen-presenting cells, BJAB 
and THP-1 stably expressing LANA through a lentiviral vector. Total RNA extracted 
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from the control (YFP-Flag, YFP) and LANA (LANA-YFP-Flag, LYF) cells were 
subjected for the analysis of MHC II genes using quantitative real-time PCR (qRT-PCR) 
assay. Since LANA also down regulates the expression of CIITA to consequently repress 
the expression of MHC II molecules (17), we took that lower levels of CIITA into 
account for determining the levels of HLA genes by normalizing the levels of CIITA in 
LANA expressing cells with the control cells. While it was intricate to distinguish the 
percentages of MHC II down-regulation due to LANA’s binding with RFX complex from 
the reduced expression of CIITA (LANA mediated down regulation of CIITA promoter) 
(17), we presumed that normalized levels of CIITA would yield comparable levels of 
MHC II genes, if no other mechanism involved. Therefore, we calculated the levels of 
MHC II genes by determining the ratios of CIITA in LANA expressing cells, which was 
0.6+0.1 as compared to the control cells. To compensate for the reduced levels of CIITA 
in LANA expressing cells, the levels of MHC II genes were determined by multiplying 
the ratios of MHC II genes with 1.66 (CIITA levels were reduced to 0.6 fold, therefore, 
the multiplication factor was 1/0.6=1.66). Importantly, the transcripts levels of all the 
classical MHC II genes (HLA-DRA, HLA-DRB, HLA-DPA, HLA-DPB, HLA-DQA and 
HLA-DQB) were down regulated significantly, even after normalizing the CIITA levels, 
in LANA expressing BJAB as well as THP-1 cells (BJAB-LYF and THP-LYF) 
compared to the respective control cells, BJAB-YFP and THP-YFP (Fig. 7 A and C). The 
results of the reporter assays, where CIITA was expressed through a CMV promoter (the 
levels of CIITA was unaltered with LANA), showing reduction in HLA promoter activity 
as well as the above CIITA levels normalized MHC II expression strongly advocates for 
an involvement of additional mechanisms in down regulation of MHC II genes by LANA 
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along with reduction of CIITA expression. Prevention of binding of CIITA to HLA 
promoters is one such plausible mechanism. The western blot analysis of MHC II levels 
in these LANA expressing, BJAB and THP-1 cells showed reduced levels of MHC II 
expression as compared to the control, YFP expressing cells (Fig. 7B and D). Immune 
blot for the detection of LANA-YFP-Flag and YFP-Flag in these BJAB and THP-1 cells 
confirmed the expression of LANA (Fig. 7B and 7D). Furthermore, the expressions of 
MHC II genes in KSHV infected PEL cells, BC-3 and BCBL-1, showed significantly 
reduced levels as compared to a KSHV negative, BJAB cells, analyzed by normalizing 
the levels of CIITA (Fig. 7E). We were unable to detect the mRNA of HLA-DQB in 
KSHV infected cells, even after multiple attempts, therefore are excluded from the 
relative mRNA calculation in this figure. Immune detection of MHCII expression in 
KSHV infected cells showed very low levels as compared to the KSHV negative cells, 
BJAB (Fig. 7F). These results are in corroboration with the results published by Cai et al 
(17), which showed reduced expression of MHC II proteins during KSHV infection. 
LANA interferes with the association of CIITA to RFXAP 
Since LANA interacted with RFX complex at the HLA-DRA promoter and down 
regulated the expression of MHC II molecules through mechanisms in addition to CIITA 
downregulation, we hypothesized that LANA might interfere with the binding of CIITA 
to RFXAP to disrupt the formation of a functional enhanceosome. To test this hypothesis, 
we immunoprecipitated CIITA and analyzed co-immunoprecipitating RFXAP in 
presence or absence of RFXAP binding region of LANA (LANA-N) in an 
overexpression system using HEK293T cells (Fig. 8A). As expected, RFXAP efficiently 
co-immunoprecipitated with CIITA in absence of LANA-N, but not with the control (Fig. 
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8A, IB: Myc panel, lanes 5 and 6). However, the amounts of co-immunoprecipitating 
RFXAP were significantly reduced in the presence of LANA-N (Fig. 8A, IB: Myc panel, 
lanes 7 and 8). The binding of RFXAP to CIITA was very weak at increased amounts of 
LANA-N (Fig. 8A, IB: Myc panel, lane 8) confirming that LANA’s binding to RFXAP 
blocked the binding of CIITA to RFXAP. Furthermore, LANA did not co-
immunoprecipitate with CIITA indicating that LANA does not directly interact with 
CIITA (Fig. 8A, IB: Myc panel, lanes 7 and 8).  
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A similar immunoprecipitation assay was also performed using cell-free system 
where CIITA, components of RFX complex and LANA-N terminus (1-340aa) were 
translated in vitro, for a co-immunoprecipitation assay with CIITA in presence of LANA-
N (1-340aa). Immunoprecipitation of CIITA with anti-Flag antibody co-precipitated 
RFX5 (component of RFX complex) (Fig. 8B, lane 6, RFX5 panel). The other 
components of RFX complex did not co-precipitate with CIITA in this cell-free system 
indicating that direct interaction between CIITA and RFXAP/RFXANK is very weak 
when these proteins are translated in vitro. Interestingly, co-immunoprecipitation of 
RFX5 was significantly reduced in the presence of LANA-N (Fig. 8B, lanes 7 and 8, 
RFX5 panel), confirming that LANA’s binding with the components of RFX complex 
results into a reduced binding of CIITA to the RFX complex.  
CIITA does not posses any direct DNA binding domain but is recruited to the 
MHC II promoters via interactions with the proteins of MHC II enhanceosome complex 
including the proteins of RFX complex (44). We speculated that a reduction in the 
binding of CIITA to the components of RFX complex would result into a reduced 
binding of CIITA to the enhanceosome of MHC II promoter. To confirm this, we 
performed anti-CIITA ChIP from BJAB cells stably expressing LANA (BJAB-LYF) and 
compared the binding of CIITA onto MHC II promoter in cells without LANA (BJAB-
YF). qPCR analysis of the ChIP assay revealed that association of CIITA with HLA-
DRA promoter was significantly reduced in LANA expressing BJAB cells as compared 
to the cells without LANA (Fig. 8C, panel a).  
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The efficiency of anti-CIITA antibody for immune precipitation were analyzed 
from BJAB cells expressing LANA-YFP-Flag and YFP-Flag, which showed comparable 
levels of CIITA in both the cells (Fig. 8D, IB: CIITA, panel a). LANA was detected with 
anti-Flag antibody in BJAB-LYF cells, as expected (Fig. 8D, IB: Flag, panel a). 
Furthermore, in PEL cell lines, BC-3 and BCBL-1, shRNA mediated reduction of LANA 
resulted into an increased association of CIITA to the chromatin of HLA-DRA (Fig. 8C, 
panels b and c), confirming a direct role of LANA in CIITA binding to the HLA-DRA 
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promoter. shRNA for LANA significantly reduced the levels of LANA confirmed by 
anti-LANA immune blot (Fig. 8D, panel b and c). Anti-CIITA antibody precipitated 
comparable amounts of CIITA from sh control (sh con) or sh LANA cells (Fig. 8D, 
panels b and c), confirming that reduced levels of HLA-DRA promoter was not due to 
reduced amounts of immunoprecipitated CIITA. While these results showed that the 
presence of LANA abrogates and depletion of LANA facilitates CIITA binding to the 
promoter to regulate MHC II expression, we performed a ChIP assay by expressing 
CIITA driven by CMV promoter (to obtain equal expressions of CIITA in all the 
samples) to rule out the possibility that reduction in CIITA binding to the HLA-DRA 
promoter was not due to a reduced expression of CIITA by LANA. We overexpressed 
Flag tagged CIITA along with or without LANA in cells transfected with HLA-DRA 
promoter plasmid and the components of the RFX complex in HEK293T cells by 
transient transfections. qPCR analysis of the HLA-DRA promoter from the chromatin 
immunoprecipitated with anti-Flag (CIITA) showed reduced levels of CIITA bound 
HLA-DRA promoter in cells expressing LANA confirmed that LANA directly reduced 
the binding of CIITA to HLA-DRA chromatin (Fig. 8C, panel d). Expression and 
immunoprecipitation of LANA and CIITA were detected by anti-Myc and anti-Flag 
immunoblots, respectively  (Fig. 8D, panel d).  
Finally, to gain a better understanding of the mechanism by which LANA could 
be interfering with the recruitment of CIITA and the assembly of functional 
enhanceosome, we investigated whether binding of the components of RFX complex to 
the enhanceosome is affected in presence of LANA.  
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To address this, we analyzed the binding of RFXAP and RFX5 on HLA-DRA 
promoter by performing ChIP assays on cells stably expressing LANA and also from 
PEL cells depleted with LANA. We did not observe any significant difference in the 
association of RFXAP to the HLA-DRA promoter in BJAB cells without or with LANA 
expression, as BJAB-YF and LYF showed almost similar levels of chromatin bound 
HLA-DRA promoter (Fig. 9A, panel a). Depletion of LANA by shRNA did not 
significantly change the association of RFXAP to HLA-DRA in both the PEL cell lines, 
BC-3 and BCBL-1, as shControl (sh con) and shLANA cells showed similar levels of 
chromatin bound HLA-DRA promoter (Fig. 9A, panels b and c). Efficiencies of RFXAP 
immunoprecipitations from BJAB and PEL cells showed comparable levels of RFXAP in 
respective set of cells (Fig. 9A, panels d, e and f). These results suggest that LANA 
interacts with RFXAP bound to the HLA-DRA promoter and does not interfere with the 
binding of RFXAP to HLA-DRA promoter. 
Since, the interaction of RFX5 with RFXAP is necessary for the binding of RFX5 
to the MHC II promoters (65), and LANA binds to the same domain of RFXAP that is 
required for RFXAP’s interaction with RFX5; we speculated that LANA’s association 
with RFXAP may result into a reduced binding of  RFX5 to HLA-DRA promoter. 
Interestingly, the association of RFX5 to the chromatin of HLA-DRA promoter was 
significantly reduced in BJAB cells expressing LANA (BJAB-LYF) as compared to 
control (BJAB-YF) cells (Fig. 9B, panel a). Additionally, RFX5 binding to chromatin of 
HLA-DRA promoter was enhanced in LANA depleted KSHV positive, BC-3 and BCBL-
1 cells (Fig. 9B, panels c and d). Immunoprecipitation with anti-RFX5 antibody showed 
comparable levels of RFX5 proteins in respective sets of cells (Fig. 9B, panels d, e and f). 
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Disrupted binding of RFX5 with RFXAP component was further confirmed in a co-
immunoprecipitation assay expressing LANA-N (RFXAP binding domain of LANA). 
While RFX5 but not the control vector efficiently co-immunoprecipitated RFXAP (Fig. 
9C, lanes 4 and 5), co-immunoprecipitation of RFXAP with RFX5 was reduced in the 
presence of LANA-N (Fig. 9C, RFXAP panel, compare lane 6 with lane 5). A detectable 
level of co-immunoprecipitating LANA-N with RFX5 (Fig. 9C, GFP LANA-N panel, 
lane 6) further supported that LANA’s binding with RFX components. Collectively, these 
data show that binding of LANA with the components of RFX complex inhibits binding 
of RFX5 and CIITA without affecting the binding of RFXAP to the HLA-DRA promoter. 
Discussion: 
KSHV has evolved excellent immune evasion and immune modulation strategies that 
allow it to establish a life long latency. Some of these strategies are identified but KSHV 
most likely have many more strategies up its sleeve that can sabotage host immunity. Of 
these, targeting MHC II antigen presentation pathway seems to be very crucial because 
MHCII molecules can present virally derived antigens to CD4+ T lymphocytes (66) and 
turn-on the adaptive antiviral immune responses. In addition to coordinating adaptive 
immune responses, activated CD4+ T cells also play a direct cytolytic role in killing the 
infected cells displaying viral antigens in conjugation with MHC II molecules (67).  So 
far, two KSHV latent proteins vIRF3 and LANA have been shown to inhibit MHC II 
antigen presenting pathway (17, 23, 25). LANA was previously reported to inhibit the 
expression of MHC II molecules via suppression of CIITA transcripts (17). The data 
presented here establishes a yet another mechanism used by LANA for evading the host 
immune system. Here, we show that LANA disrupts the assembly of functional MHC II 
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enhanceosome by interacting with the components of RFX complex and thereby 
contributes to the inhibition of MHC II pathway. To the best of our knowledge, this is the 
first study that shows a disruption of functional MHC enhanceosome by any virus to 
subvert the host immunity.  
Expression of MHC II molecules is primarily controlled at the level of 
transcription by a set of highly conserved transcription factors (29). Of these, the 
transcription factors of notable importance are CIITA and the three components of RFX 
complex, RFX5, RFXAP and RFXANK. The fact that defects in any of these four genes 
can result into a bare lymphocyte syndrome (BLS) characterized by severely reduced 
expression of MHC II genes, highlights the significance of these four proteins in 
regulation of MHC II genes (66, 68, 69). Transcription of all MHC II genes is highly 
coordinated and is strictly contingent upon binding of CIITA to the promoters of MHC II. 
CIITA is a non-DNA binding MHC II transactivator that is recruited to the promoters of 
MHC II genes via protein-protein interactions with the transcriptional factors pre-
assembled at the promoters of MHC II genes, termed as MHC II enhanceosome (29). 
RFX proteins are very important components of MHC II enhanceosome and binding of 
CIITA to the promoters of MHC II requires its interactions with the components of the 
RFX complex. Binding of CIITA to MHC II promoters is conceived to be absolutely 
essential for the expression of MHC II genes, as so far alternate pathways for MHC II 
expression are not known to exist. Targeting the RFX proteins and CIITA is therefore a 
very effective strategy for escaping the host adaptive immunity. Cai et al have previously 
reported that LANA deregulates CIITA transcription resulting into down regulate MHC 
II expression (17). In this study, we have identified a novel mechanism by which KSHV 
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LANA disrupts the association of functional enhanceosome to suppress the transcription 
of MHC II genes. Our report shows that LANA binds to the components of RFX complex, 
which prevents the recruitment of trans-activator, CIITA onto the promoters of MHC II 
genes to form a functional enhanceosome for down regulating the expression of MHC II 
genes. 
We identified RFX transcription factors as LANA interacting protein in a yeast-
two-hybrid screen. We further validated the interactions between LANA and RFX 
proteins using in-vivo and in vitro assays. Our data shows that LANA directly interacts 
with all the three components of RFX complex-RFX5, RFXAP and RFXANK and 
prevents binding of CIITA to the promoters of MHC II genes. While LANA can bind to 
all the three components of RFX complex, it has higher affinity to RFXAP. 
We demonstrated that the domain responsible for LANA’s interactions with RFX 
transcription factors is in the N terminal domain of LANA. Cai et al have reported that 
LANA’s C terminal domain is involved in the downregulation of MHC II by binding 
with IRF-4 (17). Involvement of multiple domains of LANA in the downregulation of 
MHC II emphasizes the importance of inhibiting MHC II pathway during KSHV latency. 
Since the amino terminal domain of LANA is known to associate with host chromatin (51, 
70) it raised the possibility that LANA might be interacting with the RFX proteins 
indirectly through chromatin binding factors. However, the interactions between the N 
terminus of LANA and RFX proteins was verified in cell free system, by using in vitro 
translated LANA and RFX proteins, which confirmed that these interactions are direct 
and independent of any cellular or viral factors.  
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RFXAP contains three biochemically distinct regions in its primary sequence 
including an acidic region, a basic region and a glutamine rich region. Of these regions, 
the C-terminal region, which includes the basic and the glutamine rich regions, is a highly 
conserved region (71). This region is both necessary and sufficient for its interactions 
with other components of RFX complex, RFX5 and RFXANK (32, 41, 59, 60, 72). Since 
LANA bound to the C-terminal region of RFXAP, we hypothesized that binding of 
LANA to the C- terminus of RFXAP may disrupt the assembly of functional RFX 
complex by reducing its association with either RFX5 or RFXANK or both. In support of 
this hypothesis, when we pulled down in vitro translated components of RFX complex 
through LANA, we observed a distorted stoichiometry of the RFX complex marked by a 
noticeably reduced association of RFX5 in the immunoprecipitated complex. This 
suggests that binding of RFXAP to LANA partially excludes RFX5 from the RFX 
complex, which have important implications on recruiting CIITA to the MHC II 
promoters because RFX5 and RFXANK, but not RFXAP, are known to directly interact 
with CIITA (43, 59, 71, 73). Indeed, the association of CIITA at HLA-DRA promoter 
was reduced in the presence of LANA in ChIP assays. We also demonstrated that co-
precipitation of RFX5 was reduced in presence of LANA when in vitro translated 
components of the RFX complex were co-immunoprecipitated with CIITA. RFXAP did 
not directly co-immunoprecipitate with CIITA in a cell-free system, probably due to the 
lack of direct interactions between CIITA and RFXAP in a cell-free system, or due to 
lack of proper post-translational modifications of these two proteins. However, when 
tested in vivo, co-immunoprecipitation of RFXAP with CIITA was reduced in a co-
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immunoprecipitation assay, affirming that the association of CIITA with RFX proteins 
was reduced in the presence of LANA.  
We further showed that LANA associates with MHC II promoters in order to 
disrupt the binding of CIITA with RFX complex using anti-LANA ChIP assay. However, 
LANA does not directly associate with the X box DNA sequence, a conserved cis acting 
RFX complex binding domain on MHC II promoters. Instead, LANA is recruited to the 
MHC II promoters by binding with the RFX proteins as evident by the results of 
electrophoretic mobility shift assays performed using in vitro translated RFX proteins and 
the amino terminal domain of LANA. We anticipated that association of LANA at MHC 
II promoters inhibits MHC II promoter activity, which subsequently results in reduced 
transcription and expression of MHC II genes. As expected, presence of full length as 
well as the N-terminus of LANA, which binds to RFX complex proteins, efficiently and 
dose dependently reduced the HLA-DRA promoter activity in luciferase reporter assays. 
While all the necessary component of MHC II transcription machinery is constitutively 
expressed in all cell types, expression of CIITA is restricted only to professional antigen 
presenting cells. However, the expression of CIITA can be induced in most cell types by 
IFN-ϒ treatment. Hence, in order to induce HLA-DRA promoter activity, we treated the 
cells with IFN-ϒ, which induced CIITA expression and HLA-DRA promoter activity but 
was suppressed in the presence of LANA (data not shown). While we observed an 
efficient inhibition of the HLA-DRA activity induced by IFN-ϒ treatment in presence of 
LANA, the report by Cai et al (17) raised the possibility that this inhibition could be 
because of reduced expression of CIITA, as LANA inhibits the activity of CIITA 
promoters pIII and PIV.  In order to alleviate the effect of LANA on CIITA repression 
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and subsequent reduction of HLA promoter, we modified our luciferase reporter assays 
and expressed the CIITA from a constitutively active CMV promoter, which showed 
comparable expression in presence or absence of LANA. Our data showed that even 
when the CIITA was expressed through CMV promoter, the activity of HLA-DRA 
promoter was efficiently and dose dependently downregulated by the full length as well 
as amino-terminal domain of LANA. These results confirm that in order to ensure 
efficient inhibition of MHC II transcription, LANA interferes with the binding of existing 
CIITA to the HLA promoters and disrupts the formation of functional enhanceosome. In 
our co-immunoprecipitation experiments, we did not find CIITA interacting with LANA 
suggesting that LANA does not directly associate with CIITA. Taken together, these data 
confirm that LANA binds with RFX proteins, and thereby interferes with the recruitment 
of CIITA to MHC II promoters. The eventual effect of LANA mediated interference of 
CIITA binding to MHC II promoters is reduced transcription and expression of MHC II 
genes.  
In an attempt to identify the mechanism by which LANA disrupts MHC II 
enhanceosome, we discovered that LANA’s association with RFXAP did not prevent the 
association of RFXAP with HLA-DRA promoter but it reduced the binding of RFX5 
with RFXAP, as demonstrated by ChIP assay. Reduced binding of RFX5 to HLA-DRA 
promoter in presence of LANA was most likely due to LANA’s binding to RFXAP in the 
same region as RFX5 binding, thus disrupting RFXAP’s association with RFX complex. 
Notably, association of RFXAP with RFX5 is required for relieving the auto-inhibition of 
RFX5 that prevents the DNA binding activity of RFX5 (65). Our ChIP data supported 
this hypothesis as association of RFX5 with HLA-DRA promoter was reduced in the 
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presence of LANA. Based on the overall results of this study, we propose a model (Fig. 
10) in which LANA disrupts the assembly of functional enhanceosome necessary for the 
expression of MHC II genes.  
Our findings about LANA’s association with the components of RFX complex 
have implications on the expression of MHC I molecules as well. Transcription of MHC I 
genes is regulated by the binding of NLRC5 transcriptional co-activator to MHC I 
promoter in a fashion similar to the regulation of MHC II genes by CIITA (74). NLRC5 
mediated expression of MHC I requires its association with RFX proteins for optimal 
transcription of MHC I genes (74). Hence, disruption of RFX complex by LANA may 
result into a reduced binding of NLRC5 to MHC I enhanceosome thus leading to a 
reduced expression of MHC I genes as well. MHC I antigen presentation is critical for 
activation of CD8+ T cells which has also been shown to play an important role in 
controlling KSHV infections (75, 76). The role of LANA in inhibiting MHC I through 
this mechanism remains to be explored but targeting RFX complex by KSHV appears to 
help the virus in dodging both MHC I and MHC II antigen presenting pathways and 
consequently evading the CD4+ T and CD8+ T cell immunities simultaneously. Given 
that collective T cell immunity is very critical in mounting anti-viral host response (18, 
77, 78), targeting RFX complex gives an edge to KSHV in establishing life-long 
persistence in the infected host.  
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In summary, we identified a new mechanism used by LANA to inhibit the 
expression of MHC II molecules. LANA disrupts the functional MHC II enhanceosome 
by binding with the RFX transcription factors and thus reduces the binding of master 
regulator, CIITA to the MHC II promoters. The overall effect of the disruption of 
functional enhanceosome is reduction in the transcription of MHC II genes leading to a 
lower level of MHC II expression. There may be involvement of multiple strategies by 
KSHV to completely block the expression of MHC II molecules on the cell surface as 
demonstrated previously (25). Inhibition of MHC II antigen presentation pathway is very 
crucial for the establishment of effective lifelong KSHV latency and hence LANA as 
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well as other latent proteins of KSHV are likely to target multiple immune pathways at 
multiple steps in order to efficiently block MHC II expression.  
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Abstract: 
Kaposi’s sarcoma (KS) is a highly vascularized tumor characterized by 
inflammation and extensive neo-angiogenesis. The tumor microenvironment is rich in 
inflammatory and pro-angiogenic cytokines. Epidermal growth factor-like domain 7 
(EGFL7) is a secreted pro-angiogenic cytokine that has been implicated in angiogenesis 
and the proliferation of endothelial cells during many physiological and pathological 
conditions. Here, we report that the expression of EGFL7 is upregulated in Kaposi’s 
sarcoma-associated herpes virus (KSHV) infected cells. Our data show that primary 
effusion lymphoma cells have increased levels of EGFL7 at mRNA and protein amounts 
compared with uninfected cells. We furthermore show that the KSHV latent protein, 
latency-associated nuclear antigen (LANA), is the viral factor responsible for this 
upregulation. The mechanism of EGFL7 expression by LANA seems to involve 
sequestration of death domain-associated protein 6 (Daxx), which is a suppressor of avian 
erythroblastosis virus E26 oncogene homolog 1 (Ets-1) activity, one of the core 
transcription factors required for the expression of EGFL7. We additionally show that the 
upregulation of EGFL7 contributes to the promotion of angiogenesis by LANA since 
siRNA-mediated knockdown of EGFL7 reduced in vitro tubulogenesis in LANA-
expressing HUVEC cells. EGFL7 appears to promote angiogenesis through autocrine as 
well paracrine mechanisms. We establish EGFL7 as one of the important angiogenic 
molecules secreted during KSHV infection that  may be an important therapeutic target in 
conjugation with other anti-angiogenic therapies.  
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Importance: 
Kaposi’s sarcoma (KS) is the second most common malignancy associated with 
AIDS worldwide and remains a significant cause of morbidity and mortality in AIDS 
patients. The fact that KS tumors are characterized by extensive neo-angiogenesis, even 
in early stages of development, highlights the significance of angiogenesis in the 
progression of KS tumors. Inhibiting angiogenesis is therefore an attractive therapeutic 
strategy for the treatment of KS. While many angiogenic mechanisms used by KSHV are 
known, the need for an effective anti-angiogenic therapy with long-term efficacy and a 
potent inhibition of tumor specific angiogenesis still prevails. This need calls for a deeper 
understanding of the host mechanisms manipulated by KSHV in order to promote 
angiogenesis. The present study explores one such mechanism involving a relatively 
newly identified host angiogenic cytokine EGFL7 that contributes to KSHV-induced 
angiogenesis.  
Introduction: 
 Kaposi’s sarcoma-associated herpes virus (KSHV) is an oncogenic virus 
responsible for multiple human malignancies including Kaposi’s sarcoma (KS) and two-
lymphoproliferative diseases- primary effusion lymphoma (PEL or BCBL) and 
multicentric Castleman’s disease (3, 10, 22). KS is the most common cancer associated 
with HIV infection and remains a leading cause of morbidity and mortality in AIDS 
patients. It is a highly vascular tumor of endothelial origin involving a complex interplay 
of immune evasion, inflammation and angiogenesis. Angiogenesis, the process of 
growing new blood vessels from preexisting ones, is a hallmark of KS tumors. The 
significance of angiogenesis in KS tumors is highlighted by the fact that KS tumors are 
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highly vascularized, even in early stages of development (7). Multiple angiogenic 
cytokines, including vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (b-FGF), angiopoietin-2, angiogenin and cycloxigenase-2 (COX-2), are known to 
be induced during KSHV infection (25, 30, 32, 34, 35, 37, 38, 47, 48).  
 EGFL7 (also known as a vascular endothelial (VE) statin) belongs to the 
epidermal growth factor-like domain family of growth factor. It is an angiogenic factor 
secreted by the endothelial cells that also acts on endothelial cells (26). In addition to its 
role in physiological angiogenesis, EGFL7 has also been implicated in the growth and 
metastasis of many solid tumors (6, 11, 14, 15, 20, 45, 46).  Normally, EGFL7 expression 
is restricted to endothelial cells or its expression is very weak in most human tissues. 
Under pathological conditions such as cancers, many tumors cells are known to secrete 
EGFL7 in order to promote angiogenesis (6, 15, 45). Interestingly, hypoxic conditions are 
known to induce expression of EGFL7 indicating that EGFL7 may play important roles 
in hypoxic conditions (such as are found in KS tumors) (5, 26). Since KS tumors exhibit 
extensive neo-angiogenesis, KSHV infection is likely to induce the expression of EGFL7. 
Here, we have explored the role of EGFL7 and its mechanism in KSHV-induced 
angiogenesis. Our data show that EGFL7 expression is upregulated during KSHV 
infection and potentially contributes to the angiogenesis associated with KS. 
 Latency-associated nuclear antigen (LANA) is a latent KSHV protein that is 
highly expressed in all latently infected cells (8, 16, 27). LANA is a multifunctional 
protein that is essential for establishing and maintaining a successful latency. LANA has 
been previously shown to promote angiogenesis and endothelial cell proliferation through 
manipulation of multiple signaling pathways (4, 29, 44). For example, LANA can 
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promote angiogenesis by inducing the expression of VEGF A, an important angiogenic 
cytokine by stabilizing hypoxia-induced factor 1α (HIF 1α), a transcription factor that 
upregulates VEGF A expression (2, 7, 36, 38). LANA also promotes angiogenesis by 
inhibiting the degradation of Hey1, a key component of the Notch signaling pathway with 
pronounced angiogenic activities (43). LANA regulates expression of many viral and 
cellular genes through its interactions with multiple host and viral proteins (3, 23, 41). 
One such host protein that LANA interacts with is death domain-associated protein 6 
(Daxx), a repressor of avian erythroblastosis virus E26 oncogene homolog 1 (Ets-1) (24). 
Ets-1 is a transcription factor that positively regulates expression of EGFL7 (26, 42). 
Daxx is known to inhibit the transcriptional activity of several Ets-1 responsive 
promoters through direct protein-protein interactions (18, 24). Here, we show that LANA 
induces the expression of EGFL7. This outcome can be partly attributed to the ability of 
LANA to sequester Daxx and the subsequent removal of inhibition posed on Ets-1 bound 
to EGFL7 promoter. Furthermore, when EGFL7 expression is inhibited with anti-EGFL7 
siRNA, the in vitro tubulogenic effect of LANA is also reduced.  
Materials and Methods: 
Cell culture 
The EBV- and KSHV-negative Burkitt lymphoma cell line BJAB and the KSHV-
positive but EBV-negative primary effusion lymphoma cell lines BC3 and BCBL1 were 
cultured in RPMI 1640 medium supplemented with 10% bovine growth serum, 2mM L-
glutamine and penicillin-streptomycin (5 U/ml and 5 g/ml, respectively). The HUVEC 
cells were cultured in Medium 200 supplemented (Gibco, USA) with low serum-growth 
supplement (Gibco), 5 U/ml penicillin and 5 g/ml streptomycin. HUVECs with fewer 
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than 8 passages were used. Human embryonic kidney cells HEK293L were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum, 2mM L-glutamine and penicillin-streptomycin (5 U/ml and 5 g/ml, respectively). 
All cell lines were grown at 37°C in a humidified environment supplemented with 5% 
CO2.  
Plasmids 
 Myc-tagged full-length LANA (pA3M-LANA), or Flag-tagged full-length LANA 
(pA3F-LANA), lentiviral-construct pLVX-LANA-YFP-Flag and its control construct 
pLVX-YFP-Flag, shRNA-expressing plasmids Ctrl shRNA and LANA shRNA, have 
been described previously in the literature (40). Flag-Daxx/PRK5 was obtained from 
Addgene (USA) (Cat#. 27974). For lentiviral-construct LANA-Flag-Puro, the full-length, 
Flag-tagged LANA sequence was transferred from pA3F-LANA into pLVxPuro-cloning 
vector (Ctrl Puro) between the EcoRI and XbaI restriction sites. Full-length (-1670 to 
+100) EGFL7 promoter-luciferase reporter construct was purchased from Addgene (Cat# 
32244). Its truncations (-150 to +100 and -71 to +100) were further subcloned into 
PGL3basic vector using an In-Fusion cloning kit (Takara/Clontech, USA) according to 
the manufacturer’s instructions. The primers sequences used for this cloning were:    
 (-71 to +100) EGFL7 promoter-luciferase Forward: 
 5’-AGCTCTTACGCGTGCTAGCATCCCAATCCCGATTACCCA-3’,  
(-150 to +100) EGFL7 promoter-luciferase Forward:  
5’-AGCTCTTACGCGTGCTAGCCTCAGCCTCCTGTTTGTCCGA-3’, 
(+100) EGFL7 promoter-luciferase Reverse: 
5’-AGTACCGGAATGCCAAGCTTTGGACCCTAGCCCTTGCTGG-3’. 
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Antibodies 
The following commercial antibodies were used: Mouse anti-EGFL7 (sc-373898, 
Santa Cruz, USA), mouse anti-Daxx (sc-8043, Santa Cruz), rabbit anti-Ets1 (sc-350, 
Santa Cruz), mouse anti-GAPDH (US Biological, USA), mouse anti-Flag M2 (Sigma 
Aldrich, USA) and mouse anti-Myc 9E10 (Sigma-Aldrich). Mouse anti-LANA 
monoclonal antibody was generated at Genscript (USA).  
Chromatin immunoprecipitation assays 
Chromatin immunoprecipitation (ChIP) was performed as described previously in 
the literature (9). Nearly 20 million cells were fixed with a final concentration of 1% 
formaldehyde for 10 minutes at room temperature followed by the addition of glycine at a 
final concentration of 125mM for 5 minutes to block cross-linking. The cells were rinsed 
three times with ice-cold phosphate buffered saline (PBS) and lysed in cell lysis buffer 
(5mM PIPES (pH 8.0), 85mM KCl and 0.5mM NP-40) supplemented with protease 
inhibitors for 10 minutes on ice. The nuclei were enriched by low-speed centrifugation 
and resuspended in protease inhibitor-supplemented nuclear lysis buffer containing 
50mM Tris-HCl, pH 8.1, 10 mM EDTA and 1% SDS. Chromatin was sonicated to an 
average length of 500–800 bp and centrifuged for 10 minutes at 13,000 rpm to remove 
cell debris. The resulting supernatant was diluted 5-fold with a ChIP dilution buffer 
containing 16.7mM Tris-HCl, pH 8.1, 167mM NaCl, 1.2mM EDTA, 0.01%  SDS, 1.1% 
Triton X-100 and protease inhibitors. The diluted chromatin was pre-cleared with Protein 
A and G sepharose beads pretreated with 1 mg/ml BSA and 1 mg/ml sheared salmon 
sperm DNA for 30 minutes at 4°C with rotation followed by incubation overnight with 
either control or specific antibodies at 4°C with rotation. The immune complexes were 
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collected via incubation with Protein A and G sepharose beads for 1–2 h at 4°C. The 
beads were collected and washed subsequently with a low-salt buffer (0.1% SDS, 1.0% 
Triton X-100, 2mM EDTA, 20mM Tris [pH 8.1], 150mM NaCl), a high-salt buffer (0.1% 
SDS, 1.0% Triton X-100, 2mM EDTA, 20mM Tris [pH 8.1], 500mM NaCl), and a LiCl 
wash buffer (0.25M LiCl, 1.0% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris [pH 
8.0]). The beads were then washed twice with Tris-EDTA buffer and the chromatin was 
eluted using an elution buffer (1% SDS, 0.1M NaHCO3) and reverse cross-linked by 
adding 0.3M NaCl at 65°C overnight. The eluted DNA was precipitated, treated with 
RNAse and proteinase K at 45°C for 2h and purified using a Min-Elute PCR purification 
kit (Qiagen, USA). The purified DNA was analyzed by RT-PCR for the presence of the 
EGFL7 promoter region. We used the following primers for the detection of EGFL7 
promoter during RT-PCR:  
Forward: 5’-CCA GCA GGG TCC AGC CCT GGT-3’ 
Reverse: 5’-TGG GTA ATC GGG ATT GGG ATG-3’ 
Dual luciferase reporter assays 
5×105 HEK293 L cells or 0.5×105 HUVEC cells were seeded into 6-well plates 
the day before transfection. 0.5 µg of either wild-type EGFL7 promoter, (-150 to +100) 
EGFL7 promoter-luciferase, or (-71 to +100) EGFL7 promoter-luciferase plasmids were 
co-transfected with either the variable amounts of either Flag-Daxx or pA3F-LANA or 
both, as specified in the experiments. Empty-vector plasmid pA3F was used as a filler 
plasmid. The transfection efficiencies were monitored by a transfecting green fluorescent 
protein (GFP)-containing vector, pEGFP. Renilla luciferase-expressing plasmid 
(pRRLSV40) was transfected at 40 ng/well for data normalization. All of the 
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transfections were done using Metafectene (Biontex Laboratories GmbH, Germany) 
according to the manufacturer’s protocol. Twenty-four h after transfection the cells were 
lysed in cell lysis buffer (Promega) and 50 µl of the cell lysate was used for the reporter 
assay using a dual luciferase reporter assay kit (Promega, USA). The EGFL7 promoter-
luciferase readings were normalized against Renilla luciferase to account for the 
transfection efficiencies and were reported as relative luciferase units (RLU). A portion 
of the cell lysates was used for Western blotting to detect LANA, Daxx and GAPDH. All 
of the experiments were repeated multiple times and the data shown are the mean of three 
independent experiments. 
Co-immunoprecipitation assays and Western blotting analysis 
Approximately 10 million cells expressing the proteins of interest were washed 
with PBS (10mM NaPO4, 137mM NaCl, 2.5mM KCl, pH 7.5) and lysed in RIPA cell 
lysis buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA and 1% NP-40) 
supplemented with protease inhibitors (1mM phenylmethylsulfonyl fluoride, 10mg/ml 
pepstatin, 10mg/ml leupeptin and 10mg/ml aprotinin). The cellular lysates were then 
sonicated to shear the DNA and centrifuged at 12,000 rpm for 10 minutes at 4°C to 
remove cellular debris. The supernatants were pre-cleared with protein A and G 
sepharose beads (GE Healthcare, USA) for 30 minutes at 4°C and gently rotated 
overnight at 4°C with specific antibodies. The resulting immune complexes were 
captured by the addition of protein A and G conjugated sepharose beads and rotating the 
lysates for 2 h at 4°C. The immune complexes were collected by centrifuging at 2000 
rpm for 2 minutes at 4°C. The beads were washed three times with ice-cold RIPA buffer 
supplemented with protease inhibitors and boiled in 50 µl of SDS PAGE sample loading 
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buffer for 5 minutes. The cellular lysates and immunoprecipitated proteins were separated 
on SDS-PAGE gels and transferred onto 0.45 µm nitrocellulose membranes (GE 
Healthcare, USA) at 100 V for 75 minutes. The blots were then blocked with 5% non-fat 
milk in TBST buffer (10mM Tris-HCl, pH 7.5, 150mM NaCl, 0.05% Tween 20) and 
washed three times with TBST buffer before being incubated overnight at 4°C with 
specific primary antibodies. The blots were washed three times with TBST and were then 
incubated with appropriate secondary antibodies conjugated with Alexa Fluor 680 or 
Alexa Fluor 800 (Molecular Probes, USA) secondary antibodies at 1:10,000 dilutions. 
The membranes were scanned with an Odyssey scanner (LI-COR, USA).  
Quantitative real-time PCR 
 For quantitative Reverse-Transcriptase PCR assays, we extracted the total mRNA 
from the cells using an illustra RNAspin Mini kit (GE Healthcare) according to the 
manufacturer’s instructions. The cDNA was made from the extracted mRNA using a 
High-Capacity cDNA reverse transcription kit (Applied Biosystems, USA). Each PCR 
reaction consisted of 10 µl of 2X SYBR PCR master mix (Applied Biosystems), 1µM of 
each forward and reverse primers and 2µl of the cDNA. The cDNA was amplified on an 
ABI StepOne plus real-time PCR machine (Applied Biosystems), and the relative gene 
copies or the transcripts were calculated with the ΔΔCT method. Each experiment 
included duplicate samples and the data shown represent the mean of three independent 
experiments. We calculated P values using two-tailed t-tests with Graphpad (Prism 6, 
USA) software.  
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RNA sequencing 
The RNA-seq of BJAB cells stably expressing LANA (BJAB-LYF) and the 
control cells BJAB-YFP was performed on a HiSeq next-generation sequencer (Illumina, 
Inc., USA) as described previously in the literature  (33). The total RNA was isolated 
with TRIzol reagent following the manufacturer’s instructions (Life Technologies, USA). 
The concentration and purity of the extracted RNA was determined using a Nano Drop 
2000c spectrophotometer (Nano Drop Technologies, USA). A TrueSeq RNA sample 
preparation kit v2 (Illumina, Inc.) was used to prepare the cDNA libraries for RNA-seq 
according to the manufacturer’s instructions. The fragment sizes and purity of the mature 
libraries were confirmed using a Bioanalyzer 2100 (Agilent Technologies, USA). The 
quantities of the libraries required for RNA-seq were determined by real-time qPCR 
using a KAPA library quantification kit for the Illumina platform (Kapa Biosystems, 
Location). We sequenced the libraries using HiSeq (Illumina, Inc.), and the sequences 
were mapped to a human reference genome using the RNA-Seq Analysis tool in CLC 
Genomic Workbench 7 (CLC Bio, Denmark) software.  
Lentivirus production 
 Control YFP and LANA-expressing LYF lentivirus particles were produced using 
Vesicular stomatitis virus-G envelope-pseudotyped lentiviral virions by co-transfecting 
20 µg lentiviral construct (LANA-expressing pLVx-Ac-YFP-C1-LANA-Flag or control 
pLVx-AcYFP-C1-Flag), along with pseudotyped lentiviral packaging vectors 6.0 µg 
REV, 10.0 µg GP and 3.0 µg VSV-G into a 10 cm dish of ∼85% confluent HEK293T 
cells using polyethylenimine as described previously in the literature (40). Eight h after 
transfection, the medium was changed and the cells were induced using 10 mM Sodium 
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Butyrate in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 
penicillin-streptomycin (5 U/ml and 5 g/ml, respectively) buffered with 10 mM HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). The media was changed 24 h after 
transfection to remove the Sodium Butyrate. The medium containing the lentiviral 
particles was collected, passed through a 0.45 µm filter and concentrated to 1/120 of its 
original volume. The cells to be transduced were pre-incubated with polybrene 
(Hexadimethrine bromide) at the final concentration of 8 µg/ml for 30 minutes before 
adding the concentrated lentiviral particles. The infections of the target cells were carried 
out by incubating the concentrated lentiviral particles for 12–18 h, after which the 
medium was changed. The expression of the constructs was confirmed with RT-PCR 
analysis. 
Endothelial tube formation assay 
We performed the endothelial tube formation assay using an angiogenesis starter 
kit (Life Technologies, USA) according to the manufacturer’s instructions. Briefly, the 
assay was performed using a 24-well micro-titer plate coated with 100 µl of Geltrex 
Matrix and incubated at 37°C for 30 minutes. The HUVEC cells were re-suspended in 
supplemented Medium 200 and plated on the Geltrex Matrix coated wells at a density of 
approximately 0.8 × 105 cells per well. Photographs were taken with a digital camera 
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Results: 
Identification of EGFL7 as a LANA responsive gene 
Considering the pleiotropic effects of LANA during KSHV latency, we wished to 
identify the host genes that were directly or indirectly regulated by LANA using a 
sensitive and unbiased approach of next-generation RNA sequencing. In order to identify 
the genes that were differentially regulated in response to LANA expression, we 
generated  a LANA-expressing stable cell line (BJAB-LYF) and its matching control cell 
line (BJAB-YFP) by transducing a KSHV-negative B cell line, BJAB with the lentivirus 
particles expressing the constructs of interest (Fig 1). The expression of LANA in BJAB-
LYF was confirmed with RT-PCR (data not shown) and Western blotting (Fig 2B). The 
total mRNA was isolated from these cells to prepare the cDNA libraries for RNA 
sequencing using Illumina HiSeq. The results of this screen identified more than a 
thousand cellular genes that were differentially regulated in LANA-expressing B cells. 
Some of the interesting genes identified during this screen are listed in Table 1. Among 
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these genes, the EGFL7 gene was selected for further study considering the feasibility of 
the study and the gene’s potential significance to promote angiogenesis in KS tumors.  
 
EGFL7 is upregulated during KSHV infection 
 Following the identification of EGFL7 as a gene induced in response to LANA 
expression, an increase in the transcription of EGFL7 by LANA was further confirmed 
using an independent approach of RT-PCR in the BJAB-LYF and BJAB-YFP cells (Fig 
2A). The relative mRNA expression of EGFL7 was considerably higher in the LANA-
expressing cells compared with the control cells (Fig 2A). The expression of the EGFL7 
protein in these cells was confirmed by Western blotting the cellular lysates of these cells 
for EGFL7 (anti-EGFL7 antibody) and LANA (anti-Flag antibody). GAPDH served as a 
control for equal loading. Consistent with the observed increase of the EGFL7 transcript 
Figure 1 Experimental design for the transcriptome analysis of LANA-expressing B cells. The lentivirus 
particles were concentrated from the supernatant of HEK293T cells transfected with either LANA-
expressing pLVx-Ac-YFP-C1-LANA-Flag or control pLVx-AcYFP-C1-Flag along with the packaging 
vectors and were used to transduce KSHV-negative BJAB cells. The total mRNA was extracted from the 
BJAB cells stably expressing LANA-YFP-Flag (BJAB-LYF) or the control cells expressing YFP-Flag 
(BJAB-YFP). The cDNA libraries were prepared using the TrueSeq RNA-seq library Kit. The libraries 
were sequenced using HiSeq and the sequences were mapped to the reference human genome to analyze 
the differential expression of up or down regulated cellular genes. 
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level, increased expression of the EGFL7 protein was also observed in LANA-expressing 
cells compared with the control cells (Fig 2B).  
 
 
The results of these experiments confirmed that LANA expression was sufficient to 
induce the expression of EGFL7 at both the mRNA and the protein levels. In order to 
Figure 2 LANA induces expression of EGFL7. Relative mRNA levels of EGFL7 gene in A. BJAB (LYF) 
cells compared with the control BJAB with YFP (YFP) and B. KSHV-infected PEL cells BC3 and BCBL1 
compared with the BJAB cells. The mRNA levels were quantified using RT-PCR and the expression levels 
were normalized against the GAPDH gene. The error bars represent standard deviations from the mean of 
at least three experimental replicates. * indicates P < 0.05. The immune detection of EGFL7 expression in 
C. BJAB-YFP and BJAB-LYF D. BJAB, BC3 and BCBL1 cells. GAPDH shows equal loading of the 
lysates. 
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determine whether LANA-mediated upregulation of EGFL7 was also relevant in the 
context of long-term KSHV infection, we analyzed the relative mRNA expression of 
EGFL7 using RT-PCR (Fig 2C) and EGFL7 protein expression using Western blotting 
(Fig 2D) in latently KSHV-infected primary effusion lymphoma cell lines (BC3 and 
BCBL1).	    The relative abundance of the EGFL7 transcript was significantly higher in 
both the KSHV-positive cell lines (BC3 and BCBL1) compared with the KSHV-negative 
BJAB cells at the mRNA (Figs 1A and C). This result was also reflected in the observed 
higher protein expression of EGFL7 in the corresponding cells (Fig 1D). Significant 
upregulation of EGFL7 in primary effusion lymphoma cell lines suggests that that 
EGFL7 likely plays an important role in KSHV infection.  
LANA upregulates EGFL7 promoter activity  
LANA has been shown to modulate the activities of many cellular and viral promoters. 
Hence, we examined whether LANA expression enhances EGFL7 expression by 
activating EGFL7 promoter. To this end, we performed promoter reporter assays using a 
full-length EGFL7 promoter luciferase construct that has been described previously in the 
literature (12). The reporter assays performed in two different cell lines HEK293T cells 
(Fig 3B) and endothelial HUVEC cells (Fig 3C) revealed that LANA expression in both 
of these two cell lines transactivated full-length EGFL7 promoter  (-1670 to +100) in a 
dose-dependent manner (Fig 3C). These results confirmed that LANA induces the 
expression of EGFL7 by activating EGFL7 promoter activity.  
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 Figure 3 LANA activates EGFL7 promoter by sequestering Daxx. A. Schematic full-length EGFL7 promoter-
luciferase construct showing a map of the transcription factor binding sites. This figure has been adopted 
from the paper ‘Ets-1 and Ets-2 regulate the expression of miR-126 in endothelial cell’ by Harris et al. 
(2010). The dual luciferase reporter assay results show a dose-dependent increase in EGFL7 luciferase 
activity in response to the increasing expression of LANA. B. HEK293T cells and C. HUVEC cells. The 
cells were transfected with 0.5 µg (lane 2), 1.0 µg (lane 3) or 2.0 µg (lane 4) of Flag-tagged LANA-
expressing plasmid pA3F-LANA. RLU were calculated relative to the basal (mock transfected, lane 1) 
promoter activity. The error bars represent standard deviations from the mean of at least three experimental 
replicates.  
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LANA upregulates EGFL7 expression by sequestering Daxx 
 LANA could activate the EGFL7 promoter in multiple potential ways such as the 
activation of one or more transcription factors necessary for EGFL7 expression, 
recruitment of activators, or the removal of repressors of the EGFL7 promoter. Since 
previous studies have demonstrated that LANA sequesters Daxx, which acts as a 
repressor of EGFL7 promoter by inhibiting Ets-1, one of the important transcription 
factors regulating the activity of EGFL7, we speculated that this mechanism might 
contribute to the activation of EGFL7 promoter by LANA. In order to test this hypothesis, 
we performed a series of reporter assays in HUVEC cells transfected with Daxx and/or 
LANA (Fig 4A). As expected, the overexpression of Daxx reduced the activity of the 
EGFL7 promoter (compare lanes 1 with lanes 2 and 3), confirming that Daxx represses 
the EGFL7 promoter. However, this repression of the promoter activity was not very 
significant. This effect may be explained by the nearly saturated levels of endogenous 
Daxx suppressing EGFL7 promoter activity. In support of this speculation, we failed to 
observe a dose-dependent effect of EGFL7 promoter inhibition by Daxx (lanes 2 and 3). 
Importantly, consistent with our hypothesis, when LANA was co-expressed with Daxx it 
increased the activity of EGFL7 promoter in a dose-dependent manner (lanes 4, 5 and 6). 
The increase in the promoter activity was significant, suggesting that the overexpression 
of LANA not only sequesters overexpressed Daxx but also sequesters endogenous Daxx 
(given that sequestration of Daxx is the primary mechanism responsible for the 
upregulation of EGFL7 promoter activity by LANA). Western blotting of the cellular 
lysates confirmed the expression of Daxx and LANA (Fig 4B).  
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 In the absence of LANA, Daxx associates with Ets-1 in order to repress its 
activity. However, LANA’s sequestering of Daxx disrupts its association with Ets-1 (24). 
Using co-immunoprecipitation assays, we confirmed that association of Ets-1 with Daxx 
was indeed reduced in the presence of LANA. Considerably less Ets-1 co-
Figure 4 LANA upregulates EGFL7 promoter activity by sequestering DAXX. A. Dual luciferase reporter 
assay in HUVEC cells with overexpressed DAXX and overexpressed LANA. The cells were transfected 
with DAXX and LANA as indicated. RLU were calculated relative to the basal (mock transfected, lane 1) 
promoter activity. The error bars represent standard deviations from the mean of at least three experimental 
replicates. B. Corresponding Western blotting showing the expression of DAXX and LANA. An 
immunoprecipitation assay showing reduced association of DAXX with Ets-1 in C. LANA-expressing 
BJAB cells (B-LYF) compared with the control cells (B-YFP) and D. Latently KSHV-infected B cells 
BC3. A ChIP assay showing the reduced association of EGFL7 promoter with DAXX in the presence of 
LANA in BJAB cells. 
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immunoprecipitated with Daxx in the presence of LANA in BJAB cells expressing 
LANA as a sole KSHV protein (Fig 4C; compare lanes 3 and 4). Similar results were 
obtained in latently KSHV-infected BC3 cells (Fig 4D; compare lanes 3 and 4).  
 Finally, LANA-mediated removal of Daxx from the EGFL7 promoter was 
confirmed by a ChIP assay in LANA-expressing BJAB (B-LYF) and the control cells (B-
YFP) (Fig 4E). The Daxx antibody, but not the control IgG antibody, efficiently 
precipitated the EGFL7 promoter DNA in control cells, confirming the specificity of the 
Daxx antibody in precipitating the EGFL7 promoter. However, this association was 
significantly reduced in LANA-expressing B-LYF cells, suggesting that LANA 
efficiently removes Daxx from the EGFL7 promoter. Collectively, these results point 
toward the sequestration of Daxx by LANA as a primary mechanism behind LANA-
mediated transactivation of the EGFL7 promoter.  
The Ets-1 binding region of the EGFL7 promoter is responsible for LANA-mediated 
induction of EGFL7 
 To further confirm that Daxx sequestration is a primary mechanism behind the 
transactivation of the EGFL7 promoter by LANA, we studied the regulation of the 
EGFL7 promoter in response to LANA using deletion analysis of the EGFL7 promoter 
(Fig 5). The EGFL7 promoter contains potential binding sites for several transcription 
factors including the binding sites for GATA1, GATA2, Ets-1 and Ets-2 (Fig 3A) (12). 
Of these, the EGFL7 promoter region -150 to + 100 contains binding sites for Ets-1 and 2, 
as well as for GATA 1 and 2; and the region -71 to + 100 contains binding sites for 
GATA 1 and 2 only. We cloned these two deletion constructs of the EGFL7 promoter (-
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150 to +100 and -71 to +100) in the PGL3 basic vector in order to fuse these regions with 
the luciferase reporter (Fig 5A).  
We studied the responsiveness 
of these two constructs to 
LANA using reporter assays. 
The results of these 
experiments revealed that the 
region -150 to +100 was 
transactivated in a dose-
dependent manner by LANA 
(black bars, Fig 5B and C) but 
the region -71 to +100 (white 
bars, Fig 5B and C) was not 
responsive to LANA 
expression in HEK293L (Fig 
5B) and HUVEC cells (Fig 5C). 
These results suggest that the 
LANA-responsive region of the 
EGFL7 promoter contains Ets 
binding sites but not GATA 
binding sites. The specificity of 
Daxx at repressing the EGFL7 
Figure 5 The Ets binding site is important for the transactivation of 
the EGFL7 promoter by LANA. A. Schematic showing the 
deletion constructs used in the reporter assays and dual luciferase 
assays in response to increasing concentrations of LANA B. 
HEK293L cells and C. HUVEC cells. The concentration of LANA 
expression plasmid transfected in the cells is indicated below each 
of the bars. D. Dual luciferase activity in HUVEC cells transfected 
with a variable amount of DAXX and LANA expression plasmids, 
as indicated below the bars. The black bars represent relative 
luciferase activities of the (-150 to +100) construct and the white 
bars represent relative luciferase activities of the (-71 to +100) 
construct.  RLU were calculated relative to the basal (mock 
transfected, lane 1) promoter activity. The error bars represent 
standard deviations from the mean of at least three experimental 
replicates.  
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promoter through Ets-1 binding was demonstrated by studying the responsiveness of the -
150 to +100 and -71 to +100 promoter luciferase constructs by overexpressing Daxx and 
LANA (Fig 5D). Expression of Daxx inhibited the activity of the -150 to +100 reporter 
construct containing the Ets-1 binding site (Fig 5D, lane 2, black bar) but not the -71 to 
+100 construct lacking the Ets-1 binding site (Fig 5D, lane 2, white bar). Furthermore, 
LANA expression significantly increased activity of the -150 to +100 construct but not 
the -71 to 100 construct, indicating that LANA cannot activate the EGFL7 promoter if 
the Ets-1 binding site is not present. Taken together, these results clearly demonstrate that 
the sequestration of Daxx is the primary mechanism by which LANA upregulates EGFL7.  
EGFL7 contributes to LANA-induced angiogenic phenotype in vitro 
 LANA has been demonstrated to promote angiogenesis through a variety of 
mechanisms (13, 24, 28, 43, 44). EGFL7 also has been shown to promote angiogenesis in 
a variety of cancers. We therefore investigated whether EGFL7 contributes to LANA-
induced angiogenesis. To this end, we studied the effect of EGFL7 knockdown on the 
angiogenic potential of LANA-expressing HUVEC cells using an in vitro endothelial 
tube formation assay. EGFL7 was depleted using EGFL7 siRNA in the HUVEC cells 
stably expressing LANA. As expected, the LANA-expressing cells demonstrated 
increased endothelial tube formation compared with the control cells (Fig 6A, a and b). 
However, when EGFL7 was knocked down using siRNA, tubule formation was reduced 
in LANA-expressing cells compared with the same cells transfected with control siRNA 
(Fig 6A, b and c). Western blotting analysis of the transfected cells used in the in vitro 
angiogenesis assay showed that EGFL7 expression was efficiently reduced by EGF7 
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siRNA (Fig 6B). These results demonstrated that EGFL7 is an important mediator of 
LANA-induced angiogenesis.   
Discussion: 
Angiogenesis is a critical process for the survival of tumor cells since it fulfills the 
increased demands of oxygen and nutrients required by the rapidly dividing tumor cells. 
As a result, many solid tumors induce the expression of pro-angiogenic cytokines. 
EGFL7 is one such angiogenic cytokine overexpressed in multiple malignancies such as 
Figure 6 EGFL7 contributes to LANA-induced in vitro endothelial tubule formation. A. Representative 
images of tube formation in (a) control HUVEC cells (YFP), (b) HUVEC cells stably expressing LANA 
transfected with control siRNA (LYF-control siRNA) and (c) HUVEC cells stably expressing LANA 
transfected with EGFL7 siRNA (LYF- EGFL7 siRNA). The cells were plated on Geltrex Matrix-coated 
plates 24 h after transfection and the images were taken 24 h after plating. Ten percent of the transfected 
cells were reserved for Western blotting analysis. B. Western blotting showing the expression of EGFL7 
and LANA in the cells used for the in vitro tubulogenesis assay. GAPDH expression was used as a control 
of equal loading. 
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malignant glioma, colorectal cancer, renal cell carcinoma and hepatocellular carcinoma 
(6, 11, 14, 15, 20, 45, 46). In these tumors, EGFL7 has been found to be positively 
associated with angiogenesis, growth and invasiveness. Extensive angiogenesis is an 
important feature of KS tumors. Comparable to the role of EGFL7 in other tumors that 
require extensive angiogenesis, it most likely plays important roles in the progression of 
KS tumors as well.  
We initially identified EGFL7 as one of the genes induced in response to LANA 
in a screen designed to identify differentially regulated LANA responsive cellular genes 
using next-generation RNA sequencing. Also, hypoxia has been recently shown to induce 
expression of EGFL7 (19). The KS tumor environment is also highly hypoxic; KS tumors 
frequently arise in locations with low oxygen levels such as the lower extremities (5, 21, 
49). Based on these findings, we further investigated the reactivation of EGFL7 
expression during KSHV infection and the underlying mechanism in the present study. 
Our results revealed that EGFL7 transcript and protein expression were significantly 
elevated in latently KSHV-infected primary effusion lymphoma cells (BC3 and BCBL1) 
compared with KSHV-negative B cells (BJAB). The fact that LANA is responsible for 
this upregulation was highlighted by the fact that EGFL7 expression was also 
significantly elevated in B cells expressing LANA as a sole KSHV protein. An intriguing 
aspect of these findings is the elevated expression of EGFL7 in B cells. Normally, B cells 
do not participate in angiogenesis. Hence, the significance of EGFL7 overexpression in B 
cells during KSHV infection points toward the possible involvement of the paracrine 
mechanism inducing angiogenesis in the spindle cells of KS lesions, the cells that are 
thought to be of endothelial origin and serve as perpetual reservoirs of the virus. 
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Normally, EGFL7 expression is highly restricted to endothelial cells. Under physiological 
conditions, EGFL7 is only expressed under conditions that require angiogenesis such as 
embryogenesis and wound healing. This restricted pattern of EGFL7 expression could be 
at least part due to the inhibitory effects of Daxx protein on the Ets-1-dependent 
transactivation of the EGFL7 promoter (18). The interaction of Daxx with Ets-1 has been 
previously reported to repress transcriptional activation of at least three genes involved in 
the promotion of angiogenic phenotypes (MMP1, Bcl2 and Flt-1/VEGF receptor 1) (18, 
24). Interestingly, LANA has been shown to sequester Daxx and consequently relieve 
Daxx-mediated inhibition on Ets-1-dependent VEGF receptor 1 promoter (24). Because 
the EGFL7 promoter also contains binding sites for Ets-1 we investigated whether LANA 
could activate the EGFL7 promoter by sequestering Daxx in a similar fashion. Our results 
showed that indeed LANA could activate EGFL7 promoter activity even when Daxx was 
overexpressed. This finding suggested that LANA transactivates the EGFL7 promoter by 
sequestering Daxx (Fig 4A). A deletion analysis of the EGFL7 promoter revealed that 
LANA could activate EGFL7 promoter only when an Ets-1 biding site was present. 
Irrespective of Daxx overexpression, LANA had no effect on the EGFL7 promoter when 
there was no Ets-1 binding site. Additionally, the association of Daxx protein with Ets-1 
protein and the association of Daxx protein with the EGFL7 promoter were also reduced 
in the presence of LANA. Collectively, these results suggest that the sequestration of 
Daxx is the primary mechanism behind the LANA-mediated transactivation of the 
EGFL7 promoter. Further evidence in support of this hypothesis arose by comparing the 
ability of LANA to transactivate the full-length EGFL7 promoter construct that contains 
binding sites for all of the transcription factors (-1670 to +100) versus a promoter 
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construct that contains 
Ets and GATA binding 
sites (-150 to +100) 
versus a promoter 
construct that contains 
GATA binding sites but 
not Ets-1 binding sites 
(-71 to +100). The 
magnitude of the 
LANA-mediated 
transactivation of the 
full-length EGFL7 
promoter construct and 
the construct containing 
Ets/GATA binding sites was similar (compare Fig 3C, lane 4 and Fig 5D, lane 3, black 
bar). LANA failed to transactivate the (-71 to +100) promoter construct from which the 
Ets binding sites were deleted but the GATA binding sites were intact, suggesting that 
LANA-mediated upregulation of the EGFL7 promoter was indeed dependent on Ets1. 
Figure 7 shows a schematic summary of these results. 
While the sequestration of Daxx appears to be the primary mechanism behind the 
upregulation of the EGFL7 promoter by LANA, the possibility of LANA transactivating 
the EGFL7 promoter through additional mechanisms remains. LANA has been 
Figure 7 A model depicting the possible mechanism behind LANA-
mediated upregulation of EGFL7. This figure has been adapted and 
modified from Murakami et al, (2006) (PMID: PMID: 16861237). 
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previously shown to activate hypoxia inducible factor (HIF)-α (1, 2, 4, 49).  Recently, 
EGFL7 has been identified as a gene induced in response to HIF-1α. Several studies have 
suggested that the expression of HIF-1α potentiates the expression of Ets-1, although the 
underlying mechanism is not clear (17, 31, 39). While not explored in this study, the 
possibility exists that LANA could induce Ets-1 expression through HIF-α in addition to 
relieving inhibition on existing Ets-1 bound to the EGFL7 promoter.  
The functional significance of EGFL7 upregulation by LANA was demonstrated 
by comparing the in vitro tubulogenic potential of HUVEC cells that did not express 
LANA, the cells that expressed LANA and the cells that expressed LANA but in which 
EGFL7 expression was knocked down using RNA interference. LANA-expressing cells 
showed higher tubulogenesis compared with control cells. However, when EGFL7 
expression was knocked down in these LANA-expressing cells, tubulogenesis was 
compromised. When expressed in isolation, LANA has been demonstrated to induce 
angiogenesis through multiple mechanisms (4, 13, 34, 44). Even so, the fact that 
knockdown of EGFL7 in LANA-expressing cells compromises tubulogenesis highlights 
the significant contribution of EGFL7 in LANA-mediated angiogenesis.  
 In summary, we have identified EGFL7 as an angiogenic cytokine induced 
during KSHV infection and have explored the mechanism behind its upregulation during 
KSHV infection. Anti-angiogenic therapy is a promising avenue for the treatment of KS. 
Targeting EGFL7 in combination with the other currently available anti-angiogenic 
therapies may increase the efficacy of the currently available anti-angiogenic regimen 
available for KS treatment. Furthermore, because of the highly restricted pattern of 
EGFL7 expression during normal physiological conditions, one can expect anti-EGFL7 
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therapy to be relatively safer than other anti-angiogenic therapies that target molecules 
with broader expression profiles and pleiotropic effects. This study lays the foundation 
for future research focusing on the evaluation of EGFL7 as a potential anti-angiogenic 
target for the treatment of KS. 
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